

**José Baselga, M.D., Ph.D.**  
**Physician-in-Chief & Chief Medical Officer, Memorial Sloan Kettering Cancer Center**

**A. EDUCATIONAL BACKGROUND**

1. Degree(s)

<i>Degree</i>	<i>Institution name and location</i>	<i>Dates attended</i>	<i>Year Awarded</i>
MD	Universitat Autònoma de Barcelona Barcelona, Spain	1976-1982	1982
PhD <i>Cum Laude &amp; Extraordinary Award</i>	Universitat Autònoma de Barcelona Barcelona, Spain	1988-1992	1992

2. Postdoctoral training

<i>Title</i>	<i>Institution name and location</i>	<i>Dates</i>
Army Physician	Spanish Army Hospital of Melilla North Africa, Spain	06/1983-05/1984
Resident, Department of Medicine	Vall d'Hebron University Hospital Barcelona, Spain	06/1984-05/1986
Intern, Department of Medicine	State University of New York Health Sciences Center at Brooklyn New York, NY	07/1986-06/1987
Resident, Department of Medicine	State University of New York Health Sciences Center at Brooklyn New York, NY	07/1987-06/1989
Fellow, Medical Oncology	Memorial Sloan Kettering Cancer Center New York, NY	07/1989-06/1992
Special Fellow, Department of Medicine	Memorial Sloan Kettering Cancer Center New York, NY	07/1992-06/1994

## **B. PROFESSIONAL POSITIONS AND EMPLOYMENT**

### 1. Academic positions

<i>Title</i>	<i>Institution name and location</i>	<i>Dates</i>
Instructor	Memorial Sloan Kettering Cancer Center New York, NY	07/1994-06/1996
Instructor	Weill Cornell Medical College New York, NY	07/1994-06/1996
Professor, Department of Medicine	Universitat Autònoma de Barcelona Barcelona, Spain	06/1996-07/2010
Professor, Department of Medicine	Harvard Medical School Boston, MA	09/2010-10/2012
Professor, Department of Medicine	Weill Cornell Medical College New York, NY	01/2013-Present
Member	Memorial Sloan Kettering Cancer Center New York, NY	01/2013-Present

### 2. Hospital positions

<i>Title</i>	<i>Institution name and location</i>	<i>Dates</i>
Clinical Assistant Physician, Department of Medicine, Breast/Gynecologic Oncology	Memorial Hospital for Cancer & Allied Diseases, New York, NY	07/1994-06/1996
Chairman, Department of Medical Oncology	Vall D'Hebron University Hospital Barcelona, Spain	01/1996-07/2010
Director, Department of Radiation Oncology	Vall D'Hebron University Hospital Barcelona, Spain	01/1996-07/2010
Director, Vall d'Hebron Institute of Oncology	Vall D'Hebron University Hospital Barcelona, Spain	01/2007-12/2010
Physician, Department of Medicine	Massachusetts General Hospital Boston, MA	07/2010-12/2012

Division Chief, Hematology/Oncology	Massachusetts General Hospital Boston, MA	01/2010-12/2012
Associate Director, MGH Cancer Center	Massachusetts General Hospital Boston, MA	01/2010-12/2012
Associate Director, Clinical Sciences	Dana Farber/Harvard Cancer Center Boston, MA	01/2012-12/2012
Attending Physician, Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine	Memorial Hospital for Cancer & Allied Diseases, New York, NY	01/2013-Present
Physician-in-Chief and Chief Medical Officer	Memorial Sloan Kettering Cancer Center New York, NY	01/2013-Present
Member	Human Oncology and Pathogenesis Program (HOPE)	01/2013-Present

3. Other employment N/A

**C. EMPLOYMENT STATUS**

Name of Employer(s): Memorial Sloan Kettering Cancer Center  
Employment Status: Full-time salaried

**D. INSTITUTIONAL/HOSPITAL AFFILIATION**

Primary Hospital Affiliation: **Memorial Hospital for Cancer and Allied Diseases**  
Other Hospital Affiliations: None  
Other Institutional Affiliations: None

**G. PERCENT EFFORT AND INSTITUTIONAL RESPONSIBILITIES**

	<u>Current Percent Effort (%)</u>	<u>Does the activity involve WMC students or researchers? (Y/N)</u>	<u>Does the activity involve MSK trainees or researchers? (Y/N)</u>
Teaching/Mentoring	10%	Y	Y
Clinical Care	20%	Y	Y
Administration	45%	Y	Y
Research	25%	Y	Y
	<b>100%</b>		

## INSTITUTIONAL RESPONSIBILITIES

### 1. Teaching/Mentoring

<i>Activity</i>	<i>Dates</i>
<b><u>Didactic Teaching</u></b>	
Oncology elective for 6 <sup>th</sup> Year Medical Students Universitat Autònoma de Barcelona, Vall D'Hebron University Hospital 27 Teaching Hours per Year	1996-2010
Inpatient Teaching Rounds, Medical Oncology Residents Vall D'Hebron University Hospital Once per Week	1996-2004
Weekly Teaching Conference, Medical Oncology Fellows Vall d'Hebron University Hospital 1 Hour Teaching Conference per Week	1996-2010
Breast Cancer Teaching Conference for Hematology & Medical Oncology Fellows Massachusetts General Hospital Cancer Center 1 Hour Teaching Conference, Twice per Year	2012-2013
Cancer Biology Course for Medical Oncology Fellows Memorial Sloan Kettering Cancer Center 2 Hour Teaching Conference, Twice per Year	2014-Present
<b><u>Mentorship</u></b>	
Vall d'Hebron Research Institute, Vall d'Hebron University Hospital Supervising and training pre-doctoral and post-doctoral students	1996-2006
Center for Cancer Research, Massachusetts General Hospital Supervising and training post-doctoral students	2011-2012
Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center Supervising and training post-doctoral students	2013-Present

## **Clinical Teaching**

Medical Oncology Resident Mentor 1996-2010  
Vall d'Hebron University Hospital  
Inpatient teaching rounds, 1 hr/week

Hematology & Medical Oncology Fellowship 2012  
Massachusetts General Hospital Cancer Center  
1 Hour Outpatient Joint Patient Visits with Fellows per Week

## **Administrative teaching leadership role**

Head of Laboratory Research, Vall d'Hebron Research Institute 1996-2006  
Vall d'Hebron University Hospital, directing pre- and post-doctoral students

## 2. **Clinical Care**

<i>Activity</i>	<i>Dates</i>
Clinic, Medical Oncology Service Vall d'Hebron University Hospital, Barcelona, Spain	1996-2010
Clinic, Clinica Quiron Barcelona, Spain	1999-2010
Clinic, Medical Oncology Service, Gillette Center for Women's Cancers Massachusetts General Hospital, Boston, MA	2010-2012
Clinic, Breast Medicine Service Division of Solid Tumor Oncology, Department of Medicine Memorial Sloan Kettering Cancer Center, New York, NY	2013-Present

## 3. **Research**

My long standing research interests are in the development of targeted agents for the treatment of breast cancer and in studying strategies to overcome mechanisms of resistance, with over 457 peer-reviewed publications to date. I conducted pivotal laboratory and clinical studies that led to the approval of trastuzumab, pertuzumab and everolimus, among other therapies. My current work is in targeting P13K and deciphering mechanisms of resistance to anti-estrogen therapies. I am also leading a number of neo-adjuvant trials in breast cancer and in developing biomarker-based early and translational clinical trials.

#### 4. Administrative

<i>Activity</i>	<i>Dates</i>
Chairman, Department of Medical Oncology & Director, Radiation Oncology Vall d'Hebron University Hospital, Barcelona, Spain	01/1996-07/2010
Division Chief, Hematology/Oncology & Associate Director, MGH Cancer Center, Massachusetts General Hospital, Boston, MA	01/2010-12/2012
Associate Director of Clinical Sciences Dana Farber/Harvard Cancer Center, Boston, MA	01/2012-12/2012
Co-Director, Center for Mechanism Based Therapies (CMBT) Memorial Sloan Kettering Cancer Center, New York, NY	01/2013-
Member, Human Oncology & Pathogenesis Program (HOPP) Memorial Sloan Kettering Cancer Center, New York, NY	01/2013-
Physician-in-Chief & Chief Medical Officer Memorial Sloan Kettering Cancer Center, New York, NY	01/2013-

#### **H. RESEARCH SUPPORT**

1. Title of grant, source, amount, and duration of support (dates); 2. PI; 3. Role & % effort

##### **Current Support**

###### Extramural:

###### **5 R01 CA190642-02 (PI: Baselga)**

Unraveling resistance to PI3K-alpha inhibitors in breast cancer

Source: NCI

Amount: \$248,392

Dates: 08/1/2015-07/31/2020

Role: PI (15% T/E)

###### **1 RO1 CA201247-01A1 (PI: Abdel-Wahab/Park)**

Origins of BRAF-mutant hematologic malignancies and their therapeutic resistance

Source: NCI

Amount: \$318,843

Dates: 09/1/2016 – 08/31/2021

Role: Other Significant Contributor (0% T/E)

**GC228532 (PI: Baselga)**

Identification of molecular determinants of sensitivity to PI3K p110 $\alpha$  specific inhibitors in Breast Cancer

Source: The Breast Cancer Research Foundation

Amount: \$208,333

Dates: 10/1/2013 - 09/30/2017

Role: PI (0% T/E)

**GC222389 (PI: Baselga)**

Tumor Biomarkers, Synergy in the Identification and Application of Biomarkers for Improved Cancer Therapy

Source: Fundacion BBVA

Amount: \$71,500

Dates: 01/1/2013 - 05/31/2017

Role: PI (5% T/E)

**5 P30 CA008748-50 (PI: Thompson)**

Cancer Center Support Grant (Senior Leadership/Clinical and Protocol Data Management)

Source: NCI

Amount: \$0 to the lab

Dates: 01/1/2014 - 12/31/2018

Role: Co-PI (30% T/E)

**5 P01 CA094060-12 (PI: Norton)**

Program Project in Models of Breast Cancer (Project 3: Development of Mechanism-based Strategies for the Treatment of Advanced Breast Cancer)

Source: NCI

Amount: \$310,956

Dates: 09/16/2014 - 06/30/2019

Role: Co-PI (5% T/E)

**SK2014-1760 (PI: Baselga)**

SRA-Modeling and Predicting Resistance to the Kinase Inhibitor Neratinib in HER2-Mutated Breast Cancer

Source: Puma Biotechnology, Inc.

Amount: \$185,185

Dates: 02/27/2015-02/27/2018

Role: PI (0% T/E)

**GC227703 (PI: Baselga)**

Rational design of anti-cancer drug combinations with dynamic multidimensional input

Source: The V Foundation

Amount: \$90,909

Dates: 02/1/2016 - 02/1/2019

Role: PI (0% T/E)

**GC222915 (PI: Tabernero)**

Vall d'Hebron Institute of Oncology-La Caixa Foundation Collaborative Research & Education Program

Source: La Caixa Foundation

Amount: \$240,000 (\$0 to the lab)

Dates: 02/20/2014 - 12/31/2016

Role: Co-PI (0% T/E)

Intramural:

**GC226033 (PI: Hyman)**

AKT1 Mutations in the Pathogenesis and Treatment of Advanced Solid Tumors

Source: Cycle for Survival

Amount: \$160,000

Dates: 09/1/2015 - 08/31/2017

Role: Co-PI (3% T/E)

**GC224347 (PI: Heller/Baselga)**

A Nano scale Therapeutic Platform to Target the Solid Tumor Microenvironment (Nanoparticle Enhancement of Targeted Therapies to Overcome Dose-Limiting Toxicity and Drug Resistance)

Source: Experimental Therapeutics Center

Amount: \$160,779

Dates: 01/1/2015-

Role: Co-PI (5% T/E)

**GC227327 (PI: Baselga)**

Collaborative Research: Rational Design of Anticancer Drug Combinations using Dynamic Multidimensional Theory

Source: National Science Foundation

Amount: \$116,686

Dates: 07/1/2015 – 06/30/2018

Role: PI (5% T/E)

**SU2C 2015-004 (PI: Garraway)**

Collaborative Research: Rational Design of Anticancer Drug Combinations using Dynamic Multidimensional Theory

Source: Stand Up To Cancer

Amount: \$131,273

Dates: 09/1/2015 – 08/31/2018

Role: MSK PI (0% T/E)

\*Effort for this award is subsumed under the National Science Foundation award, GC22732, all part of a Convergence Team program

**GC228764 (PI: Baselga)**

Development of an Optimal PI3K Inhibitor for Topical Application to Treat Venous Malformation (SK2015 043)

Source: Technology Development Fund

Amount: \$ 110,000



Dates: 2/1/2017 - 2/1/2019  
Role: PI (0% T/E)

**Pending:**

**1R01 CA215238-01 (PI: Morris/Plitas/Rahimi-Kashari)**

Hyperpolarized MR Metabolic Imaging of Breast Cancer

Source: NCI

Amount: \$499,987

Dates: 4/1/2017 – 3/31/2022

Role: Co-Investigator (5% T/E)

**BC161321P1 (PI: Baselga)**

0.60 calendar

Nanoparticle Delivery of HER2 Targeted Small Biologic Drug Conjugates for the Treatment of Metastatic Breast Cancer

Source: Congressionally Directed Medical Research Programs

Amount: \$ 375,000

Dates: 9/1/2017 8/31/2021

Role: PI(5%/T/E)

**5 U54 CA 224072-01 (PI: Solit / Taylor)**

1.2 calendar

MSK Drug Resistance and Sensitivity Center (Project 2: Defining Mechanisms of Resistance to Hormonal Therapy in Breast Cancer)

Source: NCI

Amount: \$ 325,000

Dates: 9/1/2017 8/31/2022

Role: PI(10%T/E)

**1 P50 CA206966 (PI: Powell/Solit)**

MSK SPORE in breast cancer (Project 2: Identifying Genetic Causes and Therapeutic Vulnerabilities in Triple Negative Breast Cancer)

Source: NCI

Amount: \$295,882

Dates: 7/1/2017 – 6/30/2022

Role: Collaborator (3% T/E)

**Completed Support**

**SAC110046 (PI: Baselga)**

Combinatorial Therapeutic Strategies to Revert Resistance To Anti-HER2 Agents in Breast Cancer

Source: Susan G. Komen Breast Cancer Foundation

Amount: \$180,000

Dates: 04/15/2014 - 04/14/2015

Role: PI (10% T/E)

**GC226308 (PI: Baselga/Scaltriti)**

Mechanisms of Resistance to PI3K p110 $\alpha$  Inhibition in Squamous Cell Head & Neck/Esophageal Cancer

Source: Cycle for Survival

Amount: \$80,000  
Dates: 09/1/2013 - 08/31/2016  
Role: PI (5% T/E)

## **I. EXTRAMURAL PROFESSIONAL RESPONSIBILITIES**

### **Grant & Program Reviewing**

#### *Program 501 (Oncology)*

Carlos III Institute of Health, Spanish Ministry of Health, Ad hoc reviewer, 2000-2009

#### *Biomedicine Program*

Spanish Agency for Evaluation and Prospective, Spanish Ministry of Science, Ad hoc reviewer, 2000-2009

#### *Advanced Investigator Grants*

European Research Council, European Commission, Expert Panel Member, 2008-2010

#### *FP7 Health Research Program*

European Research Council, European Commission, Advisory Group Member, 2009-2010

#### *CPR Scientific Advisory Board*

SAB Member, 2013

### **Editorial Activities**

#### *Founding Editor in Chief*

Cancer Discovery, 2011-Present

#### *Member, Editorial Advisory Board*

Investigational New Drugs, 2001-Present

Cancer Prevention Research, 2008-Present

Clinical Cancer Research, 1995-2011

Annals of Oncology, 1999-2002

Journal of Clinical Oncology, 2001-2005, 2006-2009

Cancer Cell, 2002-2011

#### *Ad hoc reviewer, 1995-Present*

Journal of the National Cancer Institute

Cancer Research

International Journal of Cancer

European Journal of Cancer

Journal of Cancer

New England Journal of Medicine

Cancer Cell

*Advisor of the Highlights Section*

Nature Reviews Cancer, 2009-2012

*Other activities*

Associate Editor, Annals of Oncology, 1999-2002

Senior Editor, Clinical Cancer Research, 2009-2011

**Patents**

Method for diagnosing cancers expressing the HER2 Receptor or its truncated variants

Ref. Number (Spanish Patents Agency): P200801652 - ES 2342646.

Applied: 08-06-2008; Published: 09-07-2010.

PCT Number: PCT/ EP2009/056976 - WO 2010/000565.

Applied: 05-06-2009; Published: 07-01-2010.

US application number: US 12/ 479,035 – US 2009/0311262.

Applied: 05-06-2009; Published: 17-12-2009

Antibodies against HER2 truncated variant CTF-611

EP 09380183.5. Application: 17-12-2009

Therapeutic agents for the treatment of diseases associated with undesired cell proliferation

P200900928. PCT/ EP 2010/054499. Priority Claimed: April 3, 2009

Antibody recognizing human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation

EP 1038049.6. Application: 05-04-2010

Combination of a phosphoinositide 3-kinase inhibitor and an antidiabetic compound

European Procedure/Application Number: 09160440.5. Priority Claimed: May 15, 2009. Applicant

Entities: Novartis Pharma AG

Use of Phosphoinositide 3-Kinase Inhibitors for Treatment of Vascular Malformations

US provisional patent application 62/162,534, Filed May 15, 2015.

Use of PDK1 inhibitors in combination with PI3K inhibitors

US provisional patent application 62/194,106, Filed July 17, 2015.

**Invited Lectures: National**

Head and Neck Conference / “Studies with Anti-EGF Receptor Monoclonal Antibodies in Lung Cancer” / Presenter / MD Anderson Cancer Center/ Houston, TX, 1993

Esther Zollar Breast Conference Research Lecture / “Growth Factor Receptors as Targets in Breast Cancer Therapy” / Presenter / University of California/ San Francisco, CA, 1994

Studies with Anti-Growth Factor Receptor Monoclonal Antibodies against Human Breast Cancer Xenografts / Presenter / Pacific Medical Center, Geraldine Brush Cancer Center / San Francisco, CA, 1994

“Growth Factor Receptors as Targets in Cancer Therapy” / Grand Rounds / Speaker / Yale Cancer Center / New Haven, CT, 1994

“Growth Factor Receptors as Targets for Cancer Therapy Seminar”/ Speaker /University of Virginia/ Health Sciences Center/ Charlottesville, VA, 1995

Cancer and Leukemia Group B, Breast Committee Spring Meeting / “Growth Factor Receptors as Targets for Breast Cancer Therapy” / Speaker / Providence, Rhode Island, 1995

5<sup>th</sup> Annual Solid Tumor Symposium / “Current Approaches in the Management and Screening of Breast and Ovarian Cancers” / Speaker / New York Medical College / Valhalla, New York, 1995

The Taxol Mini Symposium, San Antonio Breast Cancer Symposium / “Therapeutic Implications of the Relationship between HER2 Overexpression and Paclitaxel Sensitivity”/ Lecturer / The University of Texas / San Antonio, Texas, 1996

Breast Cancer in the next Millennium. A Comprehensive Forum: Therapeutic Implications of HER2 Overexpression in Breast Cancer/ Morristown Memorial Hospital/ Morristown, New Jersey, 1997

Docetaxel: Overview and Future Directions / 1st International Forum on Breast Cancer Treatment/ Presenter / New York, New York, 1998

The Women's Cancer Research Group, "The Epidermal Growth Factor Receptor and HER2 as Targets for Breast Cancer Therapy" and "Biosynthesis of Growth Factors: Transforming Growth Factor as a Model," / Speaker / MD Anderson Cancer Center/ Houston, Texas, 1998

“Basic Science and Clinical Aspects of Growth factor Receptor-Targeted Approaches: Herceptin and Beyond”/Vanderbilt University Cancer Center/ Nashville, Tennessee, 2000

2nd Annual Lynn Sage Breast Cancer Symposium / "Update on Herceptin" / Presenter / Robert H. Lurie Comprehensive Cancer Center of Northwestern University/ Chicago, Illinois, 2000

Integrated Symposium Targeting the EGF Receptor: A Clinical Reality / Discussant / 2001 ASCO Annual meeting/ San Francisco, California, 2001

“Clinical trials with Iressa, an EGFR TK Inhibitor” / Speaker/ 6th Madrid Breast Cancer Conference on Changes in the Treatment of Breast Cancer/ Chantilly, Virginia, 2001

“Clinical Development of Molecularly Targeted Agents” / Speaker / ASCO-NCI Scientific Symposium on Molecular Oncology for the Clinical Oncologist/ Boston, Massachusetts, 2001

93rd AACR Annual Meeting "EGF Receptor as a Target: Preclinical and Clinical Studies," / Speaker / San Francisco, California, 2002

Symposium at Radiation Research Meeting (EGFR): Molecular Inhibition of EGFR: From lab to Clinic "EGFR Inhibition Combined with Chemotherapy"/ Speaker / Reno, Nevada, 2002

Gordon Research Conferences: Chemotherapy of Experimental/Clinical Cancer. "Targeting the Epidermal Growth Factor Receptor Family: Current Status and Challenges" / Lecturer / New London, New Hampshire, 2002

1st Annual Symposium on Anti-Receptor Signaling in Human Neoplasia "Pharmacodynamic Assays in Trials with Anti-EGFR Therapies" / Speaker / Chicago, Illinois, 2002

ASCO Molecular Therapeutics Symposium " Receptor Tyrosine Kinase Inhibitors: Biological Overview"/ Lecturer / San Diego, California, 2002

25th Annual San Antonio Breast Cancer Symposium Certified Symposium Biologic Therapies: Current Therapeutic Challenges / Lecturer / San Antonio, TX, 2002

2003 ASCO Annual Meeting / "The Epidermal Growth Factor as a Therapeutic Target" / Lecturer / Chicago, Illinois, 2003

94th AACR Annual Meeting / "Tyrosine Kinase Specific Therapy: Molecular Mechanisms and Drug Development" / Lecturer / Washington, DC, 2003

2nd Annual Symposium on Anti-Signaling Strategies in Human Neoplasia (CBCE) / "Biochemical Pharmacodynamics" / Lecturer / Chicago, Illinois, 2003

"Pharmacodynamic Endpoints with Molecular Targeted Agents" / Speaker / Vanderbilt University Cancer Center / Nashville, Tennessee, 2004

2004 EGFR Summit / "Single Agent Studies in Colorectal, Head, and Neck and other Cancers" / Lecturer / Miami, Florida, 2004

95th AACR Annual Meeting / Keynote Speaker / "Pharmacodynamic Approaches to Targeted Therapy Optimization" - "New Directions in ErbB Directions Targeting" & "Small Molecule Tyrosine Kinase Inhibitors: Is the Glass Half Empty or Half Full?"/ Lecturer / Orlando, Florida, 2004

2004 ASCO Annual Meeting / "How valid are Biologic Correlates in Clinical Studies?" / Lecturer / New Orleans, Louisiana, 2004

Waun Ki Hong Visiting Professorship Award / "Pharmacodynamic Approaches to Targeted Therapy Optimization" / Lecturer / Houston, Texas, 2004

The 29th Annual Alumni Society Meetings / "EGFR Inhibitors: Current Status" / Speaker / New York, New York, 2004

Cancer Colloquium / "Freedom to Discover" / Lecturer / New Brunswick, New Jersey, 2004

27th Annual San Antonio Breast Cancer Symposium / Poster Discussant / San Antonio, Texas, 2004

Keystone Symposium / "Mechanisms of Action of EGFR-Inhibitory Antibodies and Small Molecules" / Lecturer / Santa Fe, New Mexico, 2005

2005 ASCO Annual Meeting / Poster Discussant & Presenter of Educational Sessions / Orlando, Florida, 2005

AACR Special Conference in Advances in Breast Cancer Research: Genetics, biology and clinical applications / "Pharmacodynamic Endpoints in the Clinical Development of Molecularly Targeted Agents in Breast Cancer" / Lecturer / La Jolla, California, 2005

58th Annual Symposium on Fundamental Cancer Research / "Biomarker Development for Targeted Agents Directed at the PI3K/AKT/mTOR Pathway" / Speaker / MD Anderson Cancer Center / Houston, Texas, 2005

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics / "Optimizing therapies for Inhibiting Kinase Receptors" / Speaker / Philadelphia, Pennsylvania, 2005

28th Annual San Antonio Breast Cancer Symposium / "Biomarker Strategies" and "Disease Progression Following Adjuvant Trastuzumab" / Speaker / San Antonio, Texas, 2005

AACR Special Conference in Cancer Research: Drugging the Cancer Genome: Developing Rational Combination Therapies for Multi gene Cancers. "Incorporation of Tumor Pharmacodynamic Endpoints in the Development of Molecular Targeted Agents" / Co-Chair & Speaker / Rancho Mirage, California, 2006

97th AACR Annual Meeting / "EGFR Inhibitors in the Treatment of Cancer: Current Status and Emerging Strategies" / Speaker / Washington, DC, 2006

ASCO Development in Molecular Therapeutics in Breast Cancer Conference - Session: "Growth Factors and GF Receptors as Therapeutic Targets" / Co-Chair of session and "The HER Family" / Speaker / Aspen, Colorado, 2006

Cancer Colloquium and distinguished Achievement Award Ceremony / "Mechanism of Trastuzumab Resistance in HER2 Positive Breast Cancer" / Lecturer / Princeton, New Jersey, 2006

29th Annual San Antonio Breast Cancer Symposium / "Trastuzumab Resistant metastatic Disease: Current Options and Future Targets" / Speaker / San Antonio, Texas, 2006

98th AACR Annual Meeting "Receptor Tyrosine Kinase Inhibitors" and "Small Molecules Versus Monoclonal Antibodies in Her2 Amplified Breast Cancer" / Speaker / Los Angeles, California, 2007

2007 ASCO Annual meeting - Career Choices: "Options in Academic, Private Practice, Industry and Government" / ASCO Extended Education Session: "Mentors in Academia" / Roundtable Facilitator / Chicago, Illinois, 2007

Harvard Breast Cancer Conference / "The New Generation of Targeted Therapies for Breast Cancer" / Jean H. Lubrano Distinguished Visiting Scholar Lecturer / Boston, Massachusetts, 2007

The 2007 Breast Cancer Symposium / "Other Anti-HER2 Agents" / Lecturer / San Francisco, California, 2007

MD Anderson Breast Cancer Research Program Lecture Series / "Novel anti-HER2 Strategies in the Treatment of Cancer" / Lecturer / Houston, Texas, 2007

AACR Special Conference. Advances in Breast Cancer Research: Genetics, Biology and Clinical Applications / "Mechanisms of Trastuzumab Resistance in HER2 Positive Breast Cancer" / Speaker / San Diego, California, 2007

American Italian Cancer Foundation Research Symposium / "Inhibition of the EGF Receptor Family as Cancer Therapy" / Co-Lecturer / New York, New York, 2007

30th Annual San Antonio Breast Cancer Symposium SABCA General Session VI Symposium "European and US Perspectives on Current Clinical Trials, Clinical Practice, and Treatment Guidelines" / Co-Moderator/ "Defining the Role of Targeted Therapies in Breast Cancer: How and When Should These Agents be Incorporated?" / Co-Presenter / San Antonio, Texas, 2007

99th AACR Annual Meeting / "The mTOR Pathway as a Cancer Target: Pharmacodynamic measurements of MTOR inhibition" / Speaker; "New directions in targeting the HER receptor family: A voyage to the center of the cell" / 32nd Annual AACR-Rosenthal Family Foundation Award / Lecturer / San Diego, California, 2008

2008 ASCO Annual Meeting education session: Picking the winners through biomarker enrichment: Could this be the end of phase III trials? / "Translational endpoints of today and tomorrow" / Lecturer / Chicago, Illinois, 2008

AACR Centennial Conference Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine. / "Combinatorial Approaches with Signal Transduction Inhibitors" / Lecturer / Monterey, California, 2008

ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer / "Overview: EGFR Pathway" / Lecturer / Orlando, Florida, 2008

New York University 15th Belsky Memorial Lecture / "Advances in the Therapy of HER2 Positive Breast Cancer" / Grand Rounds Speaker / New York, New York, 2008

31st Annual San Antonio Breast Cancer Symposium / "Novel Anti-HER2 Strategies in the Therapy of Breast Cancer" / Lecturer / San Antonio, Texas, 2008

100th AACR Annual Meeting / "Novel Strategies in the Therapy of HER2 Positive Breast Cancer" / Denver, Colorado, 2009

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital / "Emerging Molecular Targets in Breast Cancer: HER2 and beyond" / Invited Lecturer / Baltimore, Maryland, 2009

Chemotherapy Foundation Symposium XXVIII/ Faculty Speaker/ "PI3K inhibitors: initial Results and future Directions," / New York, New York, 2010

Bob Pinedo Cancer Care Prize Lecture, The Society for Translational Oncology (STO), /Award Recipient & Lecturer / "Targeted therapeutics in Oncology: Building a Vision for the Future"/ Durham, North Carolina, 2010

Triple Negative Breast Cancer Foundation Symposium: Molecular Therapeutic Approaches/ Presenter / "New Future Directions and Targets" / San Antonio, Texas, 2010

33<sup>rd</sup> Annual San Antonio Breast Cancer Symposium, "Cetuximab + Cisplatin in Estrogen Receptor–Negative, Progesterone Receptor–Negative, HER2–Negative (Triple–Negative) Metastatic Breast Cancer: Results of the Randomized Phase II BALI–1 Trial" Poster Presentation/ San Antonio, Texas, 2010

PRIME Oncology SABCS Symposium. "Controversial Topics in Breast CA: Straight Talk with International Experts" / Presenter / San Antonio, Texas, 2010

33<sup>rd</sup> Annual San Antonio Breast Cancer Symposium – "TDM1 and Pertuzumab" / Presenter / San Antonio, Texas, 2010

AACR Translational Cancer Research for Basic Scientists/ Keynote Speaker / Omni Parker / Boston, Massachusetts, 2010

Society for Translational Oncology/ Keynote Lecturer / "Building a Vision for the Future in Development of Targeted Therapeutic"/ Liberty Hotel / Boston, Massachusetts, 2010

Massachusetts Society of Clinical Oncologists 2010 Annual Meeting – Breast Cancer in 2010/Guest Speaker/"The Road Towards Personalizing Cancer Care." / Dedham, Massachusetts, 2010

Boston Leaders' Forum 2010 "Personalized Medicine in Cancer" / Invited Speaker / "A Physician's Perspective." / Boston, Massachusetts, 2010

Keystone Symposium: "PI 3-Kinase Signaling Pathways"/ Keystone, Colorado, 2011

AACR Targeting PI3K/mTOR Signaling in Cancer Special Conference/ San Francisco, California, 2011

Sanford Genetics, Genomics and Individualized Medicine Conference/ Fargo, North Dakota, 2011



"Targeting the PI-3 Pathway in Breast Cancer," Vanderbilt-Ingram Cancer Center/ Nashville, Tennessee, 2011

American Association for Cancer Research (AACR) Annual Meeting, "Targeting PI3K" / Speaker / Orlando, Florida, 2011

American Association of Clinical Oncologists (ASCO) Annual Meeting, Quintiles Scientific Advisory Board Meeting, "Cancer Genomics and protein based assays for treatment," / Chicago, Illinois, 2011

John Mendelsohn's Festschrift Symposium. "Targeting the PI3K in Breast Cancer," / Speaker / Houston, Texas, 2011

Aphinity Investigator Meeting "Clinical Experience with Pertuzumab and Rationale" / Chicago, Illinois, 2011

AACR Special Conference: Advances in Breast Cancer Research "Targeting the PI3K/mTOR pathway in breast cancer"/ Session Chair & Speaker / San Francisco, California, 2011

AACR Special Conference: Advances in Breast Cancer Research Session 7: Endocrine Resistance / Session Chair / San Francisco, California, 2011

Ohio State University Grand Rounds Speaker "Targeting HER2 and the PI3K/Mtor Pathway in Breast Cancer" / Columbus, Ohio, 2011

Plenary Session Leader: Novel Clinical Paradigms in Personalized Medicine / Speaker / "Combinatorial approaches to prevent adoptive responses to targeted therapeutics in breast cancer." AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, 2011

Plenary Session Leader: Novel Clinical Paradigms in Personalized Medicine / Speaker / Combinatorial approaches to prevent adoptive responses to targeted therapeutics in breast cancer. / AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, 2011

MGH-AstraZeneca Science Day, Invited speaker: "A Global Perspective on Personalized Cancer Medicine- The Center for Targeted Therapies" / Boston, Massachusetts, 2011

Chabner Colloquium: Collaborations in Cancer Drug Trials / Fellows Forum Session Chair / "PI3K Inhibitors in Breast Cancer" / Speaker / Cambridge, Massachusetts, 2011

Baylor College of Medicine M.D. Anderson Cancer Center Joint Symposium Molecular Approaches to Managing Women's Cancers / "Combinatorial Approaches to Prevent Adaptive Responses to PI3K Inhibitors in Breast Cancer" / Keynote Speaker / Houston, Texas, 2012

AACR Annual Meeting Current Concepts Session / "Preclinical and Clinical Evaluation of PI3K Pathway Inhibitors" / Co-Chair & Speaker / Chicago, Illinois, 2012

AACR Annual Meeting Press Conference / Late Breaking Clinical Trials / Moderator / Chicago, Illinois, 2012

San Antonio Breast Cancer Symposium / Speaker / “Biomarker analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC)” / General Session 5/ San Antonio, Texas/ December 7, 2012

30th Miami Breast Cancer Conference / “Targeting the phosphoinositide 3-kinase (PI3K) in breast cancer” / Speaker / Miami, Florida / March 9, 2013

Keystone Symposia: PI 3-Kinase and Interplay with Other Signaling Pathways / “PI3K/Akt/mTOR Pathway in Cancer (Clinical-Part 1)”/ Session Chair / Scientific Organizer / Keystone, Colorado, 2013

NY CEO Symposium / The Future of Drug Discovery: Is The Glass Half Empty or Half Full? / Co-Host & Panel Speaker / New York, New York / February 13, 2013

The Governor’s Conference on Effective Partnering in Cancer Research / Speaker / “PI3K Inhibitors in the Therapy of Breast Cancer” / Princeton, New Jersey / April 17, 2013

AACR Annual Meeting / Speaker and Program Committee Chairman /  
Apr 6: Speaker: Navigating the Annual Meeting  
Apr 6: Chairperson: Plenary Session  
Apr 10: Chairperson: Current Concepts in Organ Site Research  
Apr 10: Speaker: Applying the breast cancer genome to transformative clinical trials: Current Concepts in Organ Site Research/ Washington DC/April 5-April 10, 2013

ASCO Annual Meeting / ASCO, American Association for Cancer Research (AACR) Joint Session: Metastasis: Progress in Translational and Clinical Research / Co-Chair / Chicago, Illinois/ June 3, 2013

LEAD Summit XI/ Breakout Session: Clinical Data on Molecular Determinants of Sensitivity and Pathway Interactions / Speaker / Budapest, Hungary / June 28, 2013

US Oncology Forum/ Speaker/ “Targeting the PI3K/mTOR pathway in Breast Cancer: From mTOR to PI3K alpha specific inhibitors” / September 13, 2013

Cancer Advance Conference/ Co-Host and Keynote Speaker / Boston, Massachusetts / September 19, 2013

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics/ Speaker /” Rationale for combined PI3K and mTOR blockade and Chairperson: Developing Combination Therapy Approaches in the Lab and Clinic” / Boston, Massachusetts / October 22, 2013

NIH Center for Cancer Research (CCR) Grand Rounds/ Speaker/ “Implications of Genomic Profiling and Pathway Complexity in Early Drug Development”/ Bethesda, Maryland / November 8, 2013

Department of Medicine, Memorial Sloan Kettering Cancer Center / Grand Rounds Speaker / “Targeting the PI3K Pathway in Breast Cancer” / New York, New York/ January 10, 2014

AACR Annual Meeting / Speaker and Discussant / Apr 6: Discussant/ Plenary Session, Harnessing Breakthroughs, Targeting Cures/Apr 8: Speaker/“Combinatorial Approaches to Prevent Compensatory Pathways Activation” / San Diego, California / April 4-8, 2013

ASCI/AAP Joint Meeting/ Plenary Speaker / “Targeting the PI3K/AKT/mTOR pathway in breast cancer”/ Chicago, Illinois/ April 25, 2014

ASCO Annual Meeting/ Faculty Member / PLATO Foundation ASCO Fellows Forum / Chicago, Illinois / May 30, 2014

NCI Tumor Microenvironment Network Meeting/ Keynote Speaker / New York, New York /June 10, 2014

AACR Precision Medicine Series: Drug Sensitivity and Resistance: Improving Cancer Therapy/ Plenary Session Moderator /Extreme Resistance/Orlando, Florida/ June 19, 2014

IFHNOS/AHNS Centennial Congress / Keynote Speaker / “Bringing Forward the Promise of Targeted Therapy to H&N Tumors”/ New York, New York/ July 27, 2014

AACR Special Conference on Targeting the PI3K-mTOR Network in Cancer/ Speaker / “Targeting the PI3K pathway in hormone-dependent breast cancer” / Philadelphia, Pennsylvania/ September 16, 2014

AACR-ASCO-BCRF-FDA Innovations in Breast Cancer Drug Development/ Co-Chair / Bethesda, Maryland / October 2, 2014

Chemotherapy Foundation Symposium / Speaker /”Adjuvant therapy for HER2+ Breast Cancer”/ New York, New York / November 6, 2014

Memorial Sloan Kettering Cancer Center Grand Rounds/ Speaker /“Strategies for the Center: Perspectives from the President & CEO, Physician-in-Chief & Board of Managers.” / New York, New York/ December 19, 2014

Keystone Symposia Conference: PI 3-Kinase Signaling Pathways in Disease/PI3K/Akt/mTOR Clinical Translational – Oncology Session/ Speaker /”PI3k and mTOR Inhibitors in Breast Cancer”/ Keystone, Colorado / January 16, 2015

SU2C and the V Foundation Convergence Ideas Lab/ Participant and Speaker /”Important Questions in the Clinical Oncology Field”/ Princeton, New Jersey/ February 13-18, 2015

Stanford Cancer Institute Trainee Forum/ Keynote Speaker /”Challenges and Opportunities in Pursuing a Career in Biomedical Research”/ Stanford, California/ February 19, 2015

Memorial Sloan Kettering Cancer Center Grand Rounds /Speaker /"Advances in breast cancer targeted therapy"/ New York, New York/ March 06, 2015

2015 Annual Meeting of the Presidents' Circle of the NAS, NAE, and the Institute of Medicine (IOM) / Panelist / Revolutions in Medicine/ Washington D.C. / March 24, 2015

AACR Annual Meeting / Speaker /Meet-the-Expert Session /"Update on Targeting Pi3K $\alpha$  in Breast Cancer"/ Philadelphia, Pennsylvania/ April 16-22, 2015

Weill Cornell Translational Workshop / Keynote Speaker / "Targeting PI3K"/ New York, New York/ April 29, 2015

2015 Geoffrey Beene Cancer Research Retreat/Speaker/"Valley of Death. Why most of our new drugs/targets rarely go anywhere and what we can do about it"/ Hamburg, New Jersey/ May 1, 2015

Fred Hutchinson Cancer Research Center Solid Tumor Translational Research Conference / Keynote Speaker / "Bringing Cancer Precision Medicine Forward"/ Seattle, Washington / June 26, 2015

2016 AACR Annual Meeting Program Committee Planning Meeting / President / Philadelphia, Pennsylvania / July 7, 2015

AACR Strategic Planning Meeting / President / Philadelphia, Pennsylvania/ August 12, 2015

The 2015 Cancer Progress Report and Rally for Medical Research Hill Day/ Washington, DC/ September 17, 2015

Beth Israel Deaconess Medical Center Hematology/Oncology Grand Rounds / Keynote Speaker / Boston, Massachusetts / November 11, 2015

Peter Steck Memorial Lecture at MD Anderson Cancer Center/ Speaker / "Targeting Actionable Genomic Mutations"/ Houston, Texas/ January 28, 2016

John Wayne Clinical Research Lecture at Society of Surgical Oncology 69th Annual Cancer Symposium / Speaker / "Bringing Precision Cancer Medicine Forward"/ Boston, Massachusetts/ March 3, 2016

AACR Annual Meeting/AACR President/"Targeting the Breast Cancer Genome and the Shapping of Precision Medicine"/Louisiana/April 14-20, 2016

Fellows of the AACR Academy Induction Ceremony and Celebration Dinner / Keynote Speaker / "Induction Ceremony Speech"/ the Ritz-Carlton New Orleans / New Orleans, Louisiana / April 15, 2016

John Hopkins Intersession Educational Program Talk/Speaker/"Targeting the Breast Cancer Genome and the Shaping of Precision Medicine"/Baltimore, MD/May 18, 2016

ASCO 2016 Annual Meeting/AACR President/Welcome during ASCO/AACR Joint Session/Chicago, IL/June 3-7, 2016

UCLA Distinguished Lecturer/CTSI Seminar/Speaker/"Targeting the Breast Cancer Genome and the Shaping of Precision Medicine"/UCLA, California/June 8, 2016

Institute for Advanced Study SU2C Meeting/ Convergence Meeting at IAS/ Presenter/"Rationale Design of Anticancer Combinations in Breast Cancer"/Princeton, NJ/June 27 – 28, 2016

FDA's Breast Cancer Blueprint Mini-Symposium/Presenter/"Combination Strategies to Overcome Resistance in Metastatic Breast Cancer"/ FDA office in Maryland/July 7, 2016

AACR Think Tank on Genomics and Clinical Medicine/ Session Chair/Panelist/Session 8: Accelerating the Development and Approval of New Drugs/Washington, DC/July 13-15, 2016

2016 Rena Schechter Memorial Lectureship as part of Grand Rounds. On behalf of Siteman Cancer Center/Speaker/"Genomic-driven Clinical Studies in Breast Cancer"/St. Louis, MO/October 12-13, 2016

Margery Price Breast Cancer Lectureship. Mount Sinai Hospital/Speaker/"Targeting the Breast Cancer Genome and the Shaping of Precision Cancer Medicine"/New York, NY/October 27, 2016

MCI Inaugural: Alliance Mtg-Miami Cancer Institute / Speaker / "The Shaping of Precision Medicine in Oncology"/ Miami, FL / January 26 – 28, 2017

NYU Department of Medicine Grand Rounds/Speaker/"Targeting the Breast Cancer Genome and the Shaping of Precision Medicine"/March 22, 2017

Tango – 2017 Founders & Advisors Meeting/Member/Presenter/"Anchor Screens"/July 13, 2017

### **Invited Lectures: International**

6th Breast Cancer Working Conference/ Presentation EORTC: "Anti-Her2/ Monoclonal Antibody Studies in Breast Cancer," /Amsterdam, Holland, 1994

Therapy of Breast Cancer with Monoclonal Antibodies against Her2/Neu and the EGF Receptor / Speaker /Institute Curie/ Paris, France, 1995

International Symposium: Changes in the Treatment of Breast Cancer / Growth Factor Receptors as Targets for Breast Cancer Therapy / Speaker / European Society of Medical Oncology/ Madrid, Spain, 1995

VI Winter Seminar on Oncology Updates / High Risk Breast Cancer: High Dosage Chemotherapy / Speaker / Miguel Servet Hospital, Medical Oncology Department/Formigal, Spain, 1996

Therapy of Breast Cancer with Anti-HER neu Monoclonal Antibodies / Speaker / German Breast Cancer Society Congress/ Gottingen, Germany, 1996

II International Symposium - Changes in the Treatment of Breast Cancer: Growth Factor Receptor Overexpression and Chemosensitivity in Breast Cancer / Speaker / Buenos Aires, Argentina, 1996

International Symposium on Breast Cancer: Advances in Biology and Therapy Antibodies to Growth Factors and Receptors / Lecturer / Hospital Clinic Universitari/ Valencia, Spain, 1996

VI Winter Seminar on Oncology Updates: High Risk Breast Cancer: High Dosage Chemotherapy / Speaker / Miguel Servet Hospital, Medical Oncology Department / Formigal, Spain, 1996

2nd International Symposium: Changes in the Treatment of Breast Cancer / Monoclonal Antibodies Interfering with Signal Transduction pathways in the Therapy of Breast Cancer / Speaker / European Society of Medical Oncology/ Madrid, Spain, 1997

Results of HER2/Neu (C-ErbB-2) Antibody Treatment in Metastatic Breast Cancer / Speaker / 2nd Congress European Society of Gynecology/ Gottingen, Germany, 1997

Advanced Courses on Medical Treatment of Breast Cancer / the Use of Chemotherapy in Woman with Locally Advanced or Metastatic Breast Cancer / Speaker / European School of Oncology/ Budapest, Hungary, 1997

Advanced Courses on Medical Treatment of Breast Cancer: The Use of Chemotherapy in Woman with Locally Advanced or Metastatic Breast Cancer / Speaker / European School of Oncology/ Warsaw, Poland, 1997

VI International Symposium on Biology and Clinic Utility of Tumors Biomarkers: Therapeutic Implications of the Relationship between C-erbB-2 Overexpression and Paclitaxel Sensitivity / Speaker / Barcelona, Spain, 1997

5<sup>th</sup> Course on Advanced Medical Oncology Advanced Breast Cancer / Speaker / San Carlos University Hospital School of Medicine, Complutense University/ Madrid, Spain, 1997

Basic Oncology for Medical Cancer Specialists. Annals of Oncology (Spanish Edition). Diagnostic Implications and Telomerase in Cancer Therapy / Lecturer/ Almagro, Ciudad Real, Spain, 1997

Chemotherapy Intensive / Speaker / European School of Oncology/ Spanish Area, Barcelona, Spain, 1997

Scientific Sessions: Catalan Institute of Oncology. Therapeutic Implication of HER2/Neu in Breast Cancer/ Lecturer / Bellvitge University Hospital/ Barcelona, Spain, 1997

HER2/Neu as a Target for Breast Cancer Therapy / Speaker/National Institute for the Study and Treatment of Tumors/ Milan Italy, 1998

6<sup>th</sup> Course Theoretic and Practical on Medical Oncology Progress “Advanced Breast Cancer” / Lecturer / San Carlos University Hospital, School of Medicine, Complutense University/ Madrid, Spain, 1998

Controlled Clinical Trials in Ovarian and Breast Cancer "New Drugs in Breast Cancer" / Speaker / National Institute for the Study and Treatment of Tumors/ Milan, Italy, 1999

2nd International Symposium on Molecular Biology of Breast Cancer: "The EGF Receptor Family as Targets for Breast Cancer Therapy" / Speaker / Lillehammer, Norway, 2000

2nd European Breast Cancer Conference "C-erb-B2/Neu and prediction of Response to Taxanes and Anthracyclines" and "Monoclonals, Antibody-Toxins and Other Receptor Targeted Approaches" / Speaker / Brussels, Belgium, 2000

25th ESMO Congress. Chairman of the Educational Session: "Therapeutic Antibodies in Oncology"; "Monoclonal Antibodies Directed at Growth factor Receptors" / Lecturer / Hamburg, Germany, 2000

3<sup>rd</sup> Symposium: Reviews on Cancer. "AntiHER2 Therapy, Chemotherapy Combinations and Future Perspectives" / Speaker / Madrid, Spain, 2000

25<sup>th</sup> ESMO Congress. "Therapeutic Antibodies in Oncology" / Chairman/"Monoclonal Antibodies Directed at Growth factor Receptors" / Lecturer / Hamburg, Germany, 2000

Heuson Memorial Lecture / "Growth Factors as Targets for Cancer Therapy" / Speaker / 3rd Annual Symposium of the Belgium Society of Medical Oncology / Brussels, Belgium, 2001

Targeting the Epidermal Growth Factor Receptor / Speaker / 11th International Congress on Anti-Cancer Treatment / Educational Lecturer/ Paris, France, 2001

"Integration of Taxol-Herceptin into the Adjuvant Setting" / Speaker / 7th International Conference - Adjuvant Therapy of Primary Breast Cancer / St. Gallen, Switzerland, 2001

Antibodies to HER2 and EGRF-update on Early Clinical Studies / Current Topics in Breast Cancer Research-IV, Moller Centre/Churchill College/ Cambridge, United Kingdom, 2001

10th Anniversary of Medical Oncology in Pisa. "New Perspectives in Medical Oncology" / Lecturer / St. Chiara Hospital / Pisa, Italy, 2001

Oncology Seminars "RAS Farnesol Inhibitors Transferase" / Lecturer / Segovia, Spain, 2001

"Monoclonal Antibody-Directed Cytotoxic Therapy in Breast Cancer" / Speaker / the Madrid Breast Cancer Conference on Changes in the Treatment of Breast Cancer/ Madrid, Spain, 2001

Emerging Role of Receptor-Based Therapy in Breast Cancer / 5th Pan-European Cancer Symposium: A New Era in the Management of Breast Cancer: Improving Outcome by Targeted Treatment/ Speaker / Prague, Czech Republic, 2002

12th International Congress on Anti-Cancer Treatment "EGF EGFR" / Speaker / Paris, France, 2002

27th ESMO Congress - Young Medical Oncologists Forum in Collaboration with the Films Alumni Clum "Education in Modern Medical Oncology" / Lecturer / Nice, France, 2002

27th ESMO Congress - ESMO/ASCO Joint Symposium "Novel Targeted Treatment: is it promise being realized?" "Current Status of Anti-Tyrosine Kinase Receptor Therapies"/ Lecturer / Nice, France, 2002

14th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics "EGF-Receptor Targeting - Clinical Achievements: "Strategies to Optimize Anti-Receptor Therapies"/ Speaker / Frankfurt, Germany, 2002

3rd European Breast Cancer Conference / Chair in Opening Ceremony; "Tyrosine Kinase Inhibitors" / A New Look at Breast Cancer Heterogeneity"/ Lecturer / Barcelona, Spain, 2002

6<sup>th</sup> Symposium: Reviews on Cancer "Monoclonal Antibodies Facing Tيروسина-quinasa Receptors (Anti-EGFR)," / Lecturer / Madrid, Spain, 2002

CNIO Symposium on Basic and Translational Cancer Research. Molecular Pathology and Pharmacogenomics "Clinical Trials in the XXI Century" / Lecturer / Madrid, Spain, 2002

5<sup>th</sup> Course on Medical Oncology. "New Therapeutic Targets", "Monoclonal Antibodies Anti-EGFR y Anti-HER2"/ Speaker / Madrid, Spain, 2002

2<sup>nd</sup> European Spring Oncology Conference (ESOC-2). "Clinical Results Studies with EGFR Inhibitors" and Pharmacodynamic and Molecular Studies for Patients Selection and Monitoring Responses with Molecular targeted Agents" / Lecturer / Malaga, Spain, 2002

European Association for Cancer Research (EACR) – Spanish Association for Cancer Research. Translational Research Symposium/ Chairman / Granada, Spain, 2002

14th International Congress on Anti-Cancer Treatment. Educational Lecture / "New Anti-EGFR Strategies" / Lecturer / Paris, France, 2003

8th International Conference - Primary Therapy of Early Breast Cancer / "Biological Targets in Breast Cancer Therapeutics' & "Future Directions in the Treatment of Early Breast Cancer" / Lecturer / St. Gallen, Switzerland, 2003

Clinical Cancer Research in Europe Symposium / "Advances in Molecular Targeted Therapies" / Lecturer / Milan, Italy, 2003

5th International Congress: Perspectives in Colorectal Cancer-PICC 2003 / "Signal Transduction Inhibition" / Lecturer/ Barcelona, Spain, 2003

1st Nordic Course in Molecular Oncology / "Clinical Studies on Tyrosine Kinases as Cancer Drug Targets" / Speaker / Copenhagen, Denmark, 2003



FLASCA-ASCO Meeting / "Update on Anti-Epidermal Growth Factor Receptor Therapies in Cancer" / Lecturer / Cordoba, Argentina, 2003

The European Cancer Conference - ECCO12 / "EGFR Therapies in Other Tumor Types" / Lecturer / Copenhagen, Denmark, 2003

2nd International Symposium on Signal Transduction Modulators in Cancer Therapy-NDDO Research Foundation Cancer Therapy Conferences Series / "Anti EGFR Antibodies: An Overview"/ Lecturer /Amsterdam, Holland, 2003

5<sup>th</sup> Symposium on Cancer Reviews: Cancer Medical Treatment. "Neoadjuvant Treatment of Breast Cancer: The European Experience"/ Lecturer / Madrid, Spain, 2003

Oncology Seminar. "New Therapeutic Targets" / Lecturer / Santiago de Compostela, Spain, 2003

V Oncology Seminar on "Breast Cancer" / Lecturer / Madrid, Spain, 2003

3<sup>rd</sup> Scientific Symposium Lilly Foundation. "Tyrosine Kinase Inhibitors"/ Lecturer / Madrid, Spain, 2003

IX Spanish Society of Medical Oncology Symposium. "Oncology Investigation" / Lecturer / Tenerife, Spain, 2003

Seminar on Prostate, Breast and Ovarian Cancer. "Biological Therapies" / Lecturer / Menendes y Pelayo International University/ Santander, Spain, 2003

Cancer Complexity 2004 Symposium / "Complexity and Intervention Strategies II" / Lecturer / Institute Gustave-Roussy / Villejuif, France, 2004

Inspiration for Life: Optimizing Survival in Breast Cancer / "HER-Targeted Therapies: Using Tumor Biology to Guide Drug Development" / Lecturer / Prague, Czech Republic, 2004

4th European Breast Cancer Conference / "Optimal Management of the Patient with a Her2 Overexpressing Tumor" and "Receptor Targeted Therapies" / Lecturer / Hamburg, Germany, 2004

Science Forum "Gefitinib": The developing Science / "Other EGFR Related Approaches"/ Lecturer / London, England, 2004

FECS-AAACR-ASCO Workshop Methods in Clinical Cancer Research / "Translational Medicine" / Keynote Speaker & "Efficacy Studies and Ethical Considerations"/ Session Chair / Flims, Switzerland, 2004

2nd Inter-American Breast Cancer Conference "Targeted Therapies in Breast Cancer-Part II" / Lecturer / Cancun, Mexico, 2004

16th EORTC-NCI-AAACR Symposium on Molecular Targets and Cancer Therapeutics / Chair of Plenary Session & Poster Discussant / Geneva, Switzerland, 2004

The European Society for Therapeutic Radiology and Oncology (ESTRO 23) / "Pharmacodynamic Endpoints in the Clinical Development of Molecularly Targeted Agents" / Lecturer / Amsterdam, Holland, 2004

29th ESMO Congress "Critical Issues in Molecular Targeted Therapies" / Lecturer / Vienna, Austria, 2004

29th ESMO Congress "Critical Issues in Molecular Targeted Therapies" / Lecturer / Vienna, Austria, 2004

6th International Workshop on Pharmacodynamics of Anticancer Agents / "Pharmacodynamics of EGFR-Targeting Drugs" / Lecturer / Venice, Italy, 2004

XXXI Symposium Internacional Oncologia Mamaria / "Monoclonal Antibody Therapy / Keynote Lecturer / Barcelona, Spain, 2004

CNIO Symposium on Molecular Taxonomy of Cancer. "Pharmacodynamic Endpoints and Patient Selection with Targeted Therapies" / Lecturer / Madrid, Spain, 2004

VI Symposium on Cancer Reviews. "Limitations of Directed Treatments against EGFR in the Treatment of Cancer of the Colon, Lung, Head and Neck" / Lecturer / Madrid, Spain, 2004

I Meeting of the Spanish Cooperative Groups, Spanish Society of Medical Oncology. "Relevance on Clinical Investigation on Oncology" / Lecturer / Madrid, Spain, 2004

3<sup>rd</sup> European Spring Oncology Conference (ESOC-3) "Clinical Development of mTOR Targeted Drugs CCI-& (RAD001)" / Lecturer / Marbella, Spain, 2004

II Oncology Seminar for the Pharmaceutical Industry. "The importance of the Medical Oncology Investigation" / Lecturer / Guadalajara, Spain, 2004

CNIO. Master en Oncologia Molecular "Concept of Molecular Oncology and Its Actual Developer Level" / Lecturer / Madrid, Spain, 2004

Colloquium "Present and Future of the Biomedical Research in the University Hospitals" / Participant / Sevilla, Spain, 2004

XI Santiago Ramon y Cajal Medical Lecture organized by the Queen Sofia Spanish Institute of New York with the presence of Her Majesty Queen Sofia of Spain. "Advances in the Treatment of Cancer in the Genomic Era: Evolution or Revolution?" / Lecturer / Barcelona, Spain, 2004

Teknon Medical Center. Barcelona Pharmaceutical Association: Conference Series: Health Meditation: "Cancer Treatment in 2004: Advances and Challenges" / Lecturer / Barcelona, Spain, 2004

Molecular Targeted Therapy of Cancer. "Targeting EGFR – A Promising Clinical Therapeutic Approach," / Barcelona, Spain, 2004

Appropriate Dose-Optimal Results. Scientific Course “The Dose-dense Concept Needs to Take anew Drugs Adapted to Tumor Biology in Account” / Lecturer / Barcelona, Spain, 2004

3<sup>rd</sup> Annual Symposium on Anti-Signaling Strategies in Human Neoplasia. “Pharmacodynamic Endpoints of Target Inhibition and Biological Activity in Clinical Trials with Anti Signaling Agents” / Lecturer / “Molecular and Signaling Profiling in Patient Selection and Monitoring / Session Chair/ Barcelona, Spain, 2004

Colloquium. The Future of Medicine: from Disappointment to Hope. “Future Hopes and Progress in Medicine” / Lecturer / Barcelona, Spain, 2004

9th International Conference - Primary Therapy of Early Breast Cancer 2005 / "Novel Biological Therapeutic Targets" / Lecturer / St. Gallen, Switzerland, 2005

16th International Congress on Anti-Cancer Treatment / "New Targeted Therapies" / Lecturer / Paris, France, 2005

3rd International Symposium on Targeted Anticancer Therapies (TAT 2005) / "Antibodies Directed Against the Her Family of Receptors" / Lecturer / Amsterdam, Holland, 2005

87th American Radium Society (ARS) / Keynote Speaker / Barcelona, Spain, 2005

World Congress on Lung Cancer Session: / "Targeted Therapies I" "current Issues in translational research and targeted therapies" / Co-Chair and Discussant / and "Biotherapies and molecular targeted therapies in the adjuvant setting" / Co-Chair & Lecturer / Barcelona, Spain, 2005

The European Cancer Conference - ECCO13 / "Basic Science/Medicine" and "Breast Cancer" / Speaker / Paris, France, 2005

VI Oncology Seminar. “Drug Development in the Genomic Age” / Lecturer / Segovia, Spain, 2005

6<sup>th</sup> Breast Cancer Conference: Changes in the Treatment of Breast Cancer “The Role of Small Molecules TKI” / Lecturer / Madrid, Spain, 2005

X Spanish Society of Medical Oncology Symposium. Session “Breast II: Advanced Illness” / Chair/ Zaragoza, Spain, 2005

Spanish Association against Cancer Forum. “Achievements and Deceptions on the Battle against Cancer” / Lecturer / Madrid, Spain, 2005

Teknon Medical Center. Barcelona Pharmaceutical Association: Conference Series: Health Dialogues: “Advances in Breast Cancer Treatment” / Lecturer / Barcelona, Spain, 2005

Closing Ramon y Cajal Lectures. “From the Laboratory to the Patient: The promise of Molecular Medicine in the Fight against Cancer” / Lecturer / Barcelona, Spain, 2006

5th International congress on Breast Cancer: From Gene to Cure / "Her2-Neu" / Speaker / Amsterdam, Holland, 2006

5th European Breast Cancer Conference / "Novel Approaches to Targeting the ErbB Pathway in Breast Cancer / Presidential Symposium Speaker / Nice, France, 2006

19th European Association for Cancer Research (EACR) Meeting / "Targeted Therapy" Presentation of the prestigious Mike Price Award / Lecturer / Budapest, Hungary, 2006

International Breast Cancer Symposium / "Optimal Use of Herceptin in Breast Cancer Adjuvant Therapy"/ Speaker / Taipei, Taiwan, 2006

The 7th International Conference of the Asian Clinical Oncology Society (ACOS) and CSCO-ASCO-ESMO Joint Symposium / "Genetic Profiling of Breast Cancer"/ Speaker / Beijing, China, 2006

31st ESMO Congress / "Practical Examples Based on Published Papers" and "How to Write a Translational Research Paper. The Editor's Point of View" / Co-Chair & Session Speaker/ "Management of Advance Breast Cancer in 2006: Evolving Options" / Special Symposium Speaker/ "Evolving Landscape in Advanced Breast Cancer: from Genomic Signatures to Novel Agents" / Chair Symposium & Lecturer/ "Should we Use Gene Signatures to Guide Treatment Decisions Today? The Example of Breast Cancer" / Controversy Session, Pro-Speaker/ "Trastuzumab plus Anastrozole Prolongs Progression-Free Survival in Postmenopausal Women with HER2-Positive, Hormone-Dependent Metastatic Breast Cancer (MBC) / Presidential Symposium / Discussant / Istanbul, Turkey, 2006

18th EORTC-NCI-AACR Symposium "Targeted Therapies" / Michael Clavel Lecturer/"Antibody versus Small Molecule Inhibitors of Receptor Tyrosine Kinases" / Plenary Session/ "Combination of Monoclonal Antibodies and Tyrosine Kinase Inhibitors with the Same Target"/ Speaker / Prague, Czech Republic, 2006

VII Congress of the Italian Association of Medical Oncology (AIOM) / "New Frontiers of the Therapies of Breast Cancer" / Special Session; Update on Her2 Targeting in Breast Cancer" / Lecturer / Milan, Italy. 2006

Seminars on Science and Society. "Cornering Cancer" / Lecturer / Madrid, Spain, 2006

4<sup>th</sup> European Spring Oncology Conference (ESOC-IV) "Determinants of Response to ErbB Receptor Inhibitors" / Co-Chair and "Lapatinib in Breast Cancer: Place for Hope" / Speaker / Marbella, Spain, 2006

CNIO Symposium on Molecular Markers in Cancer Therapy "Incorporating Molecular Markers in Early Clinical Trials with Targeted Agents" / Keynote Lecturer / Madrid, Spain, 2006

German Breast Group Annual Meeting / "From Bench to Bedside-Current Understanding of Her2-Positive Disease / Keynote Lecturer / Frankfurt, Germany, 2007

ESMO Conference Lugano (ECLU). ESMO Young Oncologists Master class I: Practical Aspects for A Successful Career in Oncology;" / "How can ESMO Help Young Oncologists and how can Young Oncologists Help ESMO" / Speaker / 6th ESMO Patient Seminar "Latest Developments in Breast Cancer" / Session Co-Chair/ Breast Controversy Session: "Will Molecular Diagnostics Become Part of Routine Clinical Practice?" "Pro" Speaker "Yes" Argument / Lugano, Switzerland, 2007

34th Symposium Internacional Avances y Controversias en Ginecologia Oncologica de la Fundacion santiagoDexeus / "New Drugs in the Therapy of Ovarian Cancer" / Lecturer / Barcelona, Spain, 2007

Institute Claudius Regaud / "New Approaches in the Therapy of Breast Cancer" / Lecturer / Toulouse, France, 2007

The Euro-Region Academic-Industrial Partnering Conference / "New Challenges in Oncology" / Keynote Lecturer / Toulouse, France, 2007

VII Madrid Breast Cancer Conference. "Targeted Therapy: Present and Future" Co-Chair of Symposium "Novel Targeted Agents in the Treatment of Breast Cancer" / Lecturer / Madrid, Spain, 2007

I Seminar on Cancer Strategies. National Health Department. "Practical, Clinical and Investigative Epidemiology" / Roundtable Chair / Madrid, Spain, 2007

Severo Ochoa Lecture organized by the Queen Sofia Spanish Institute of New York with the presence of Her Majesty queen Sofia of Espana y los Hospitales Ruber "Cancer, its treatment: Realities and Hopes" / Lecturer / Madrid, Spain, 2007

XI Spanish Society of Medical Oncology Symposium. "Advances in Breast Cancer 2007: from Genomic Signatures to New Therapies" / Presidential Session Lecturer / Madrid, Spain, 2007

European Cancer Conference – ECCO 14. "Approaches to Targeted Therapy Optimization: The epidermal Growth Factor Receptor Family as a Model System" / Keynote Lecturer/ "Advances in New Drugs for Breast Cancer" Scientific Symposium "The Pros and Cons of Signal Transduction Inhibitors in Breast Cancer" / Symposium Chair & Lecturer / Barcelona, Spain, 2007

XV Professional Schools and Association Annual Meeting. "Biomedical Research. Promises and Opportunities" / Lecturer / Barcelona, Spain, 2007

I Symposium Esteve on Breast Cancer. "Hormonal Therapy in Breast Cancer, New Combinations" / Co-Chair & Lecturer / Barcelona, Spain, 2007

The 6th European Breast Cancer Conference (EBCC-6) / "Targeting Her Family" / Lecturer / Keynote Symposium on Challenges in breast cancer molecular targeting / Berlin, Germany, 2008

13th Taiwan Joint Cancer Conference / "Novel approaches with targeted therapy in breast cancer: Anti-Her2 agents and beyond" / Lecturer / Taipei, Taiwan, 2008

33rd ESMO Congress / "Understanding and Preparing a Paper on Translational Research. How to Write a Translational Research paper" / "Novel Agents in the Era of Targeted Therapy - What have we Learned and How has our Practice Changed?" / Lecturer / Stockholm, Sweden, 2008

AACR Centennial Conference Translational Cancer medicine 2008: Bridging the Lab and the Clinic in Cancer medicine / "Biomarker Driven Clinical Trials with Molecular Targeted Agents" / Lecturer / Jerusalem, Israel, 2008

The Institute of Cancer Research Distinguished Lecture / "New Directions in Targeting the Her Receptor Family: A Voyage to the Center of the Cell" / London, England, 2008

V European Spring Oncology Conference "Emerging Kinase Targets: Mtor/PI3K Small Molecules Inhibitors and Targeted Agent-based Combination Strategies: Combining Endocrine Therapy and (other) Targeted Therapies" / Lecturer / Malaga, Spain, 2008

XXIX National Meeting of the Society of Gynecologic Oncology and Breast Pathology/ "New Therapeutic Targets in Breast Cancer" / Lecturer / Barcelona, Spain, 2008

British Breast Group Meeting / "New approaches to Anti-HER2 Therapy" / Lecturer / West Midlands, United Kingdom, 2009

20th International Congress on Anti-Cancer Treatment (ICACT) / "Targeting the PI3K Pathway in Cancer" / Presidential Lecturer / Paris, France, 2009

Foundation Ipsen Seminar: Molecular Targets of Cancer Therapy / "Emerging Molecular Targets in Breast Cancer: HER2 and beyond" / Lecturer / Jaipur, India, 2009

11th International Conference primary Therapy of Early Breast Cancer - Evidence, Controversies and Consensus / "Review of New Targeted Drugs: Crawling toward the Adjuvant Setting" / Lecturer / St. Gallen, Switzerland, 2009

IMPAKT 2009 Breast Cancer Conference / "Is Dormancy Targetable? The Clinician: A Point of View" / Lecturer / "Pathways for PI3Kinase Session / Discussant / Brussels, Belgium, 2009

Champalimaud Foundation Cancer Symposium 2009 / " Emerging Molecular Targets in Breast Cancer: HER2 and Beyond" / Speaker / Lisbon, Portugal, 2009

The Institute of Cancer Research Centenary Conference / "Targeting PI3 Kinase in the Clinic" / Lecturer / London, England, 2009

Joint ECCO 15 - 34th ESMO Multidisciplinary Congress Scientific Symposium / Co-Chair / "Resistance Mechanism to EGFR and HER2 Inhibitors and Strategies to Overcome them" / Lecturer / "An Overview of Resistance to Anti-EGFR/HER2 Agents" / Discussant: Presidential Session V Best of 2009 / Berlin, Germany, 2009

XI Congress of the Italian Association of Medical Oncology (AIOM) / "AIOM incontra ESMO" / Chair / Turin, Italy, 2009

Institute Gustave Roussy / "Targeting HER2 Resistance in Breast Cancer" / Lecturer / Villejuif, France, 2009

The 14th Annual Scientific Symposium of Hong Kong Cancer Institute / "Novel directions in the therapy of HER2 positive breast cancer" / Speaker / Hong Kong, Republic of China, 2009

European Society of Cardiology Congress 2009 "Cardiotoxic anti-cancer treatments" "Cardiotoxicity of new anticancer agents" / Lecturer / Barcelona, Spain, 2009

15<sup>th</sup> Scientific Symposium of the Lilly Foundation "Targeting HER2 in Breast Cancer - Novel Therapies and mechanisms of Resistance" / Lecturer / Madrid, Spain, 2009

VIII Madrid Breast Cancer Conference "Pertuzumab, a HER2 Dimerization Inhibitor, as novel Anti-HER2 therapy of Breast Cancer" "The Role of M-TOR/PI3K Inhibitors in the Treatment of Breast Cancer" / Lecturer / Madrid, Spain, 2009

XII Spanish Society of Medical Oncology National Symposium. "Emerging Molecular Therapies in the Treatment of Breast Cancer" / Lecturer / Barcelona, Spain, 2009

King Jaime I Foundation. "New Therapeutic Targets in Breast Cancer" / Distinguished Lecturer / King Jaime I Awards / Barcelona, Spain, 2009

Institute of Medical Biology / "Targeting the PI3K Pathway as Cancer Therapeutics" / Distinguished Lecturer / Singapore, Singapore, 2010

ACCR Translational Cancer Medicine / "Targeting PI3K in Breast Cancer" / Lecturer / Amsterdam, Netherlands, 2010

MK8669 Protocol 041 Investigator Meeting / "Current Trends in Breast Cancer" / Co-Lead Investigator / Prague, Czech Republic, 2010

35th European Society of Medical Oncology (ESMO) / "Treatment of Her-2 Neu Overexpressing breast cancer" / Chair / Milan, Italy, 2010

PRIME Oncology Satellite Symposium at the 35th European Society of Medical Oncology (ESMO) Cases in Contemporary Breast Oncology / "Strategies for improving outcomes in HER2-negative breast cancer" / Faculty Speaker / Milan, Italy, 2010

35th European Society of Medical Oncology (ESMO) / "Diagnostic management issues in breast cancer Tx of Her2-Neu overexpressing Breast Cancer" / Speaker / Milan, Italy, 2010

35th European Society of Medical Oncology (ESMO) / "The addition of cetuximab to cisplatin increases overall response rate" / Speaker / Milan, Italy, 2010

SOLTI Scientific Meeting 2010 / "Transatlantic Partnerships" / Inaugural Lecturer / Madrid, Spain, 2010

7<sup>th</sup> European Breast Cancer Conference (EBCC). / Chair/Clinical Science Symposia: "Multi-Targeting Therapies in Breast Cancer"/ Lecturer / "Multiple Pathway Targeting Strategies in HER2 Over-expressing Breast Cancer Points" /Chair and Discussant/"Europa Donna Wrap Up Session," / Barcelona, Spain, 2010

Plenary Session Leader: Novel Clinical Paradigms in Personalized Medicine.  
/ Speaker / Combinatorial approaches to prevent adoptive responses to targeted therapeutics in breast cancer. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, 2011

Plenary Session Leader: Novel Clinical Paradigms in Personalized Medicine / Speaker / Combinatorial approaches to prevent adoptive responses to targeted therapeutics in breast cancer. / AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, 2011

Understanding Life, Royal Netherlands Academy of Arts and Sciences / Speaker / Amsterdam, Netherlands, 2011

IBCC-5 / "Pathways for PI3K and ErbB inhibition" / Speaker / Paris, France, 2011

12th International St. Gallen Breast Conference / "Multiple cellular pathways: Evolving targets for successful treatment" / Speaker / St. Gallen, Switzerland, 2011

ESMO IMPAKT Breast Cancer Conference / "IGF1R + mTOR," / Speaker / Brussels, Belgium, 2011

Canadian Breast Cancer Symposium / "Targeting the PI3K Pathway in Breast Cancer," / Speaker / Toronto, Ontario, 2011

International Academy for Advanced Oncology (IAAO) Oncology Forum 2011 / "PI3K Pathway: Therapeutic Targeting of Malignancy" / Speaker / Tokyo, Japan, 2011

Bayer 1244 Investigator Meeting, Latin America / "MBC Treatment Landscape" / Speaker / Buenos Aires, Argentina, 2011

European Multidisciplinary Cancer Congress 2011/ "Personalized Medicine is the Future" / Speaker / Stockholm, Sweden, 2011

European Multidisciplinary Cancer Congress 2011 / "mTOR an Attractive Drug Target in Breast Cancer: How to Reverse Resistance to mTOR Inhibitors" / Speaker / Stockholm, Sweden, 2011

European Multidisciplinary Cancer Congress 2011 / "Everolimus in Combination with Exemestane for Postmenopausal Women with Advanced Breast Cancer Who Are Refractory to Letrozole or Anastrozole: Results of the BOLERO-2 Phase III Trial" / Speaker / Stockholm, Sweden, 2011



IX Madrid Breast Cancer Conference / "Biomarker Analysis for the Selection of anti-HER2 Targeted Treatment: Ready for Its Use in the Clinic?" / Speaker / Madrid, Spain, 2011

8th European Breast Cancer Conference / "Modulation of Resistance to Hormonal Agents / Speaker / Vienna, Austria, 2012

ESMO / "Can neo-adjuvant breast cancer data be used to accelerate drug approval?" / "New Targeted Agents in Luminal BC" / Speaker / Vienna, Austria, 2012

IMPAKT Breast Cancer Conference / "Clinical Perspectives and Implications for Biomarker Development" / Keynote Speaker / Brussels, Belgium, 2012

UAE Cancer Congress / Keynote Speaker / Dubai, UAE / October 11-13, 2012

13th International St.Gallen Breast Cancer Conference / Discussion of Clinical Trials-APHINITY (BIG) and NeoALTTO (SOLTI)/ St. Gallen, Switzerland / March 13, 2013

LEAD Summit XI/ Breakout Session: Clinical Data on Molecular Determinants of Sensitivity and Pathway Interactions / Speaker / Budapest, Hungary / June 28, 2013

US Oncology Forum/ Speaker/ "Targeting the PI3K/mTOR pathway in Breast Cancer: From mTOR to PI3K alpha specific inhibitors" / September 13, 2013

European Cancer Congress 2013 (ECCO-ESMO-ESTRO) /Speaker and Chair/  
Sept 29: Speaker: PI3KCA mutations and correlation with pCR in the NeoALTTO trial (BIG 01-06)  
Sept 29: Chair: Drug Development Scientific Symposium: Optimal use of Targeted Kinase Inhibitors (TKIs)  
Sept 29: Speaker /"The concept of Basket Trials and Concluding Remarks"/ Amsterdam, Netherlands/  
September 28- October 1, 2013

Nature-CNIO Cancer Symposium/ Keynote Speaker / "Targeting tumor heterogeneity and plasticity: A view from the clinical side"/ Madrid, Spain/ October 30, 2013

IPSEN Foundation 30<sup>th</sup> Anniversary Conference on Cancer Science / Chair, Session 8 / Chantilly, France/April 14, 2014

LEAD Summit XII/ Breakout Session: Treatment Landscape Patient Selection / Speaker / Montreal, Canada / June 20, 2014

ESMO 2014 Congress/Co-Chair and Presenter/Special Session: Precision medicine: Panacea or false dawn? / "Drug registration strategies: How will these change with precision medicine?"/ Madrid, Spain / September 29, 2014

Ramón Areces Foundation's Advanced Oncological Therapies Symposium/ Speaker /"The road to precision medicine in cancer therapy"/ Madrid, Spain / October 15, 2014

DAVOS World Economic Forum/ Panelist and Discussion Leader / January 21-24/ Jan 21: Panelist: A New Era in the Fight Against Cancer Session/ Jan 23: Discussion Leader: Cancer- Pathways to a Cure Session / Davos-Klosters, Switzerland, 2015

14<sup>th</sup> St. Gallen International Breast Cancer Conference Primary Therapy of Early Breast Cancer / Session Speaker / “Targeting PIK3CA pathway”/ Vienna, Austria/ March 19, 2015

Annual Pezcoller Symposium/ Speaker & Moderator / Clinical Research Roadblocks/”Targeting tumor heterogeneity” / Trento, Italy / June 20, 2015

EACR-AACR-SIC Special Conference 2015/ Keynote Speaker / “Genomically-Driven “Basket” Clinical Trials” /Florence, Italy/ June 21, 2015

World Economic Forum Annual Meeting/Cancer Moonshot: A Call to Action / Panelist & Discussion Leader / Davos-Klosters, Switzerland/ January 19-23, 2016

ISREC Symposium 2016/Presenter/”Targeting Actionable Mutations in Breast Cancer”/Lausanne, Switzerland/September 7-10, 2016

Japanese Cancer Association Annual Meeting in Yokohama, Japan for AACR/Presenter/”Genomic-driven clinical studies in breast cancer”/Yokohama, Japan/October 6-8/2016

AACR New Horizons Conference/Keynote Speaker/”Genomic-Driven Clinical Studies in Breast Cancer”/Shanghai, China/November 2, 2016

AACR New Horizons Conference/Presenter/”Getting your Research Published”/Shanghai, China/November 3, 2016

15<sup>th</sup> St. Gallen International Breast Cancer Conference/”Targeting PIK3CA pathways”/Vienna, Austria/March 15 – 18, 2017

Prime Oncology Symposium/”Thoughts from a grand master: Biological insights into improved HER2 targeting”/Vienna, Austria/March 16, 2017

13<sup>th</sup> Ispen Cancer Series Mtg/”Integration of immunotherapy with other targeted therapies”/Johannesburg, South Africa/April 22 – 26, 2017

Sergio Lombroso Trust and the Weitzmann Institute of Science/”Targeting the Breast Cancer Genome and the Shaping of Precision Medicine”/David Lopatie Conference Center in Rehovot, Israel/May 14, 2017

Worldwide Innovative Network Consortium 9<sup>th</sup> Annual Symposium in Personalized Cancer Medicine (WIN 2017 symposium Mendolsohn) / Keynote Lecturer / “Genomic-driven clinical studies in breast cancer” /Paris, France? June 24 – 26, 2017

## **J. PROFESSIONAL MEMBERSHIPS**

<i>Activity</i>	<i>Dates</i>
<i>American College of Physicians</i> Member	1990-Present
<i>American Society of Clinical Oncology (ASCO)</i> Member	1990-Present
Board of Directors	2003-2006
Chair, Annual Meeting, Subcommittee Breast Cancer	2005
International Affairs Committee	2003-2006
Educational Committee	2003-2006
Strategic Planning Committee	2003-2006
Grant Selection Committee	2005-2006
Annual Meeting Subcommittee Developmental Therapeutics	2005-2006
Trials in Progress Track, Scientific Program Committee	2008-2011
Special Awards Selection Committee	2010-2013
Co-Chair, ASCO/AACR Session, Metastasis: Progress in Translational & Clinical Research	2013
<i>American Association for Cancer Research (AACR)</i> Member	1990-Present
92 <sup>nd</sup> AACR Annual Meeting, Scientific Committee	2001
International Conference on Molecular Targets & Therapeutics, Scientific Committee	2001
Clinical Cancer Research Committee	
94 <sup>th</sup> AACR Annual Meeting, Educational Committee	2003
Pezcoller Foundation- AACR International Award for Cancer Research Selection Committee	2004-2005
Chair, 96 <sup>th</sup> AACR Program Subcommittee, Experimental Therapeutics Section	2005
96 <sup>th</sup> Annual AACR Annual Meeting, Clinical Cancer Research Committee	2005
AACR Oncogenomics Conference, Program Committee	2005
Co-Chair, 97 <sup>th</sup> AACR Annual Meeting, Program Committee	2006
Dorothy P. Landon-AACFR Prize Committee for Translational Research Selection Committee	2006-2008
Co-Chair, AACR Special Conference, Drugging the Genome	2006
International Affairs Committee	2007-2010
Special Conference Committee	2007-2010
Board of Directors	2008-2011
98 <sup>th</sup> AACR Annual Meeting, Program Subcommittee, Experimental Therapeutics Section	2008
99 <sup>th</sup> AACR Annual Meeting, Program Committee, Experimental and Molecular Therapeutics Section and Mechanisms of Drug Action Subcommittee	2008
AACR-NCI-EORTC Molecular Targets Conference, Scientific Committee	2008
AACR's Translational Cancer Medicine Conference Series, 3 <sup>rd</sup> Joint American-Israeli Conference on Cancer, Program Committee	2008

AACR Centennial Conference on Translational Cancer Medicine 2008: Advances in Biology Driven Cancer Clinical Trials, Organizing Committee	2008
Chair, Landon Foundation-AACR Innovator Award for International Collaboration in Cancer Research, Scientific Review Committee	2009
100 <sup>th</sup> Annual Meeting, Education Committee	2009
Co-Chair, 101 <sup>st</sup> Annual Meeting, Program Committee	2010
8 <sup>th</sup> AACR-Japanese Cancer Association International Conference, Organizing Committee	2010
AACR Translational Cancer Medicine 2010 Conference, Program Committee	2010
Chair, Clinical Trials Committee, AACR	2012-2013
Chair, 2013 Annual Meeting Program Committee	2012-2013
AACR Annual Meeting Clinical Trials Committee	2013-2015
Fellow, AACR Academy Class of 2014	2014-Present
President-Elect, AACR	2014-2015
President, AACR	2015-2016
Past President, AACR	2016-Present
<i>Spanish Cooperative Breast Cancer Group (SOLTI)</i>	
Member	1996-Present
Scientific Committee	2000-2009
<i>Spanish Society of Medical Oncology</i>	
Member	1996-Present
<i>European Society of Medical Oncology (ESMO)</i>	
Member	1996-Present
Scientific Committee, 27 <sup>th</sup> European Society for Medical Oncology Congress	2002
Member & Chair, Scientific Committee, 29 <sup>th</sup> European Society for Medical Oncology Congress	2004
President, Young Medical Oncologists (YMO) Working Group	2004-2008
Member & Chair, Scientific Committee, 31 <sup>st</sup> European Society for Medical Oncology Congress	2006 2006-2012
Member, Board of Directors	
President, 33 <sup>rd</sup> European Society for Medical Oncology Congress	2008
President	2008-2009
Founder & Co-Chair, IPAKT Breast Cancer Conference	2009
Co-Founder, 2010 IPAKT Breast Cancer Conference	2010
Member, Executive Committee, 2011 IPAKT Breast Cancer Conference	2011
<i>The American Society of Breast Disease</i>	
Member	1999-Present
<i>Spanish National Cancer Research Center</i>	
Scientific Advisory Board	2000-2003
Member, Board of Directors	2004-2009

<i>Foundation for Oncology Studies and Research (FERO)</i>	
Member	2000-
Founder, FERO	2000-2007
 <i>European Cancer Organization</i>	
Member	2002-Present
National Organizer Committee, 3 <sup>rd</sup> European Breast Cancer Conference	2002
Scientific Committee, Science & Basic Medicine, The European Cancer Conference – ECCO 12	2003
Scientific Committee, 4 <sup>th</sup> European Breast Cancer Conference-EBCC 4	2004
Scientific Committee, Science & Basic Medicine, The European Cancer Conference – ECCO 13	2005
Vice President, the European Cancer Conference-ECCO 14	2007
Member, Board of Directors	2008-2009
Member, Organizing and Executive Scientific Program Committees, Joint European Cancer Conference-ECCO 15-34 <sup>th</sup> European Society for Medical Oncology Multidisciplinary Congress	2009
Member, Board of Directors (re-elected)	2010-2011
 <i>European Commission-Research Management</i>	
Member	2002-Present
Expert Assessor & Member, Genomics & Biotechnology for Health (combating cancer) Expressions of Interest	2002
 <i>European Organization for Cancer Research and Treatment of Cancer (EORTC)</i>	
Member	2003-Present
Board of Directors	2003-Present 2003-2006
 <i>International Agency for Research on Cancer (IARC) Scientific Committee</i>	
Member	2004-2009
 <i>American Society of Clinical Investigation (ASCI)</i>	
Member	2004-Present
 <i>The Prince of Asturias Foundation</i>	
Jury, Prince of Asturias Award in the category of Scientific Investigation	2004-2006
 <i>National Cancer Institute, France</i>	
International Advisory Board	2005-2007
 <i>Ludwig Institute for Cancer Research</i>	
Scientific Advisory Committee	2006-2016
 <i>American-Italian Cancer Foundation</i>	
Scientific Advisory Board	2008-2011

<i>San Antonio Breast Cancer Symposium (SABCS)</i> Program Planning Committee	2008
Systemic Therapies I- Targeted Abstract Review Committee	2011
<i>Breast International Group</i> Board of Directors	2010-Present
<i>Susan G. Komen for the Cure</i> Scientific Advisory Board	2012-Present
<i>Aura Biosciences Inc.</i> Board of Directors	2013-Present
<i>Infinity Pharmaceuticals</i> Board of Directors	2014-Present
<i>Juno Therapeutics</i> Scientific Advisory Committee	2014-Present
<i>TANGO (formerly called Synthetic Lethal)</i> Co-Founder	2016-Present
<i>GRAIL</i> Chair, Scientific Advisory Committee	2016-Present
Member, Board of Directors	2017-Present
<i>Siteman Cancer Center, Washington University in St. Louis</i> Member, External Advisory Committee	2016-Present
<i>Varian, Inc.</i> Member, Board of Directors	2017-Present
<i>Foghorn Therapeutics, Inc.</i> Member, Board of Directors	2017-Present

## **K. HONORS AND AWARDS**

<i>Name of award</i>	<i>Date</i>
Annual Research Competition for Residents First Prize, Department of Medicine State University of New York Health Sciences Center	1989
Lederle Scholar in Clinical Oncology Memorial Sloan Kettering Cancer Center	1990

Travel Award, American Society of Clinical Oncology (ASCO)	1992
Young Investigator Award, American Society of Clinical Oncology (ASCO)	1992-1993
Career Development Award, American Society of Clinical Oncology (ASCO)	1994
Young Investigator Award, American Association for Cancer Research (AACR)	1999
Honorary Membership Award: European Society for Therapeutic Radiology and Oncology (ESTRO)	2003
Waun Ki Hong Visiting Professorship, UTMD Anderson Cancer Center	2004
Distinguished Alumni Award, 29 <sup>th</sup> Annual Alumni Society Meeting Memorial Sloan Kettering Cancer Center	2004
Annual Award, European Society of Medical Oncology (ESMO)	2005
Professional Excellence Award in Biomedicine Research Barcelona College of Physicians	2005
City Award, "The Key to the City of Barcelona," Francisco Godia Foundation	2006
Michael Clavel Lecture Award, 18 <sup>th</sup> EORTC-NCI-AACR Symposium on Molecular Targets & Cancer Therapeutics	2006
San Salvatore Prize 2006, San Salvatore Foundation	2006
AICF Prize for Scientific Excellence in Medicine American Italian Cancer Foundation	2007
Civil Order of Health-Commander with Plaque Ministry of Health, Government of Spain	2008
Rosenthal Family Foundation Award American Association for Cancer Research (AACR)	2008
Rey Jaime I Award in Medical Research, King Jaime I Foundation	2008
Bruce A. Chabner Chair in Hematology Oncology Massachusetts General Hospital Center	2010
Bob Pinedo Cancer Care Prize, The Society for Translational Oncology (STO)	2010
Gold Medal, Queen Sofia Spanish Institute	2010

Honorary Doctoral Degree, Valencia University	2011
Joseph B. Martin Award, Massachusetts General Hospital	2012
Mike Price Gold Medal Award The European Association for Cancer Research	2012
Second International Award for Cancer Research Foundation Carregal Ramiro La Rosaleda	2013
Elected Fellow of the AACR Academy Class of 2014	2014
President-Elect, AACR	2014-2015
Elected Member of the Association of American Physicians	2014
Susan Komen Physician Impact Award	2014
Honorary Member, Royal National Academy of Pharmacy, Spain	2014
Elected Member, Institute of Medicine of the National Academies	2014
Thomson Reuters, Highly Cited Researcher in the Field of Clinical Medicine	2014
President, AACR	2015-2016
John Wayne Clinical Research Lecture Award, Society of Surgical Oncology	2016
XXVIII Catalonia International Prize (XXVIII Premi Internacional Catalunya)	2016
Sergio Lombroso Award in Cancer Research, Sergio Lombroso Trust and the Weizmann Institute of Science	2017
Lifetime Achievement Award, European Society for Medical Oncology	2017



## L. BIBLIOGRAPHY

### Peer-Reviewed Articles

1. Martínez Pérez J, **Baselga J**, Monsó E, Fernández JM. "Value of the electrophysiologic study of the diaphragm in the diagnosis of phrenic paralysis". *Med Clin (Barc)*. 1985 Apr 30;84(16):674. . PubMed PMID: 4033244.
2. Casper ES, **Baselga J**, Smart TB, Magill GB, Markman M, Ranhosky A. "A phase II trial of PALA + dipyridamole in patients with advanced soft-tissue sarcoma." *Cancer Chemother Pharmacol*. 1991;28(1):51-4. PubMed PMID: 2040033.
3. **Baselga J**. "Sarcoma of soft tissue". *Med Clin (Barc)*. 1991 Jan 12;96(1):16-7. Spanish. PubMed PMID: 2023463.
4. **Baselga J**, Reich L, Doherty M, Gulati S. "Fat embolism syndrome following bone marrow harvesting." *Bone Marrow Transplant*. 1991 Jun;7(6):485-6. PubMed PMID: 1873595.
5. Atlas I, Mendelsohn J, **Baselga J**, Fair WR, Masui H, Kumar R. "Growth regulation of human renal carcinoma cells: role of transforming growth factor alpha." *Cancer Res*. 1992 Jun 15;52(12):3335-9. PubMed PMID: 1596891.
6. **Baselga J**, Kris MG, Scher HI, Phillips M, Heelan RT. "Phase II trial of gallium nitrate in previously treated patients with small cell lung cancer." *Invest New Drugs*. 1993 Feb;11(1):85-6. PubMed PMID: 8394297.
7. **Baselga J**, Krown SE, Telzak EE, Filippa DA, Straus DJ. "Acquired immune deficiency syndrome-related pulmonary non-Hodgkin lymphoma regressing after zidovudine therapy." *Cancer*. 1993 Apr 1;71(7):2332-4. PubMed PMID: 8453555.
8. Rusch V, **Baselga J**, Cordon-Cardo C, Orazem J, Zaman M, Hoda S, McIntosh J, Kurie J, Dmitrovsky E. "Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung." *Cancer Res*. 1993 May 15;53(10 Suppl):2379-85. PubMed PMID: 7683573
9. **Baselga J**, Norton L, Masui H, Pandiella A, Coplan K, Miller WH Jr, Mendelsohn J. "Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies." *J Natl Cancer Inst*. 1993 Aug 18;85(16):1327-33. PubMed PMID: 8340945.
10. Fan Z, **Baselga J**, Masui H, Mendelsohn J. "Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts." *Cancer Res*. 1993 Oct 1;53(19):4637-42. PubMed PMID: 8402640.
11. **Baselga J**, Maerz WJ, Moy D, Miller WH Jr, Castro L, Reuter VE, Yao TJ, Masui H, Dmitrovsky E. "Over-expression of transforming growth factor alpha antagonizes the anti-tumorigenic but not the differentiation actions of retinoic acid in a human teratocarcinoma cell." *Oncogene*. 1993 Dec;8(12):3257-63. PubMed PMID: 8247529.
12. **Baselga J**, Mendelsohn J. "The epidermal growth factor receptor as a target for therapy in breast carcinoma." *Breast Cancer Res Treat*. 1994 Jan;29(1):127-38. Review. PubMed PMID: 8018961.

13. Miller WH Jr, Maerz WJ, Kurie J, Moy D, **Baselga J**, Lucas DA, Grippo JF, Masui H, Dmitrovsky E. "All-trans-retinoic acid and hexamethylene bisacetamide (HMBA) regulate TGF-alpha and Hst-1/kFGF expression in differentiation sensitive but not in resistant human teratocarcinomas." *Differentiation*. 1994 Jan;55(2):145-52. PubMed PMID: 8143931.
14. **Baselga J**, Mendelsohn J. "Receptor blockade with monoclonal antibodies as anti-cancer therapy." *Pharmacol Ther*. 1994 Oct;64(1):127-54. Review. PubMed PMID: 7846112.
15. Ciardiello F, Damiano V, Bianco C, di Isernia G, Ruggiero A, Caraglia M, Tagliaferri P, **Baselga J**, Mendelsohn J, Bianco AR, et al. "Cooperative antiproliferative effects of 8-chloro-cyclic AMP and 528 anti-epidermal growth factor receptor monoclonal antibody on human cancer cells." *Clin Cancer Res*. 1995 Feb;1(2):161-7. PubMed PMID: 9815969.
16. Seidman AD, Reichman BS, Crown JP, Yao TJ, Currie V, Hakes TB, Hudis CA, Gilewski TA, **Baselga J**, Forsythe P. "Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response." *J Clin Oncol*. 1995 May;13(5):1152-9. PubMed PMID: 7537798.
17. Seidman AD, Tiersten A, Hudis C, Gollub M, Barrett S, Yao TJ, Lepore J, Gilewski T, Currie V, Crown J, Hakes T, **Baselga J**, Sklarin N, Maynihan ME, Tong W, Egorin M, Kearns C, Springgs D, Norton L. "Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer." *J Clin Oncol*. 1995 Oct;13(10):2575-81. PubMed PMID: 7595709.
18. Seidman AD, Hudis CA, Fennelly D, Raptis G, **Baselga J**, Norton L. "Memorial Sloan-Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer." *Semin Oncol*. 1995 Oct;22(5 Suppl 12):108-16. Review. PubMed PMID: 7481852.
19. Hudis CA, Seidman AD, **Baselga J**, Raptis G, Lebwohl D, Gilewski T, Currie V, Moynahan ME, Sklarin N, Fennelly D, et al. "Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes." *Semin Oncol*. 1995 Dec;22(6 Suppl 15):18-23. PubMed PMID: 8643965.
20. Hudis CA, Seidman AD, Crown JP, Balmaceda C, Freilich R, Gilewski TA, Hakes TB, Currie V, Lebwohl DE, **Baselga J**, Raptis G, Gollub M, Robles M, Bruno R, Norton L. "Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer." *J Clin Oncol*. 1996 Jan;14(1):58-65. PubMed PMID: 8558221.
21. Hudis C, Seidman A, Raptis G, Fennelly D, Gilewski T, **Baselga J**, Theodoulou M, Sklarin N, Moynahan M, Surbone A, Currie V, Lebwohl D, Uhlenhopp M, Crown J, Norton L. "Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience." *Semin Oncol*. 1996 Feb;23(1 Suppl 1):58-64. PubMed PMID: 8629040.
22. **Baselga J**, Mendelsohn J, Kim YM, Pandiella A. "Autocrine regulation of membrane transforming growth factor-alpha cleavage." *J Biol Chem*. 1996 Feb 9;271(6):3279-84. PubMed PMID: 8621731.
23. **Baselga J**, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. "Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer." *J Clin Oncol*. 1996 Mar;14(3):737-44. PubMed PMID: 8622019.

24. Zamora-León SP, Golde DW, Concha II, Rivas CI, Delgado-López F, **Baselga J**, Nualart F, Vera JC. "Expression of the fructose transporter GLUT5 in human breast cancer." *Proc Natl Acad Sci U S A*. 1996 Mar 5;93(5):1847-52. Erratum in: *Proc Natl Acad Sci U S A* 1996 Dec 24;93(26):15522. PubMed PMID: 8700847; PubMed Central PMCID: PMC39870.
25. Ribas A, Albanell J, Bellmunt J, Solé-Calvo LA, Bermejo B, Gallardo E, Vidal R, Vera R, Eres N, Carulla J, **Baselga J**. "Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity." *J Clin Oncol*. 1996 May;14(5):1573-80. PubMed PMID: 8622074.
26. Seidman AD, Hochhauser D, Gollub M, Edelman B, Yao TJ, Hudis CA, Francis P, Fennelly D, Gilewski TA, Moynahan ME, Currie V, **Baselga J**, Tong W, O'Donoghue M, Salvaggio R, Auguste L, Spriggs D, Norton L. "Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer." *J Clin Oncol*. 1996 Jun;14(6):1877-84. PubMed PMID: 8656256.
27. Bellmunt J, Eres N, Ribas A, Casado S, Albanell J, **Baselga J**. "Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis." *Cancer Chemother Pharmacol*. 1997;40(3):273-6. PubMed PMID: 9219513.
28. Seidman AD, Hudis CA, Raptis G, **Baselga J**, Fennelly D, Norton L. "Paclitaxel for breast cancer: the Memorial Sloan-Kettering Cancer Center experience." *Oncology (Williston Park)*. 1997 Mar;11(3 Suppl 2):20-8. Review. PubMed PMID: 9110339.
29. **Baselga J**, Seidman AD, Rosen PP, Norton L. "HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications." *Oncology (Williston Park)*. 1997 Mar;11(3 Suppl 2):43-8. Review. PubMed PMID: 9110342
30. **Baselga J**, Mendelsohn J. "Type I receptor tyrosine kinases as targets for therapy in breast cancer." *J Mammary Gland Biol Neoplasia*. 1997 Apr;2(2):165-74. Review. PubMed PMID: 10882302
31. Bellmunt J, Ribas A, Eres N, Albanell J, Almanza C, Bermejo B, Sole LA, **Baselga J**. "Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma." *Cancer*. 1997;80(10):1966-72. Epub 1997/11/20. PubMed PMID: 9366300.
32. Hudis C, Riccio L, Holmes F, Seidman A, **Baselga J**, Currie V, Fennelly D, Gilewski T, Moynahan M, Raptis G, Sklarin N, Surbone A, Uhlenhopp M, Maickel N, Yao TJ, Hellmann S, Usakewicz J, Hortobagyi G, Norton L. "Phase II study of semisynthetic paclitaxel in metastatic breast cancer." *Eur J Cancer*. 1997 Nov;33(13):2198-202. PubMed PMID: 9470806.
33. Bos M, Mendelsohn J, Kim YM, Albanell J, Fry DW, **Baselga J**. "PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner." *Clin Cancer Res*. 1997 Nov;3(11):2099-106. PubMed PMID: 9815602.
34. Agus DB, Gambhir SS, Pardridge WM, Spielholz C, **Baselga J**, Vera JC, Golde DW. "Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters." *J Clin Invest*. 1997 Dec 1;100(11):2842-8. PubMed PMID: 9389750; PubMed Central PMCID: PMC508490.

35. Ribas A, Albanell J, Solé-Calvo LA, Gallardo E, Bellmunt J, Vera R, Vidal R, Carulla J, **Baselga J**. "Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinoma." *Cancer*. 1998 Mar 1;82(5):878-85. PubMed PMID: 9486577.
36. Hudis C, Riccio L, Seidman A, **Baselga J**, Currie V, Fennelly D, Gilewski T, Lebwohl D, Moynahan M, Raptis G, Surbone A, Sklarin N, Yao TJ, Keefe D, Norton L. "Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel." *Cancer Invest*. 1998;16(2):67-71. PubMed PMID: 9512671.
37. **Baselga J**, Norton L, Albanell J, Kim YM, Mendelsohn J. "Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts." *Cancer Res*. 1998 Jul 1;58(13):2825-31. Erratum in: *Cancer Res* 1999 Apr 15;59(8):2020. PubMed PMID: 9661897.
38. Pegram MD, Lipton A, Hayes DF, Weber BL, **Baselga J**, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ. "Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment." *J Clin Oncol*. 1998 Aug;16(8):2659-71. PubMed PMID: 9704716.
39. Maerz WJ, **Baselga J**, Reuter VE, Mellado B, Myers ML, Bosl GJ, Spinella MJ, Dmitrovsky E. "FGF4 dissociates anti-tumorigenic from differentiation signals of retinoic acid in human embryonal carcinomas." *Oncogene*. 1998 Aug 13;17(6):761-7. PubMed PMID: 9715278.
40. Merlos-Suárez A, Fernández-Larrea J, Reddy P, **Baselga J**, Arribas J. "Pro-tumor necrosis factor-alpha processing activity is tightly controlled by a component that does not affect notch processing." *J Biol Chem*. 1998 Sep 18;273(38):24955-62. PubMed PMID: 9733803.
41. Seidman AD, Hudis CA, Albanell J, Tong W, Tepler I, Currie V, Moynahan ME, Theodoulou M, Gollub M, **Baselga J**, Norton L. "Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer." *J Clin Oncol*. 1998 Oct;16(10):3353-61. Review. Erratum in: *J Clin Oncol*. 2006 May 10;24(14):2220. Albanell J [corrected to Albanell, J]. PubMed PMID: 9779712.
42. Felip E, Massuti B, Camps C, Benito D, Isla D, González-Larriba JL, López-Cabrerizo MP, Salamanca O, Puerto-Pica J, Moyano A, **Baselga J**, Rosell R. "Superiority of sequential versus concurrent administration of paclitaxel with etoposide in advanced non-small cell lung cancer: comparison of two Phase II trials." *Clin Cancer Res*. 1998 Nov;4(11):2723-8. PubMed PMID: 9829735.
43. Hudis C, Seidman A, **Baselga J**, Raptis G, Lebwohl D, Gilewski T, Moynahan M, Sklarin N, Fennelly D, Crown JP, Surbone A, Uhlenhopp M, Riedel E, Yao TJ, Norton L. "Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy." *J Clin Oncol*. 1999 Jan;17(1):93-100. PubMed PMID: 10458222.
44. D'Andrea G, Fennelly D, Norton L, **Baselga J**, Gilewski T, Hudis C, Moynahan ME, Raptis G, Sklarin N, Surbone A, Theodoulou M, Templeton MA, Yao TJ, Seidman AD. "Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer." *Clin Cancer Res*. 1999 Feb;5(2):275-9. PubMed PMID: 10037175.

45. Ureña JM, Merlos-Suárez A, **Baselga J**, Arribas J. "The cytoplasmic carboxy-terminal amino acid determines the subcellular localization of proTGF-(alpha) and membrane type matrix metalloprotease (MT1-MMP)." *J Cell Sci.* 1999 Mar;112 ( Pt 6):773-84. PubMed PMID: 10036228.
46. Codony-Servat J, Albanell J, Lopez-Talavera JC, Arribas J, **Baselga J**. "Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells." *Cancer Res.* 1999 Mar 15;59(6):1196-201. PubMed PMID: 10096547.
47. Fernández-Larrea J, Merlos-Suárez A, Ureña JM, **Baselga J**, Arribas J. "A role for a PDZ protein in the early secretory pathway for the targeting of proTGF-alpha to the cell surface." *Mol Cell.* 1999 Apr;3(4):423-33. PubMed PMID: 10230395.
48. **Baselga J**, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. "Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer." *Semin Oncol.* 1999 Aug;26(4 Suppl 12):78-83. PubMed PMID: 10482197.
49. **Baselga J**. "New horizons: gene therapy for cancer." *Anticancer Drugs.* 1999 Nov;10 Suppl 1:S39-42. Review. PubMed PMID: 10630368.
50. Albanell J, **Baselga J**. "Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer." *Drugs Today (Barc).* 1999 Dec;35(12):931-46. PubMed PMID: 12973420.
51. **Baselga J**, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D'Andrea G, Seidman A, Norton L, Gunnett K, Falcey J, Anderson V, Waksal H, Mendelsohn J. "Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin." *J Clin Oncol.* 2000 Feb;18(4):904-14. PubMed PMID: 10673534.
52. Albanell J, **Baselga J**. "Systemic therapy emergencies." *Semin Oncol.* 2000 Jun;27(3):347-61. Review. PubMed PMID: 10864222.
53. Bellmunt J, Guillem V, Paz-Ares L, González-Larriba JL, Carles J, Albanell J, Tabernero JM, Cortés-Funes H, **Baselga J**. "Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer." *Eur J Cancer.* 2000 Jul;36 Suppl 2:17-25. Review. PubMed PMID: 10908844.
54. Bellmunt J, Guillem V, Paz-Ares L, González-Larriba JL, Carles J, Batiste-Alentorn E, Sáenz A, López-Brea M, Font A, Nogué M, Bastús R, Climent MA, de la Cruz JJ, Albanell J, Banús JM, Gallardo E, Diaz-Rubio E, Cortés-Funes H, **Baselga J**. "Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group." *J Clin Oncol.* 2000 Sep 15;18(18):3247-55. PubMed PMID: 10986057.
55. **Baselga J**. "Clinical trials of single-agent trastuzumab (Herceptin)." *Semin Oncol.* 2000 Oct;27(5 Suppl 9):20-6. Review. PubMed PMID: 11049053.
56. **Baselga J**. "Current and planned clinical trials with trastuzumab (Herceptin)." *Semin Oncol.* 2000 Oct;27(5 Suppl 9):27-32. Review. PubMed PMID: 11049054.
57. **Baselga J**. "New therapeutic agents targeting the epidermal growth factor receptor." *J Clin Oncol.* 2000 Nov 1;18(21 Suppl):54S-9S. Review. PubMed PMID: 11060328.

58. **Baselga J.** "Monoclonal antibodies directed at growth factor receptors." *Ann Oncol.* 2000;11 Suppl 3:187-90. Review. PubMed PMID: 11079139.
59. Borrell-Pagès M, Fernández-Larrea J, Borroto A, Rojo F, **Baselga J**, Arribas J. "The carboxy-terminal cysteine of the tetraspanin L6 antigen is required for its interaction with SITAC, a novel PDZ protein." *Mol Biol Cell.* 2000 Dec;11(12):4217-25. PubMed PMID: 11102519; PubMed Central PMCID: PMC15068.
60. **Baselga J**, Averbuch SD. "ZD1839 ('Iressa') as an anticancer agent." *Drugs.* 2000;60 Suppl 1:33-40; discussion 41-2. Review. PubMed PMID: 11129170.
61. Mendelsohn J, **Baselga J.** "The EGF receptor family as targets for cancer therapy." *Oncogene.* 2000 Dec 27;19(56):6550-65. Review. PubMed PMID: 11426640.
62. **Baselga J.** "Clinical trials of Herceptin(R) (trastuzumab)." *Eur J Cancer.* 2001 Jan;37 Suppl 1:18-24. PubMed PMID: 11342196.
63. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, **Baselga J**, Norton L. "Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2." *N Engl J Med.* 2001 Mar 15;344(11):783-92. PubMed PMID: 11248153.
64. **Baselga J**, Taberero JM. "Weekly docetaxel in breast cancer: applying clinical data to patient therapy." *Oncologist.* 2001;6 Suppl 3:26-9. Review. PubMed PMID: 11346682.
65. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, **Baselga J.** "Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells." *Cancer Res.* 2001 Jun 15;61(12):4744-9. PubMed PMID: 11406546.
66. **Baselga J**, Albanell J. "Mechanism of action of anti-HER2 monoclonal antibodies." *Ann Oncol.* 2001;12 Suppl 1:S35-41. Review. PubMed PMID: 11521720.
67. **Baselga J.** "Phase I and II clinical trials of trastuzumab." *Ann Oncol.* 2001;12 Suppl 1:S49-55. PubMed PMID: 11521722.
68. Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J, Raspall G, Giralt J, Roselló J, Nicholson RI, Mendelsohn J, **Baselga J.** "Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments." *Cancer Res.* 2001 Sep 1;61(17):6500-10. PubMed PMID: 11522647.
69. **Baselga J.** "Is circulating HER-2 more than just a tumor marker?" *Clin Cancer Res.* 2001 Sep;7(9):2605-7. PubMed PMID: 11555569.
70. **Baselga J.** "Targeting the epidermal growth factor receptor: a clinical reality." *J Clin Oncol.* 2001 Sep 15;19(18 Suppl):41S-44S. PubMed PMID: 11560970.
71. **Baselga J.** "The EGFR as a target for anticancer therapy--focus on cetuximab." *Eur J Cancer.* 2001 Sep;37 Suppl 4:S16-22. Review. PubMed PMID: 11597400.

72. Carson WE, Parihar R, Lindemann MJ, Personeni N, Dierksheide J, Meropol NJ, **Baselga J**, Caligiuri MA. "Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells." *Eur J Immunol*. 2001 Oct;31(10):3016-25. PubMed PMID: 11592078.
73. **Baselga J**, Albanell J, Molina MA, Arribas J. "Mechanism of action of trastuzumab and scientific update." *Semin Oncol*. 2001 Oct;28(5 Suppl 16):4-11. Review. PubMed PMID: 11706390.
74. Albanell J, Rojo F, **Baselga J**. "Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839." *Semin Oncol*. 2001 Oct;28(5 Suppl 16):56-66. Review. PubMed PMID: 11706397.
75. Bellmunt J, de Wit R, Albanell J, **Baselga J**. "A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer." *Eur J Cancer*. 2001 Nov;37(17):2212-5. PubMed PMID: 11677109.
76. Merlos-Suárez A, Ruiz-Paz S, **Baselga J**, Arribas J. "Metalloprotease-dependent protransforming growth factor-alpha ectodomain shedding in the absence of tumor necrosis factor-alpha-converting enzyme." *J Biol Chem*. 2001 Dec 21;276(51):48510-7. PubMed PMID: 11600492.
77. **Baselga J**. "Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials." *Oncology*. 2001;61 Suppl 2:14-21. Review. PubMed PMID: 11694783.
78. Albanell J, **Baselga J**. "Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect." *J Natl Cancer Inst*. 2001 Dec 19;93(24):1830-2. PubMed PMID: 11752000.
79. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI, **Baselga J**. "Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition." *J Clin Oncol*. 2002 Jan 1;20(1):110-24. PubMed PMID: 11773160.
80. **Baselga J**. "Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing." *Ann Oncol*. 2002 Jan;13(1):8-9. PubMed PMID: 11863116.
81. Molina MA, Sáez R, Ramsey EE, Garcia-Barchino MJ, Rojo F, Evans AJ, Albanell J, Keenan EJ, Lluch A, García-Conde J, **Baselga J**, Clinton GM. "NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer." *Clin Cancer Res*. 2002 Feb;8(2):347-53. PubMed PMID: 11839648.
82. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, **Baselga J**, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC. "Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery." *Clin Cancer Res*. 2002 Apr;8(4):1172-81. PubMed PMID: 11948130.
83. Díaz-Rubio E, Evans TR, Tabemero J, Cassidy J, Sastre J, Eatock M, Bisset D, Regueiro P, **Baselga J**. "Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors." *Ann Oncol*. 2002 Apr;13(4):558-65. PubMed PMID: 12056706.

84. **Baselga J.** "Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes." *J Clin Oncol.* 2002 May 1;20(9):2217-9. PubMed PMID: 11980990.
85. **Baselga J,** Norton L. "Focus on breast cancer." *Cancer Cell.* 2002 May;1(4):319-22. Review. PubMed PMID: 12086846.
86. **Baselga J,** Albanell J. "Targeting epidermal growth factor receptor in lung cancer." *Curr Oncol Rep.* 2002 Jul;4(4):317-24. Review. PubMed PMID: 12044241.
87. Bellmunt J, Cos J, Clèries R, Pérez M, Ribas A, Eres N, Murio JE, Margarit C, **Baselga J.** "Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer." *Cancer Invest.* 2002;20(5-6):673-85. PubMed PMID: 12197223.
88. **Baselga J.** "Why the epidermal growth factor receptor? The rationale for cancer therapy." *Oncologist.* 2002;7 Suppl 4:2-8. Review. PubMed PMID: 12202782.
89. **Baselga J.** "A new anti-ErbB2 strategy in the treatment of cancer: prevention of ligand-dependent ErbB2 receptor heterodimerization." *Cancer Cell.* 2002 Aug;2(2):93-5. PubMed PMID: 12204526.
90. Bellmunt J, Albanell J, Paz-Ares L, Climent MA, González-Larriba JL, Carles J, de la Cruz JJ, Guillem V, Díaz-Rubio E, Cortés-Funes H, **Baselga J;** Spanish Oncology Genitourinary Group.. "Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine." *Cancer.* 2002 Aug 15;95(4):751-7. PubMed PMID: 12209718.
91. Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, **Baselga J,** Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM. "Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial." *J Clin Oncol.* 2002 Sep 15;20(18):3815-25. PubMed PMID: 12228201.
92. Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, **Baselga J,** Arteaga CL. "PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization." *Nat Med.* 2002 Oct;8(10):1145-52. PubMed PMID: 12244301.
93. **Baselga J,** Hammond LA. "HER-targeted tyrosine-kinase inhibitors." *Oncology.* 2002;63 Suppl 1:6-16. Review. PubMed PMID: 12422050.
94. **Baselga J,** Albanell J. "Epithelial growth factor receptor interacting agents." *Hematol Oncol Clin North Am.* 2002 Oct;16(5):1041-63. Review. PubMed PMID: 12512382.
95. Baum M, Buchanan M, **Baselga J,** Cataliotti L, Jassem J, Piccart M. "The future of breast cancer research in danger." *Eur J Cancer.* 2002 Nov;38(17):2210-3. PubMed PMID: 12441256.
96. **Baselga J,** Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T, Averbuch SD, Feyereislova A, Swaisland H, Rojo F, Albanell J. "Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types." *J Clin Oncol.* 2002 Nov 1;20(21):4292-302. PubMed PMID: 12409327.



97. Green MD, Koelbl H, **Baselga J**, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ; International Pegfilgrastim 749 Study Group. "A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy." *Ann Oncol*. 2003 Jan;14(1):29-35. PubMed PMID: 12488289.
98. Motzer RJ, Amato R, Todd M, Hwu WJ, Cohen R, **Baselga J**, Muss H, Cooper M, Yu R, Ginsberg MS, Needle M. "Phase II trial of anti-epidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma." *Invest New Drugs*. 2003 Feb;21(1):99-101. PubMed PMID: 12795534.
99. Borrell-Pagès M, Rojo F, Albanell J, **Baselga J**, Arribas J. "TACE is required for the activation of the EGFR by TGF- $\alpha$  in tumors." *EMBO J*. 2003 Mar 3;22(5):1114-24. PubMed PMID: 12606576; PubMed Central PMCID: PMC150344.
100. Anido J, Matar P, Albanell J, Guzmán M, Rojo F, Arribas J, Averbuch S, **Baselga J**. "ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells." *Clin Cancer Res*. 2003 Apr;9(4):1274-83. PubMed PMID: 12684395.
101. Arteaga CL, **Baselga J**. "Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice." *Clin Cancer Res*. 2003 May;9(5):1579-89. Review. PubMed PMID: 12738709.
102. **Baselga J**. "A review of EGFR targeted therapy." *Clin Adv Hematol Oncol*. 2003 Apr;1(4):218-9. PubMed PMID: 16224409.
103. Kuenen BC, Tabernero J, **Baselga J**, Cavalli F, Pfanner E, Conte PF, Seeber S, Madhusudan S, Deplanque G, Huisman H, Scigalla P, Hoekman K, Harris AL. "Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma." *Clin Cancer Res*. 2003 May;9(5):1648-55. PubMed PMID: 12738717.
104. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, **Baselga J**. "Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]." *J Clin Oncol*. 2003 Jun 15;21(12):2237-46. Erratum in: *J Clin Oncol*. 2004 Dec 1;22(23):4863. PubMed PMID: 12748244.
105. LoRusso PM, Herbst RS, Rischin D, Ranson M, Calvert H, Raymond E, Kieback D, Kaye S, Gianni L, Harris A, Bjork T, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Feyereislova A, Heyes A, Averbuch SD, Ochs J, **Baselga J**. "Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors." *Clin Cancer Res*. 2003 Jun;9(6):2040-8. PubMed PMID: 12796366.

106. Borroto A, Ruiz-Paz S, de la Torre TV, Borrell-Pages M, Merlos-Suarez A, Pandiella A, Blobel CP, **Baselga J**, Arribas J. "Impaired trafficking and activation of tumor necrosis factor-alpha-converting enzyme in cell mutants defective in protein ectodomain shedding." *J Biol Chem*. 2003 Jul 11;278(28):25933-9. Erratum in: *J Biol Chem*. 2004 Jan 23;279(4):3119. PubMed PMID: 12714588.
107. Boyle P, Autier P, Bartelink H, **Baselga J**, Boffetta P, Burn J, Burns HJ, Christensen L, Denis L, Dicato M, Diehl V, Doll R, Franceschi S, Gillis CR, Gray N, Griciute L, Hackshaw A, Kasler M, Kogevinas M, Kvinnsland S, La Vecchia C, Levi F, McVie JG, Maisonneuve P, Martin-Moreno JM, Bishop JN, Oleari F, Perrin P, Quinn M, Richards M, Ringborg U, Scully C, Siracka E, Storm H, Tubiana M, Tursz T, Veronesi U, Wald N, Weber W, Zaridze DG, Zatonski W, zur Hausen H. "European Code Against Cancer and scientific justification: third version (2003)." *Ann Oncol*. 2003 Jul;14(7):973-1005. PubMed PMID: 12853336.
108. **Baselga J**. "Skin as a surrogate tissue for pharmacodynamic end points: is it deep enough?" *Clin Cancer Res*. 2003 Jul;9(7):2389-90. PubMed PMID: 12855608.
109. Mendelsohn J, **Baselga J**. "Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer." *J Clin Oncol*. 2003 Jul 15;21(14):2787-99. Review. PubMed PMID: 12860957.
110. Bellmunt J, de Wit R, Albiol S, Tabernero J, Albanell J, **Baselga J**. "New drugs and new approaches in metastatic bladder cancer." *Crit Rev Oncol Hematol*. 2003 Aug;47(2):195-206. Review. PubMed PMID: 12900012.
111. **Baselga J**, Llombart-Cussac A, Bellet M, Guillem-Porta V, Enas N, Krejcy K, Carrasco E, Kayitalire L, Kuta M, Lluch A, Vodvarka P, Kerbrat P, Namer M, Petruzella L. "Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients." *Ann Oncol*. 2003 Sep;14(9):1383-90. PubMed PMID: 12954577.
112. Felip E, Rosell R, Domine M, Santomé L, Garrido P, Font A, Carrato A, Terrasa J, Vadell C, Mañé JM, **Baselga J**; "Spanish Lung Cancer Group.. Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study." *Ann Oncol*. 2003 Oct;14(10):1549-54. PubMed PMID: 14504057.
113. Bianchi G, Albanell J, Eiermann W, Vitali G, Borquez D, Viganò L, Molina R, Raab G, Locatelli A, Vanhauwere B, Gianni L, **Baselga J**. "Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer." *Clin Cancer Res*. 2003 Dec 1;9(16 Pt 1):5944-51. PubMed PMID: 14676119.
114. Vanhoefler U, Tewes M, Rojo F, Dirsch O, Schleucher N, Rosen O, Tillner J, Kovar A, Braun AH, Trarbach T, Seeber S, Harstrick A, **Baselga J**. "Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor." *J Clin Oncol*. 2004 Jan 1;22(1):175-84. PubMed PMID: 14701780.
115. Villanueva de la Torre T, Bech-Serra JJ, Ruiz-Paz S, **Baselga J**, Arribas J. "Inactivating mutations block the tumor necrosis factor-alpha-converting enzyme in the early secretory pathway." *Biochem Biophys Res Commun*. 2004 Feb 20;314(4):1028-35. PubMed PMID: 14751236.

116. **Baselga J.** “Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact?” *J Clin Oncol.* 2004 Mar 1;22(5):759-61. PubMed PMID: 14990627.
117. Arteaga CL, **Baselga J.** “Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?” *Cancer Cell.* 2004 Jun;5(6):525-31. PubMed PMID: 15193255.
118. **Baselga J,** Arribas J. “Treating cancer's kinase 'addiction'.” *Nat Med.* 2004 Aug;10(8):786-7. PubMed PMID: 15286778.
119. Tabernero J, Climent MA, Lluch A, Albanell J, Vermorken JB, Barnadas A, Antón A, Laurent C, Mayordomo JI, Estaun N, Losa I, Guillem V, Garcia-Conde J, Tisaire JL, **Baselga J.** “A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer.” *Ann Oncol.* 2004 Sep;15(9):1358-65. PubMed PMID: 15319242.
120. Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, **Baselga J.** “Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.” *Clin Cancer Res.* 2004 Oct 1;10(19):6487-501. PubMed PMID: 15475436.
121. Tabernero J, Salazar R, Casado E, Martinelli E, Gómez P, **Baselga J.** “Targeted therapy in advanced colon cancer: the role of new therapies.” *Ann Oncol.* 2004;15 Suppl 4:iv55-62. Review. PubMed PMID: 15477336.
122. Yarden Y, **Baselga J,** Miles D. “Molecular approach to breast cancer treatment.” *Semin Oncol.* 2004 Oct;31(5 Suppl 10):6-13. Review. PubMed PMID: 15490369.
123. **Baselga J,** Gianni L, Geyer C, Perez EA, Riva A, Jackisch C. “Future options with trastuzumab for primary systemic and adjuvant therapy.” *Semin Oncol.* 2004 Oct;31(5 Suppl 10):51-7. Review. PubMed PMID: 15490375.
124. Herbst RS, Fukuoka M, **Baselga J.** “Gefitinib--a novel targeted approach to treating cancer.” *Nat Rev Cancer.* 2004 Dec;4(12):956-65. Review. PubMed PMID: 15573117.
125. Hidalgo A, Tabernero J, Rojo F, Marimon I, Andreu J, **Baselga J.** “Feasibility of CT scan-guided Tru-Cut serial liver biopsies to evaluate pharmacodynamic endpoints in patients with liver metastasis treated with experimental drugs.” *Abdom Imaging.* 2005 Jan-Feb;30(1):65-8. PubMed PMID: 15647873.
126. Camps C, Felip E, Sanchez JM, Massuti B, Artal A, Paz-Ares L, Carrato A, Alberola V, Blasco A, **Baselga J,** Astier L, Voi M, Rosell R; Spanish Lung Cancer Group.. “Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer.” *Ann Oncol.* 2005 Apr;16(4):597-601. PubMed PMID: 15684226.
127. Tabernero J, Rojo F, Marimón I, Voi M, Albanell J, Guix M, Vázquez F, Carulla J, Cooper M, Andreu J, Van Vreckem A, Bellmunt J, Manne V, Manning JA, Garrido C, Felip E, Del Campo JM, García M, Valverde S, **Baselga J.** “Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors.” *J Clin Oncol.* 2005 Apr 10;23(11):2521-33. Erratum in: *J Clin Oncol.* 2010 Dec 20;28(36):5350. PubMed PMID: 15710949.

128. **Baselga J**, Arteaga CL. "Critical update and emerging trends in epidermal growth factor receptor targeting in cancer." *J Clin Oncol*. 2005 Apr 10;23(11):2445-59. Review. Erratum in: *J Clin Oncol*. 2005 Sep 1;23(25):6281. PubMed PMID: 15753456.
129. **Baselga J**, Carbonell X, Castañeda-Soto NJ, Clemens M, Green M, Harvey V, Morales S, Barton C, Ghahramani P. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. *J Clin Oncol*. 2005 Apr 1;23(10):2162-71. PubMed PMID: 15800309.
130. Arribas J, **Baselga J**. "Who will benefit from treatment against EGFR?." *Lancet Oncol*. 2005 May;6(5):257-8. PubMed PMID: 15863372.
131. Miller KD, Trigo JM, Wheeler C, Barge A, Rowbottom J, Sledge G, **Baselga J**. "A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer." *Clin Cancer Res*. 2005 May 1;11(9):3369-76. PubMed PMID: 15867237.
132. Boyle P, Ariyaratne M, Bartelink H, **Baselga J**, Berns A, Brawley OW, Burns H, Davidov M, Dinshaw KA, Dresler C, Eggermont AM, Gajurel D, Gordina G, Gray N, Kakizoe T, Karki BS, Kásler M, Kerr DJ, Khayat D, Kiselev A, Khuhaprema T, Klocker H, Levshin V, Martin-Moreno JM, McVie JG, Mendelsohn J, Napalkov NP, Ngoma TA, Park JG, Philip T, Pötschke-Langer M, Poudal HN, Rajan B, Ringborg U, Rodger A, Seffrin JR, Shanta V, Shrestha MM, Thomas R, Tursz T, de Valeriola D, Veronesi U, Wiestler OD, Zaridze D, Zatonski W, Zeng YX. "Curbing tobacco's toll starts with the professionals: World No Tobacco Day." *Lancet*. 2005 Jun 11-17;365(9476):1990-2. PubMed PMID: 15950704.
133. **Baselga J**. "Does epidermal growth factor receptor status predict activity of cetuximab in colorectal cancer patients?" *Nat Clin Pract Oncol*. 2005 Jun;2(6):284-5. PubMed PMID: 16264980.
134. **Baselga J**, Albanell J, Ruiz A, Lluch A, Gascon P, Guillem V, Gonzalez S, Sauleda S, Marimon I, Tabernero JM, Koehler MT, Rojo F. "Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer". *J Clin Oncol*. 2005 Aug 10; 23(23):5323-33.
135. **Baselga J**, Albanell J, Ruiz A, Lluch A, Gascón P, Guillém V, González S, Sauleda S, Marimón I, Tabernero JM, Koehler MT, Rojo F. "Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer." *J Clin Oncol*. 2005 Aug 10;23(23):5323-33. PubMed PMID: 15939921.
136. Spano JP, Milano G, **Baselga J**. "EGFR/VEGF signalling pathway in colorectal cancer: the way we are!" *Bull Cancer*. 2005 Aug;92(Spec no):S3-4. English, French. PubMed PMID: 16387661.
137. **Baselga J**, Trigo JM, Bourhis J, Tortochaux J, Cortés-Funes H, Hitt R, Gascón P, Amellal N, Harstrick A, Eckardt A. "Phase II multicenter study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck." *J Clin Oncol*. 2005 Aug 20;23(24):5568-77. PubMed PMID: 16009950.
138. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, **Baselga J**, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E. "Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study." *J Clin Oncol*. 2005 Sep 1;23(25):5960-72. PubMed PMID: 16087945.

139. **Baselga J**, Cortes J. "Epidermal growth factor receptor pathway inhibitors." *Cancer Chemother Biol Response Modif.* 2005;22:205-23. Review. PubMed PMID: 16110613.
140. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, **Baselga J**, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Rüschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD; Herceptin Adjuvant (HERA) Trial Study Team.. "Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer." *N Engl J Med.* 2005 Oct 20;353(16):1659-72. PubMed PMID: 16236737.
141. Tabernero J, Macarulla T, Ramos FJ, **Baselga J**. "Novel targeted therapies in the treatment of gastric and esophageal cancer." *Ann Oncol.* 2005 Nov;16(11):1740-8. Review. PubMed PMID: 15980157.
142. Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, **Baselga J**, Ochs JS, Haber DA. "Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials." *J Clin Oncol.* 2005 Nov 1;23(31):8081-92. PubMed PMID: 16204011.
143. Gianni L, **Baselga J**, Eiermann W, Guillem Porta V, Semiglazov V, Lluch A, Zambetti M, Sabadell D, Raab G, Llombart Cussac A, Bozhok A, Martinez-Agulló A, Greco M, Byakhov M, Lopez Lopez JJ, Mansutti M, Valagussa P, Bonadonna G; European Cooperative Trial in Operable Breast Cancer Study Group.. "Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy." *Clin Cancer Res.* 2005 Dec 15;11(24 Pt 1):8715-21. PubMed PMID: 16361558.
144. Sáez R, Molina MA, Ramsey EE, Rojo F, Keenan EJ, Albanell J, Lluch A, García-Conde J, **Baselga J**, Clinton GM. "p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer." *Clin Cancer Res.* 2006 Jan 15;12(2):424-31. PubMed PMID: 16428482.
145. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, **Baselga J**, Rosen N. "mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt." *Cancer Res.* 2006 Feb 1;66(3):1500-8. PubMed PMID: 16452206; PubMed Central PMCID: PMC3193604.
146. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, **Baselga J**, Yousoufian H, Amellal N, Rowinsky EK, Ang KK. "Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck." *N Engl J Med.* 2006 Feb 9;354(6):567-78. PubMed PMID: 16467544.
147. Wu FY, Wang SE, Sanders ME, Shin I, Rojo F, **Baselga J**, Arteaga CL. "Reduction of cytosolic p27(Kip1) inhibits cancer cell motility, survival, and tumorigenicity." *Cancer Res.* 2006 Feb 15;66(4):2162-72. PubMed PMID: 16489017.
148. Calvo E, **Baselga J**. "Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors." *J Clin Oncol.* 2006 May 10;24(14):2158-63. Review. PubMed PMID: 16682734.

149. **Baselga J.** “Is there a role for the irreversible epidermal growth factor receptor inhibitor EKB-569 in the treatment of cancer? A mutation-driven question.” *J Clin Oncol.* 2006 May 20;24(15):2225-6. PubMed PMID: 16710019.
150. **Baselga J.** “Targeting tyrosine kinases in cancer: the second wave.” *Science.* 2006 May 26;312(5777):1175-8. PubMed PMID: 16728632.
151. Bech-Serra JJ, Santiago-Josefat B, Esselens C, Saftig P, **Baselga J**, Arribas J, Canals F. “Proteomic identification of desmoglein 2 and activated leukocyte cell adhesion molecule as substrates of ADAM17 and ADAM10 by difference gel electrophoresis.” *Mol Cell Biol.* 2006 Jul;26(13):5086-95. PubMed PMID: 16782893; PubMed Central PMCID: PMC1489169.
152. Anido J, Scaltriti M, Bech Serra JJ, Santiago Josefat B, Todo FR, **Baselga J**, Arribas J. “Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation.” *EMBO J.* 2006 Jul 12;25(13):3234-44. PubMed PMID: 16794579; PubMed Central PMCID: PMC1500971.
153. Mendelsohn J, **Baselga J.** “Epidermal growth factor receptor targeting in cancer.” *Semin Oncol.* 2006 Aug;33(4):369-85. Review. PubMed PMID: 16890793.
154. Rojo F, Tabernero J, Albanell J, Van Cutsem E, Ohtsu A, Doi T, Koizumi W, Shirao K, Takiuchi H, Ramon y Cajal S, **Baselga J.** “Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma.” *J Clin Oncol.* 2006 Sep 10;24(26):4309-16. Erratum in: *J Clin Oncol.* 2006 Dec 10;24(35):5620. Ramon Cajal, S [corrected to Ramon y Cajal, S]. PubMed PMID: 16963731.
155. **Baselga J**, Perez EA, Pienkowski T, Bell R. “Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.” *Oncologist.* 2006;11 Suppl 1:4-12. Review. PubMed PMID: 16971734.
156. Scaltriti M, **Baselga J.** “The epidermal growth factor receptor pathway: a model for targeted therapy.” *Clin Cancer Res.* 2006 Sep 15;12(18):5268-72. Review. PubMed PMID: 17000658.
157. Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, **Baselga J**, Ramon y Cajal S. “Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer.” *Cancer.* 2006 Oct 15;107(8):1801-11. PubMed PMID: 16983702.
158. Rojo F, Najera L, Lirola J, Jiménez J, Guzmán M, Sabadell MD, **Baselga J**, Ramon y Cajal S. “4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis.” *Clin Cancer Res.* 2007 Jan 1;13(1):81-9. PubMed PMID: 17200342.
159. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, **Baselga J**, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sánchez Rovira P, Piccart-Gebhart MJ; HERA study team.. “2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.” *Lancet.* 2007 Jan 6;369(9555):29-36. PubMed PMID: 17208639.
160. Bruna A, Darken RS, Rojo F, Ocaña A, Peñuelas S, Arias A, Paris R, Tortosa A, Mora J, **Baselga J**, Seoane J. “High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene.” *Cancer Cell.* 2007 Feb;11(2):147-60. PubMed PMID: 17292826.

161. Sessa C, Cresta S, Cerny T, **Baselga J**, Rota Caremoli E, Malossi A, Hess D, Trigo J, Zucchetti M, D'Incalci M, Zaniboni A, Capri G, Gatti B, Carminati P, Zanna C, Marsoni S, Gianni L. "Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors." *Ann Oncol*. 2007 Mar;18(3):561-8. PubMed PMID: 17150998.
162. Bellmunt J, Paz-Ares L, Cuello M, Cecere FL, Albiol S, Guillem V, Gallardo E, Carles J, Mendez P, de la Cruz JJ, Taron M, Rosell R, **Baselga J**; Spanish Oncology Genitourinary Group. "Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy." *Ann Oncol*. 2007 Mar;18(3):522-8. PubMed PMID: 17229776.
163. Piccart M, Goldhirsch A, Wood W, Pritchard K, **Baselga J**, Reaby L, Kössler I, Kyriakides S, Norton L, Coates A. "Keeping faith with trial volunteers." *Nature*. 2007 Mar 8;446(7132):137-8. PubMed PMID: 17344833.
164. Cortes J, **Baselga J**. "Targeting the microtubules in breast cancer beyond taxanes: the epothilones." *Oncologist*. 2007 Mar;12(3):271-80. Review. PubMed PMID: 17405891.
165. Scaltriti M, Rojo F, Ocaña A, Anido J, Guzman M, Cortes J, Di Cosimo S, Matias-Guiu X, Ramon y Cajal S, Arribas J, **Baselga J**. "Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer." *J Natl Cancer Inst*. 2007 Apr 18;99(8):628-38. PubMed PMID: 17440164.
166. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A, **Baselga J**. "Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy." *J Clin Oncol*. 2007 Jun 1;25(16):2171-7. PubMed PMID: 17538161.
167. Curran D, Giralt J, Harari PM, Ang KK, Cohen RB, Kies MS, Jassem J, **Baselga J**, Rowinsky EK, Amellal N, Comte S, Bonner JA. "Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab." *J Clin Oncol*. 2007 Jun 1;25(16):2191-7. Erratum in: *J Clin Oncol*. 2007 Aug 20;25(24):3790. PubMed PMID: 17538164.
168. Prat A, **Baselga J**. "Biologic therapy: current and future applications in oncology". *Med Clin (Barc)*. 2007 Jun 30;129(5):184-93. Review. Spanish. PubMed PMID: 17669336.
169. Di Cosimo S, **Baselga J**. "Pharmacodynamic endpoints in primary breast cancer." *Ann Oncol*. 2007 Jul;18 Suppl 9:ix21-3. Review. PubMed PMID: 17631590.
170. Thomas E, Tabernero J, Fournier M, Conté P, Fumoleau P, Lluch A, Vahdat LT, Bunnell CA, Burris HA, Viens P, **Baselga J**, Rivera E, Guarneri V, Poulart V, Klimovsky J, Lebwohl D, Martin M. "Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer." *J Clin Oncol*. 2007 Aug 10;25(23):3399-406. PubMed PMID: 17606975.
171. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris HA 3rd, Poplin EA, Hidalgo M, **Baselga J**, Clark EA, Mauro DJ. "Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab." *J Clin Oncol*. 2007 Aug 1;25(22):3230-7. PubMed PMID: 17664471.

172. Armengol G, Rojo F, Castellví J, Iglesias C, Cuatrecasas M, Pons B, **Baselga J**, Ramón y Cajal S. "4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications." *Cancer Res*. 2007 Aug 15;67(16):7551-5. Review. PubMed PMID: 17699757.
173. **Baselga J**, Tabernero J. "Combined antiangiogenesis and antiepidermal growth factor receptor targeting in the treatment of cancer: hold back, we are not there yet." *J Clin Oncol*. 2007 Oct 10;25(29):4516-8. PubMed PMID: 17876011.
174. Folprecht G, Tabernero J, Köhne CH, Zacharchuk C, Paz-Ares L, Rojo F, Quinn S, Casado E, Salazar R, Abbas R, Lejeune C, Marimón I, Andreu J, Ubbelohde U, Cortes-Funes H, **Baselga J**. "Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer." *Clin Cancer Res*. 2008 Jan 1;14(1):215-23. doi: 10.1158/1078-0432.CCR-07-1053. PubMed PMID: 18172273.
175. Prat A, Parera M, Peralta S, Perez-Benavente MA, Garcia A, Gil-Moreno A, Martinez-Palones JM, Roxana I, **Baselga J**, Del Campo JM. "Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer." *Ann Oncol*. 2008 Feb;19(2):327-31. PubMed PMID: 18065408.
176. Twelves C, Trigo JM, Jones R, De Rosa F, Rakhit A, Fettner S, Wright T, **Baselga J**. "Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: a dose-escalation study." *Eur J Cancer*. 2008 Feb;44(3):419-26. doi: 10.1016/j.ejca.2007.12.011. PubMed PMID: 18249110.
177. **Baselga J**, Rothenberg ML, Tabernero J, Seoane J, Daly T, Cleverly A, Berry B, Rhoades SK, Ray CA, Fill J, Farrington DL, Wallace LA, Yingling JM, Lahn M, Arteaga C, Carducci M. "TGF-beta signalling-related markers in cancer patients with bone metastasis." *Biomarkers*. 2008 Mar;13(2):217-36. doi: 10.1080/13547500701676019. PubMed PMID: 18270872.
178. **Baselga J**, Rosen N. "Determinants of RASistance to anti-epidermal growth factor receptor agents." *J Clin Oncol*. 2008 Apr 1;26(10):1582-4. doi: 10.1200/JCO.2007.15.3700. Review. PubMed PMID: 18316790.
179. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Ramon y Cajal S, Jones S, Vidal L, Shand N, Macarulla T, Ramos FJ, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane HA, Lebowitz D, **Baselga J**. "Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors." *J Clin Oncol*. 2008 Apr 1;26(10):1603-10. doi: 10.1200/JCO.2007.14.5482. Erratum in: *J Clin Oncol*. 2010 Dec 20;28(36):5350. PubMed PMID: 18332469.
180. Awada A, Albanell J, Canney PA, Dirix LY, Gil T, Cardoso F, Gascon P, Piccart MJ, **Baselga J**. "Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study." *Br J Cancer*. 2008 May 6;98(9):1500-7. doi: 10.1038/sj.bjc.6604347. PubMed PMID: 18454159; PubMed Central PMCID: PMC2391111.
181. Felip E, Rojo F, Reck M, Heller A, Klughammer B, Sala G, Cedres S, Peralta S, Maacke H, Foerzler D, Parera M, Möcks J, Saura C, Gatzemeier U, **Baselga J**. "A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with



- platinum-based chemotherapy.” *Clin Cancer Res*. 2008 Jun 15;14(12):3867-74. doi: 10.1158/1078-0432.CCR-07-5186. PubMed PMID: 18559607.
182. Untch M, Gelber RD, Jackisch C, Procter M, **Baselga J**, Bell R, Cameron D, Bari M, Smith I, Leyland-Jones B, de Azambuja E, Wermuth P, Khasanov R, Feng-Yi F, Constantin C, Mayordomo JI, Su CH, Yu SY, Lluch A, Senkus-Konefka E, Price C, Haslbauer F, Suarez Sahui T, Srimuninnimit V, Colleoni M, Coates AS, Piccart-Gebhart MJ, Goldhirsch A; HERA Study Team.. “Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial.” *Ann Oncol*. 2008 Jun;19(6):1090-6. doi: 10.1093/annonc/mdn005. PubMed PMID: 18296421.
183. Vermorken JB, Herbst RS, Leon X, Amellal N, **Baselga J**. “Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies.” *Cancer*. 2008 Jun 15;112(12):2710-9. doi: 10.1002/cncr.23442. PubMed PMID: 18481809.
184. **Baselga J**, Senn HJ; European Society for Medical Oncology.. “The perspective and role of the medical oncologist in cancer prevention: a position paper by the European Society for Medical Oncology.” *Ann Oncol*. 2008 Jun;19(6):1033-5. doi: 10.1093/annonc/mdn366. PubMed PMID: 18508858.
185. ESMO., **Baselga J**. “Creating a stronger front against cancer: ESMO and ECCO join forces.” *Ann Oncol*. 2008 Aug;19(8):1367-8. doi: 10.1093/annonc/mdn425. PubMed PMID: 18662956.
186. Prat A, **Baselga J**. “The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.” *Nat Clin Pract Oncol*. 2008 Sep;5(9):531-42. doi: 10.1038/nncponc1179. Review. PubMed PMID: 18607391.
187. Boyle P, Anderson BO, Andersson LC, Ariyaratne Y, Auleley GR, Barbacid M, Bartelink H, **Baselga J**, Behbehani K, Belardelli F, Berns A, Bishop J, Brawley O, Burns H, Clanton M, Cox B, Currow D, Dangou JM, de Valeriola D, Dinshaw K, Eggermont A, Fitzpatrick J, Forstmane M, Garaci E, Gavin AT, Kakizoe T, Kasler M, Keita N, Kerr D, Khayat D, Khleif S, Khuhaprema T, Knezevic T, Kubinova R, Mallath M, Martin-Moreno J, McCance D, McVie JG, Merriman A, Ngoma T, Nowacki M, Orgelbrand J, Park JG, Pierotti M, Ashton LP, Puska P, Escobar CV, Rajan B, Rajkumar T, Ringborg U, Robertson C, Rodger A, Roovali L, Santini LA, Sarhan M, Seffrin J, Semiglazov V, Shrestha BM, Soo KC, Stamenic V, Tamblyn C, Thomas R, Tuncer M, Tursz T, Vaitkiene R, Vallejos C, Veronesi U, Wojtyla A, Yach D, Yoo KY, Zatonski W, Zaridze D, Zeng YX, Zhao P, Zheng T. “Need for global action for cancer control.” *Ann Oncol*. 2008 Sep;19(9):1519-21. doi: 10.1093/annonc/mdn426. PubMed PMID: 18723552.
188. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, **Baselga J**, Pandolfi PP. “Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer.” *J Clin Invest*. 2008 Sep;118(9):3065-74. doi: 10.1172/JCI34739. PubMed PMID: 18725988; PubMed Central PMCID: PMC2518073.
189. Rao S, Starling N, Cunningham D, Benson M, Wotherspoon A, Lüpfer C, Kurek R, Oates J, **Baselga J**, Hill A. “Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer.” *Br J Cancer*. 2008 Sep 16;99(6):868-74. doi: 10.1038/sj.bjc.6604622. PubMed PMID: 19238629; PubMed Central PMCID: PMC2538760.

190. Firestein R, Bass AJ, Kim SY, Dunn IF, Silver SJ, Guney I, Freed E, Ligon AH, Vena N, Ogino S, Chheda MG, Tamayo P, Finn S, Shrestha Y, Boehm JS, Jain S, Bojarski E, Mermel C, Barretina J, Chan JA, **Baselga J**, Tabernero J, Root DE, Fuchs CS, Loda M, Shivdasani RA, Meyerson M, Hahn WC. "CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity." *Nature*. 2008 Sep 25;455(7212):547-51. doi: 10.1038/nature07179. PubMed PMID: 18794900; PubMed Central PMCID: PMC2587138.
191. **Baselga J**. "Novel agents in the era of targeted therapy: what have we learned and how has our practice changed?" *Ann Oncol*. 2008 Sep;19 Suppl 7:vii281-8. doi: 10.1093/annonc/mdn433. PubMed PMID: 18790967.
192. O'Brien PJ, Ramanathan R, Yingling JM, **Baselga J**, Rothenberg ML, Carducci M, Daly T, Adcock D, Lahn M. "Analysis and variability of TGFbeta measurements in cancer patients with skeletal metastases." *Biologics*. 2008 Sep;2(3):563-9. PubMed PMID: 19707386; PubMed Central PMCID: PMC2721365.
193. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, **Baselga J**. "NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations." *Cancer Res*. 2008 Oct 1;68(19):8022-30. doi: 10.1158/0008-5472.CAN-08-1385. PubMed PMID: 18829560.
194. Vilar E, Scaltriti M, Balmaña J, Saura C, Guzman M, Arribas J, **Baselga J**, Tabernero J. "Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines." *Br J Cancer*. 2008 Nov 18;99(10):1607-12. doi: 10.1038/sj.bjc.6604691. PubMed PMID: 18941461; PubMed Central PMCID: PMC2584960.
195. Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernardis R, **Baselga J**. "Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235." *Cancer Res*. 2008 Nov 15;68(22):9221-30. doi: 10.1158/0008-5472.CAN-08-1740. PubMed PMID: 19010894; PubMed Central PMCID: PMC2587064.
196. Domingo E, Suriñach JM, Murillo J, Duran M, Suriñach J, **Baselga J**, de Sevilla TF. "Prognostic factors in the diagnostic work-up of cancer patients in an internal medicine department: does age matter?" *Int J Clin Pract*. 2008 Nov;62(11):1723-9. doi: 10.1111/j.1742-1241.2008.01886.x. PubMed PMID: 19143858.
197. Di Cosimo S, **Baselga J**. "Targeted therapies in breast cancer: where are we now?" *Eur J Cancer*. 2008 Dec;44(18):2781-90. doi: 10.1016/j.ejca.2008.09.026. Review. PubMed PMID: 19013786.
198. Carracedo A, **Baselga J**, Pandolfi PP. "Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors." *Cell Cycle*. 2008 Dec 15;7(24):3805-9. Review. PubMed PMID: 19098454; PubMed Central PMCID: PMC3130531.
199. Cortes J, Di Cosimo S, Climent MA, Cortés-Funes H, Lluch A, Gascón P, Mayordomo JI, Gil M, Benavides M, Cirera L, Ojeda B, Rodríguez CA, Trigo JM, Vazquez J, Regueiro P, Dorado JF, **Baselga J**; Spanish Breast Cancer Cooperative Group SOLTI. "Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study." *Clin Cancer Res*. 2009 Jan 1;15(1):307-14. doi: 10.1158/1078-0432.CCR-08-1113. Erratum in: *Clin Cancer Res*. 2009 Mar 1;15(5):1843. PubMed PMID: 19118059.

200. Prat A, Parera M, Adamo B, Peralta S, Perez-Benavente MA, Garcia A, Gil-Moreno A, Martinez-Palones JM, **Baselga J**, del Campo JM. "Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels." *Ann Oncol*. 2009 Feb;20(2):294-7. doi: 10.1093/annonc/mdn601. PubMed PMID: 18820245.
201. **Baselga J**, Zambetti M, Llombart-Cussac A, Manikhas G, Kubista E, Steger GG, Makhson A, Tjulandin S, Ludwig H, Verrill M, Ciruelos E, Egyhazi S, Xu LA, Zerba KE, Lee H, Clark E, Galbraith S. "Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer." *J Clin Oncol*. 2009 Feb 1;27(4):526-34. doi: 10.1200/JCO.2007.14.2646. PubMed PMID: 19075286.
202. Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K, Smith DJ, Landolfi S, Ramon y Cajal S, Arribas J, **Baselga J**. "Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity." *Oncogene*. 2009 Feb 12;28(6):803-14. doi: 10.1038/onc.2008.432. PubMed PMID: 19060928.
203. Lennon S, Barton C, Banken L, Gianni L, Marty M, **Baselga J**, Leyland-Jones B. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer." *J Clin Oncol*. 2009 Apr 1;27(10):1685-93. doi: 10.1200/JCO.2008.16.8351. Review. PubMed PMID: 19255335.
204. Peñuelas S, Anido J, Prieto-Sánchez RM, Folch G, Barba I, Cuartas I, García-Dorado D, Poca MA, Sahuquillo J, **Baselga J**, Seoane J. "TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma." *Cancer Cell*. 2009 Apr 7;15(4):315-27. doi: 10.1016/j.ccr.2009.02.011. PubMed PMID: 19345330.
205. Gianni L, **Baselga J**, Eiermann W, Porta VG, Semiglazov V, Lluch A, Zambetti M, Sabadell D, Raab G, Cussac AL, Bozhok A, Martinez-Agulló A, Greco M, Byakhov M, Lopez JJ, Mansutti M, Valagussa P, Bonadonna G. "Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer." *J Clin Oncol*. 2009 May 20;27(15):2474-81. doi: 10.1200/JCO.2008.19.2567. PubMed PMID: 19332727.
206. **Baselga J**, Gianni L, Gradishar WJ, Hudis C, Perez EA, Piccart-Gebhart M, Schwartzberg LS, Sledge G, Fleming TR. "Phase IIb double-blind, randomized, placebo-controlled trials for the efficacy and safety of sorafenib in patients (pts) with metastatic or locally advanced breast cancer (BC): Review of the Trials to Investigate the Effects of Sorafenib in BC (TIES) program." *J Clin Oncol*. 2009 May 20;27(15\_suppl):e12000. PubMed PMID: 27964262.
207. Saura C, **Baselga J**, Herbst R, Del Campo J, Marotti M, Tessier J, Collins B, Heymach J. "Antitumor activity of cediranib in patients with metastatic or recurrent head and neck cancer (HNC) or recurrent non-small cell lung cancer (NSCLC): An open-label exploratory study." *J Clin Oncol*. 2009 May 20;27(15\_suppl):6023. PubMed PMID: 27962431.
208. Macarulla T, Rodríguez-Braun E, Tabernero J, Roselló S, **Baselga J**, Lee Y, Manfredi M, Liu H, Fingert H, Cervantes A. "Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of the selective aurora A kinase (AAK) inhibitor MLN8054 in patients (pts) with advanced solid tumors." *J Clin Oncol*. 2009 May 20;27(15\_suppl):2578. PubMed PMID: 27961890.
209. Capdevila J, Clive S, Tabernero J, Lardelli P, Soto-Matos A, **Baselga J**, Piera A, Pardos I, Rye R, Smyth JF. "Phase I study of the novel anticancer drug PM00104 as a 24-hour IV infusion every 3

weeks (q3w) in patients (pts) with advanced solid tumors or lymphoma.” *J Clin Oncol*. 2009 May 20;27(15\_suppl):2568. PubMed PMID: 27961881.

210. Horak CE, Lee FY, Xu L, Galbraith S, **Baselga J**. “High  $\beta$ -III tubulin expression in triple-negative (TN) breast cancer (BC) subtype and correlation to ixabepilone response: A retrospective analysis.” *J Clin Oncol*. 2009 May 20;27(15\_suppl):3587. PubMed PMID: 27961747.
211. Perez Garcia JM Sr, Saura C, Muñoz E, Sanchez-Olle G, Gomez P, Peg V, Sabadell D, Cortes J, **Baselga J**, Bellet M. “Role of progesterone receptor status (PR) as predictive factor of pathological complete response (pCR) to neoadjuvant chemotherapy (NACT) in breast cancer (BC) patients (pts).” *J Clin Oncol*. 2009 May 20;27(15\_suppl):637. PubMed PMID: 27961451.
212. Tabernero J, Dirix L, Schoffski P, Cervantes A, Capdevila J, **Baselga J**, van Beijsterveldt L, Winkler H, Kraljevic S, Zhuang SH. “Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of HDM-2 antagonist JNJ-26854165 in patients with advanced refractory solid tumors.” *J Clin Oncol*. 2009 May 20;27(15\_suppl):3514. PubMed PMID: 27961305.
213. Eskens FA, Ramos FJ, Burger H, de Jonge MJ, Wanders J, Lopez-Anaya A, **Baselga J**, Tabernero J. “First-in-human clinical, pharmacokinetic (PK), and pharmacodynamic (PD) phase I study of the first-in-class spliceosome inhibitor E7107 administered IV (bolus) on days 1, 8, and 15 every 28 days to patients with solid tumors.” *J Clin Oncol*. 2009 May 20;27(15\_suppl):3508. PubMed PMID: 27961296
214. Shapiro G, Kwak E, **Baselga J**, Rodon J, Scheffold C, Laird AD, Bedell C, Edelman G. “Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors.” *J Clin Oncol*. 2009 May 20;27(15\_suppl):3500. PubMed PMID: 27961287.
215. Prudkin L, Aura CM, Jimenez J, Scaltriti M, Ellis C, Gagnon R, Arbushites M, Liu Y, Koehler M, **Baselga J**. “Clinical benefit of lapatinib-based therapy in patients with HER2-positive breast tumors expressing p95HER2.” *J Clin Oncol*. 2009 May 20;27(15\_suppl):1048. PubMed PMID: 27961096.
216. Cortés J, **Baselga J**, Petrella T, Gelmon K, Fumoleau P, Verma S, Pivot X, Ross G, Szado T, Gianni L. “Pertuzumab monotherapy following trastuzumab-based treatment: Activity and tolerability in patients with advanced HER2- positive breast cancer.” *J Clin Oncol*. 2009 May 20;27(15\_suppl):1022. PubMed PMID: 27961043.
217. Serrano C, Cortés J, Bellet M, Gómez P, Saura C, Martínez P, Pérez J, Atzori F, **Baselga J**, Di Cosimo S. “Trastuzumab in the elderly: Is it age or cardiovascular risk profile that really matters?” *J Clin Oncol*. 2009 May 20;27(15\_suppl):e20527. PubMed PMID: 27961003
218. **Baselga J**, Semiglazov V, Van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W and Rugo HS. "Phase II randomized neoadjuvant study of the mTOR inhibitor everolimus (RAD001) in combination with letrozole versus placebo and letrozole in patients with ER+ breast cancer." *J Clin Oncol*. 2009 Jun 1; 27(16):2630-7. doi: 10.1200/JCO.2008.18.8391. PubMed PMID: 19380449.
219. Pedersen K, Angelini PD, Laos S, Bach-Faig A, Cunningham MP, Ferrer-Ramón C, Luque-García A, García-Castillo J, Parra-Palau JL, Scaltriti M, Ramón y Cajal S, **Baselga J**, Arribas J. “A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and

metastasis." *Mol Cell Biol*. 2009 Jun;29(12):3319-31. doi: 10.1128/MCB.01803-08. PubMed PMID: 19364815; PubMed Central PMCID: PMC2698729.

220. **Baselga J**, Swain SM. "Novel anticancer targets: revisiting ERBB2 and discovering ERBB3." *Nat Rev Cancer*. 2009 Jul;9(7):463-75. doi: 10.1038/nrc2656. Review. PubMed PMID: 19536107.
221. Di Cosimo S, **Baselga J**. "Phosphoinositide 3-kinase mutations in breast cancer: a "good" activating mutation?" *Clin Cancer Res*. 2009 Aug 15;15(16):5017-9. doi: 10.1158/1078-0432.CCR-09-1173. PubMed PMID: 19671849.
222. Pomerantz MM, Ahmadiyah N, Jia L, Herman P, Verzi MP, Doddapaneni H, Beckwith CA, Chan JA, Hills A, Davis M, Yao K, Kehoe SM, Lenz HJ, Haiman CA, Yan C, Henderson BE, Frenkel B, Barretina J, Bass A, Tabernero J, **Baselga J**, Regan MM, Manak JR, Shivdasani R, Coetzee GA, Freedman ML. "The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer." *Nat Genet*. 2009 Aug;41(8):882-4. doi: 10.1038/ng.403. PubMed PMID: 19561607; PubMed Central PMCID: PMC2763485.
223. Garcia-Castillo J, Pedersen K, Angelini PD, Bech-Serra JJ, Colome N, Cunningham MP, Parra Palau JL, Canals F, **Baselga J**, Arribas J. "HER2 carboxy terminal fragments regulate cell migration and cortactin phosphorylation". *J Biol Chem*. 2009 Sep 11; 284(37):25302-13.
224. Cortes J, **Baselga J**. "How to treat hormone receptor positive, HER2 amplified breast cancer?". *J Clin Oncol*. 2009 Nov 20; 27(33):5492-4. doi: 10.1200/JCO.2009.23.8089. PubMed PMID: 19786653.
225. Mittendorf EA, Wu Y, Scaltriti M, Meric-Bernstam F, Hunt KK, Dawood S, Esteva FJ, Buzdar AU, Chen H, Eksambi S, Hortobagyi GN, **Baselga J**, Gonzalez-Angulo AM. "Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes." *Clin Cancer Res*. 2009 Dec 1;15(23):7381-8. doi: 10.1158/1078-0432.CCR-09-1735. PubMed PMID: 19920100; PubMed Central PMCID: PMC2788123.
226. Nemunaitis J, Clayman G, Agarwala SS, Hrushesky W, Wells JR, Moore C, Hamm J, Yoo G, **Baselga J**, Murphy BA, Menander KA, Licato LL, Chada S, Gibbons RD, Olivier M, Hainaut P, Roth JA, Sobol RE, Goodwin WJ. "Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck." *Clin Cancer Res*. 2009 Dec 15;15(24):7719-7725. PubMed PMID: 19996201.
227. Markman B, Atzori F, Pérez-García J, Tabernero J, **Baselga J**. "Status of PI3K inhibition and biomarker development in cancer therapeutics." *Ann Oncol*. 2010 Apr;21(4):683-91. doi: 10.1093/annonc/mdp347. Review. PubMed PMID: 19713247.
228. Chandarlapaty S, Scaltriti M, Angelini P, Ye Q, Guzman M, Hudis CA, Norton L, Solit DB, Arribas J, **Baselga J**, Rosen N. "Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth." *Oncogene*. 2010 Jan 21;29(3):325-34. doi: 10.1038/onc.2009.337. PubMed PMID: 19855434; PubMed Central PMCID: PMC3057066.
229. Ellis MJ, Lin L, Crowder R, Tao Y, Hoog J, Snider J, Davies S, DeSchryver K, Evans DB, Steinseifer J, Bandaru R, Liu W, Gardner H, Semiglazov V, Watson M, Hunt K, Olson J, **Baselga J**. "Phosphatidylinositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer." *Breast Cancer Res Treat*. 2010 Jan;119(2):379-90. doi: 10.1007/s10549-009-0575-y. PubMed PMID: 19844788; PubMed Central PMCID: PMC2810126.

230. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, **Baselga J**, Spencer SA, Zhu J, Yousoufian H, Rowinsky EK, Ang KK. "Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival." *Lancet Oncol*. 2010 Jan;11(1):21-8. doi: 10.1016/S1470-2045(09)70311-0. Erratum in: *Lancet Oncol*. 2010 Jan;11(1):14. PubMed PMID: 19897418.
231. Cedrés S, Prat A, Martínez P, Pallisa E, Sala G, Andreu J, del Campo JM, Quispe I, **Baselga J**, Felip E. "Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib." *Lung Cancer*. 2009 Nov;66(2):257-61. doi: 10.1016/j.lungcan.2009.01.014. PubMed PMID: 19231023.
232. Tabernero J, Ciardiello F, Rivera F, Rodriguez-Braun E, Ramos FJ, Martinelli E, Vega-Villegas ME, Roselló S, Liebscher S, Kisker O, Macarulla T, **Baselga J**, Cervantes A. "Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study." *Ann Oncol*. 2010 Jul;21(7):1537-45. doi: 10.1093/annonc/mdp549. PubMed PMID: 19940007.
233. Ciruelos EM, Cortés J, Cortés-Funes H, Mayordomo JI, Bermejo B, Ojeda B, García E, Rodríguez CA, Muñoz M, Gómez P, Manso L, Andrés R, Lluch A, Saura C, Mendiola C, **Baselga J**. "Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial)." *Ann Oncol*. 2010 Jul;21(7):1442-7. doi: 10.1093/annonc/mdp536. PubMed PMID: 19940004.
234. Gianni L, Lladó A, Bianchi G, Cortes J, Kellokumpu-Lehtinen PL, Cameron DA, Miles D, Salvagni S, Wardley A, Goeminne JC, Hersberger V, **Baselga J**. "Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer." *J Clin Oncol*. 2010 Mar 1;28(7):1131-7. doi: 10.1200/JCO.2009.24.1661. PubMed PMID: 20124183; PubMed Central PMCID: PMC4979215.
235. **Baselga J**, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally VA, Ross GA, Fumoleau P, Gianni L. "Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy." *J Clin Oncol*. 2010 Mar 1;28(7):1138-44. doi: 10.1200/JCO.2009.24.2024. PubMed PMID: 20124182; PubMed Central PMCID: PMC4979216.
236. Tabernero J, Cervantes A, Rivera F, Martinelli E, Rojo F, von Heydebreck A, Macarulla T, Rodriguez-Braun E, Eugenia Vega-Villegas M, Senger S, Ramos FJ, Roselló S, Celik I, Stroh C, **Baselga J**, Ciardiello F. "Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study." *J Clin Oncol*. 2010 Mar 1;28(7):1181-9. doi: 10.1200/JCO.2009.22.6043. PubMed PMID: 20100964.
237. Beroukhi R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, **Baselga J**, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR,

- Lander ES, Getz G, Sellers WR, Meyerson M. "The landscape of somatic copy-number alteration across human cancers." *Nature*. 2010 Feb 18;463(7283):899-905. doi: 10.1038/nature08822. PubMed PMID: 20164920; PubMed Central PMCID: PMC2826709.
238. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Bozhok A, Baronio R, Feyereislova A, Valagussa P, **Baselga J**. "Neoadjuvant Trastuzumab in patients with HER2-positive locally advanced breast cancer: a randomized phase III trial with a parallel HER2-negative cohort (the NOAH trial)". *Lancet*. 2010 Jan 30;375(9712):377-84.
239. Parra-Palau JL, Pedersen K, Peg V, Scaltriti M, Angelini PD, Escorihuela M, Mancilla S, Sánchez Pla A, Ramón Y Cajal S, **Baselga J**, Arribas J. "A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers." *Cancer Res*. 2010 Nov 1;70(21):8537-46. doi: 10.1158/0008-5472.CAN-10-1701. PubMed PMID: 20978202.
240. **Baselga J**, Cervantes A, Martinelli E, Chirivella I, Hoekman K, Hurwitz HI, Jodrell DI, Hamberg P, Casado E, Elvin P, Swaisland A, Iacona R, Tabernero J. "Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors." *Clin Cancer Res*. 2010 Oct 1;16(19):4876-83. doi: 10.1158/1078-0432.CCR-10-0748. PubMed PMID: 20805299.
241. Colomer R, Alba E, González-Martin A, Paz-Ares L, Martín M, Llombart A, Rodríguez Lescure A, Salvador J, Albanell J, Isla D, Lomas M, Rodríguez CA, Trigo JM, Germà JR, Bellmunt J, Tabernero J, Rosell R, Aranda E, Cubedo R, **Baselga J**; Spanish Society of Medical Oncology.. "Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM)." *Ann Oncol*. 2010 Feb;21(2):195-8. doi: 10.1093/annonc/mdp595. PubMed PMID: 20110291; PubMed Central PMCID: PMC2813309.
242. Tan EH, Ramlau R, Pluzanska A, Kuo HP, Reck M, Milanowski J, Au JS, Felip E, Yang PC, Damyranov D, Orlov S, Akimov M, Delmar P, Essioux L, Hillenbach C, Klughammer B, McLoughlin P, **Baselga J**. "A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer." *Ann Oncol*. 2010 Feb;21(2):217-22. doi: 10.1093/annonc/mdp520. PubMed PMID: 20110292; PubMed Central PMCID: PMC2813308.
243. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, **Baselga J**, O'Shaughnessy J. "Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer." *J Clin Oncol*. 2010 Mar 1;28(7):1124-30. doi: 10.1200/JCO.2008.21.4437. PubMed PMID: 20124187.
244. Cherny NI, **Baselga J**, de Conno F, Radbruch L. "Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC Opioid Policy Initiative." *Ann Oncol*. 2010 Mar;21(3):615-26. doi: 10.1093/annonc/mdp581. PubMed PMID: 20176694.
245. Di Cosimo S, **Baselga J**. "Correction: Management of breast cancer with targeted therapies: importance of heterogeneity". *Nat Rev Clin Oncol*. 2010 Apr; 7(4):184.
246. Macarulla T, Cervantes A, Elez E, Rodríguez-Braun E, **Baselga J**, Roselló S, Sala G, Blasco I, Danaee H, Lee Y, Ecsedy J, Shinde V, Chakravarty A, Bowman D, Liu H, Eton O, Fingert H, Tabernero J. "Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with

- advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics.” *Mol Cancer Ther.* 2010 Oct;9(10):2844-52. doi: 10.1158/1535-7163.MCT-10-0299. PubMed PMID: 20724522.
247. Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin D, Mazzucchelli L, Sasazuki T, Shirasawa S, Geuna M, Frattini M, **Baselga J**, Gallicchio M, Biffo S, Bardelli A. “Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.” *J Clin Invest.* 2010 Aug;120(8):2858-66. doi: 10.1172/JCI37539. PubMed PMID: 20664172; PubMed Central PMCID: PMC2912177.
248. Scaltriti M, Chandarlapaty S, Prudkin L, Aura C, Jimenez J, Angelini PD, Sánchez G, Guzman M, Parra JL, Ellis C, Gagnon R, Koehler M, Gomez H, Geyer C, Cameron D, Arribas J, Rosen N, **Baselga J**. “Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.” *Clin Cancer Res.* 2010 May 1;16(9):2688-95. doi: 10.1158/1078-0432.CCR-09-3407. PubMed PMID: 20406840; PubMed Central PMCID: PMC3243489.
249. Eichhorn PJ, **Baselga J**. “HER2 signatures in breast cancer: ready to go to print?” *J Clin Oncol.* 2010 Apr 10;28(11):1809-10. doi: 10.1200/JCO.2009.26.7146. PubMed PMID: 20231675.
250. Pomerantz MM, Shrestha Y, Flavin RJ, Regan MM, Penney KL, Mucci LA, Stampfer MJ, Hunter DJ, Chanock SJ, Schafer EJ, Chan JA, Tabernero J, **Baselga J**, Richardson AL, Loda M, Oh WK, Kantoff PW, Hahn WC, Freedman ML. “Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis.” *PLoS Genet.* 2010 Nov 11;6(11):e1001204. doi: 10.1371/journal.pgen.1001204. PubMed PMID: 21085629; PubMed Central PMCID: PMC2978684.
251. **Baselga J**, Swain SM. “CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.” *Clin Breast Cancer.* 2010 Dec 1;10(6):489-91. doi: 10.3816/CBC.2010.n.065. PubMed PMID: 21147694.
252. Anido J, Sáez-Borderías A, González-Juncà A, Rodón L, Folch G, Carmona MA, Prieto-Sánchez RM, Barba I, Martínez-Sáez E, Prudkin L, Cuartas I, Raventós C, Martínez-Ricarte F, Poca MA, García-Dorado D, Lahn MM, Yingling JM, Rodón J, Sahuquillo J, **Baselga J**, Seoane J. “TGF- $\beta$  Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma.” *Cancer Cell.* 2010 Dec 14;18(6):655-68. doi: 10.1016/j.ccr.2010.10.023. PubMed PMID: 21156287.
253. **Baselga J**. “Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer.” *Oncologist.* 2011;16 Suppl 1:12-9. doi: 10.1634/theoncologist.2011-S1-12. Review. PubMed PMID: 21278436.
254. Cheek CF, Verma CS, **Baselga J**, Lane DP. “Translating p53 into the clinic.” *Nat Rev Clin Oncol.* 2011 Jan;8(1):25-37. doi: 10.1038/nrclinonc.2010.174. Review. PubMed PMID: 20975744.
255. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, **Baselga J**, Rosen N. “AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.” *Cancer Cell.* 2011 Jan 18;19(1):58-71. doi: 10.1016/j.ccr.2010.10.031. PubMed PMID: 21215704; PubMed Central PMCID: PMC3025058.
256. Isakoff SJ, **Baselga J**. “Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer.” *J Clin Oncol.* 2011 Feb 1;29(4):351-4. doi: 10.1200/JCO.2010.31.6679. PubMed PMID: 21172881.



257. Scaltriti M, Eichhorn PJ, Cortés J, Prudkin L, Aura C, Jiménez J, Chandarlapaty S, Serra V, Prat A, Ibrahim YH, Guzmán M, Gili M, Rodríguez O, Rodríguez S, Pérez J, Green SR, Mai S, Rosen N, Hudis C, **Baselga J**. “Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.” *Proc Natl Acad Sci U S A*. 2011 Mar 1;108(9):3761-6. doi: 10.1073/pnas.1014835108. PubMed PMID: 21321214; PubMed Central PMCID: PMC3048107.
258. Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, **Baselga J**, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulou G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R; Herceptin Adjuvant (HERA) Trial Study Team.. “Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.” *Lancet Oncol*. 2011 Mar;12(3):236-44. doi: 10.1016/S1470-2045(11)70033-X. PubMed PMID: 21354370.
259. Faber AC, Corcoran RB, Ebi H, Sequist LV, Waltman BA, Chung E, Incio J, Digumarthy SR, Pollack SF, Song Y, Muzikansky A, Lifshits E, Roberge S, Coffman EJ, Benes CH, Gómez HL, **Baselga J**, Arteaga CL, Rivera MN, Dias-Santagata D, Jain RK, Engelman JA. “BIM expression in treatment-naïve cancers predicts responsiveness to kinase inhibitors.” *Cancer Discov*. 2011 Sep;1(4):352-65. doi: 10.1158/2159-8290.CD-11-0106. PubMed PMID: 22145099; PubMed Central PMCID: PMC3229203.
260. Wu Y, Amonkar MM, Sherrill BH, O'Shaughnessy J, Ellis C, **Baselga J**, Blackwell KL, Burstein HJ. “Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.” *Ann Oncol*. 2011 Dec;22(12):2582-90. doi: 10.1093/annonc/mdr014. PubMed PMID: 21406472.
261. Haber DA, Gray NS, **Baselga J**. “The evolving war on cancer.” *Cell*. 2011 Apr 1;145(1):19-24. doi: 10.1016/j.cell.2011.03.026. PubMed PMID: 21458664.
262. Scaltriti M, Serra V, Normant E, Guzman M, Rodriguez O, Lim AR, Slocum KL, West KA, Rodriguez V, Prudkin L, Jimenez J, Aura C, **Baselga J**. “Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer.” *Mol Cancer Ther*. 2011 May;10(5):817-24. doi: 10.1158/1535-7163.MCT-10-0966. PubMed PMID: 21383049.
263. Soria JC, Cortes J, Massard C, Armand JP, De Andreis D, Ropert S, Lopez E, Catteau A, James J, Marier JF, Beliveau M, Martell RE, **Baselga J**. “Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.” *Ann Oncol*. 2012 Feb;23(2):463-71. doi: 10.1093/annonc/mdr137. PubMed PMID: 21576284.
264. Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S, Markman B, Rodriguez O, Guzman M, Rodriguez S, Gili M, Russillo M, Parra JL, Singh S, Arribas J, Rosen N, **Baselga J**. “PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer.” *Oncogene*. 2011 Jun 2;30(22):2547-57. doi: 10.1038/onc.2010.626. PubMed PMID: 21278786; PubMed Central PMCID: PMC3107390.
265. Lenihan D, Suter T, Brammer M, Neate C, Ross G, **Baselga J**. “Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab.” *Ann Oncol*. 2012 Mar;23(3):791-800. doi: 10.1093/annonc/mdr294. PubMed PMID: 21665955; PubMed Central PMCID: PMC3331733.

266. Bass AJ, Lawrence MS, Brace LE, Ramos AH, Drier Y, Cibulskis K, Sougnez C, Voet D, Saksena G, Sivachenko A, Jing R, Parkin M, Pugh T, Verhaak RG, Stransky N, Boutin AT, Barretina J, Solit DB, Vakiani E, Shao W, Mishina Y, Warmuth M, Jimenez J, Chiang DY, Signoretti S, Kaelin WG, Spardy N, Hahn WC, Hoshida Y, Ogino S, Depinho RA, Chin L, Garraway LA, Fuchs CS, **Baselga J**, Tabernero J, Gabriel S, Lander ES, Getz G, Meyerson M. "Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion." *Nat Genet.* 2011 Sep 4;43(10):964-8. doi: 10.1038/ng.936. PubMed PMID: 21892161; PubMed Central PMCID: PMC3802528.
267. Semiglazov V, Eiermann W, Zambetti M, Manikhas A, Bozhok A, Lluch A, Tjulandin S, Sabadell MD, Caballero A, Valagussa P, **Baselga J**, Gianni L. "Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study." *Eur J Surg Oncol.* 2011 Oct;37(10):856-63. doi: 10.1016/j.ejso.2011.07.003. PubMed PMID: 21843921.
268. Serrano C, Cortés J, De Mattos-Arruda L, Bellet M, Gómez P, Saura C, Pérez J, Vidal M, Muñoz-Couselo E, Carreras MJ, Sánchez-Ollé G, Tabernero J, **Baselga J**, Di Cosimo S. "Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors." *Ann Oncol.* 2012 Apr;23(4):897-902. doi: 10.1093/annonc/mdr348. PubMed PMID: 21828361.
269. Paz-Ares LG, Gomez-Roca C, Delord JP, Cervantes A, Markman B, Corral J, Soria JC, Bergé Y, Roda D, Russell-Yarde F, Hollingsworth S, **Baselga J**, Umana P, Manenti L, Tabernero J. "Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors." *J Clin Oncol.* 2011 Oct 1;29(28):3783-90. doi: 10.1200/JCO.2011.34.8888. PubMed PMID: 21900113.
270. Atzori F, Tabernero J, Cervantes A, Prudkin L, Andreu J, Rodríguez-Braun E, Domingo A, Guijarro J, Gamez C, Rodon J, Di Cosimo S, Brown H, Clark J, Hardwick JS, Beckman RA, Hanley WD, Hsu K, Calvo E, Roselló S, Langdon RB, **Baselga J**. "A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors." *Clin Cancer Res.* 2011 Oct 1;17(19):6304-12. doi: 10.1158/1078-0432.CCR-10-3336. PubMed PMID: 21810918.
271. Higgins MJ, **Baselga J**. "Targeted therapies for breast cancer." *J Clin Invest.* 2011 Oct;121(10):3797-803. doi: 10.1172/JCI57152. Review. PubMed PMID: 21965336; PubMed Central PMCID: PMC3195649.
272. Cortes J, Calvo V, Ramírez-Merino N, O'Shaughnessy J, Brufsky A, Robert N, Vidal M, Muñoz E, Perez J, Dawood S, Saura C, Di Cosimo S, González-Martín A, Bellet M, Silva OE, Miles D, Llombart A, **Baselga J**. "Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis." *Ann Oncol.* 2012 May;23(5):1130-7. doi: 10.1093/annonc/mdr432. Review. PubMed PMID: 21976387.
273. Kostic AD, Gevers D, Pedomallu CS, Michaud M, Duke F, Earl AM, Ojesina AI, Jung J, Bass AJ, Tabernero J, **Baselga J**, Liu C, Shivdasani RA, Ogino S, Birren BW, Huttenhower C, Garrett WS, Meyerson M. "Genomic analysis identifies association of Fusobacterium with colorectal carcinoma." *Genome Res.* 2012 Feb;22(2):292-8. doi: 10.1101/gr.126573.111. PubMed PMID: 22009990; PubMed Central PMCID: PMC3266036.

274. Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, Lennes IT, Digumarthy S, Waltman BA, Bast E, Tammireddy S, Morrissey L, Muzikansky A, Goldberg SB, Gainor J, Channick CL, Wain JC, Gaissert H, Donahue DM, Muniappan A, Wright C, Willers H, Mathisen DJ, Choi NC, **Baselga J**, Lynch TJ, Ellisen LW, Mino-Kenudson M, Lanuti M, Borger DR, Iafrate AJ, Engelman JA, Dias-Santagata D. "Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice." *Ann Oncol*. 2011 Dec;22(12):2616-24. doi: 10.1093/annonc/mdr489. PubMed PMID: 22071650; PubMed Central PMCID: PMC3493130.
275. **Baselga J**, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. "Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer." *N Engl J Med*. 2012 Feb 9;366(6):520-9. doi: 10.1056/NEJMoa1109653. PubMed PMID: 22149876.
276. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birlle D, Demanse D, De Buck SS, Ru QC, Peters M, Goldbrunner M, **Baselga J**. "Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors." *J Clin Oncol*. 2012 Jan 20;30(3):282-90. doi: 10.1200/JCO.2011.36.1360. PubMed PMID: 22162589.
277. **Baselga J**, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM; CLEOPATRA Study Group. "Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer." *N Engl J Med*. 2012 Jan 12;366(2):109-19. doi: 10.1056/NEJMoa1113216. PubMed PMID: 22149875.
278. Hannon RA, Finkelman RD, Clack G, Iacona RB, Rimmer M, Gossiel F, **Baselga J**, Eastell R. "Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study." *Bone*. 2012 Apr;50(4):885-92. doi: 10.1016/j.bone.2011.12.017. PubMed PMID: 22245630.
279. Markman B, Tabernero J, Krop I, Shapiro GI, Siu L, Chen LC, Mita M, Melendez Cuero M, Stutvoet S, Birlle D, Anak O, Hackl W, **Baselga J**. "Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors." *Ann Oncol*. 2012 Sep;23(9):2399-408. doi: 10.1093/annonc/mds011. PubMed PMID: 22357447.
280. Juric D, **Baselga J**. "Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors." *J Clin Oncol*. 2012 Mar 10;30(8):765-6. doi: 10.1200/JCO.2011.39.6390. PubMed PMID: 22271482.
281. Eichhorn PJ, Rodón L, González-Juncà A, Dirac A, Gili M, Martínez-Sáez E, Aura C, Barba I, Peg V, Prat A, Cuartas I, Jimenez J, García-Dorado D, Sahuquillo J, Bernards R, **Baselga J**, Seoane J. "USP15 stabilizes TGF- $\beta$  receptor I and promotes oncogenesis through the activation of TGF- $\beta$  signaling in glioblastoma." *Nat Med*. 2012 Feb 19;18(3):429-35. doi: 10.1038/nm.2619. PubMed PMID: 22344298.
282. **Baselga J**, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gómez H, Dinh P, Fauria K, Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horváth Z, Coccia-Portugal M, Domont J, Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Puztai L, Untch M, Gelber RD, Piccart-Gebhart M; NeoALTTO Study Team. "Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial." *Lancet*. 2012 Feb 18;379(9816):633-40. doi: 10.1016/S0140-

6736(11)61847-3. Erratum in: *Lancet*. 2012 Feb 18;379(9816):616. Dosage error in published abstract; MEDLINE/PubMed abstract corrected. PubMed PMID: 22257673.

283. Vilar E, Grünwald V, Schöffski P, Singer H, Salazar R, Iglesias JL, Casado E, Cullell-Young M, **Baselga J**, Tabernero J. "A phase I dose-escalating study of ES-285, a marine sphingolipid-derived compound, with repeat dose administration in patients with advanced solid tumors." *Invest New Drugs*. 2012 Feb;30(1):299-305. doi: 10.1007/s10637-010-9529-9. PubMed PMID: 20820909.
284. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, Bignell GR, Tam AT, Davies H, Stevenson JA, Barthorpe S, Lutz SR, Kogera F, Lawrence K, McLaren-Douglas A, Mitropoulos X, Mironenko T, Thi H, Richardson L, Zhou W, Jewitt F, Zhang T, O'Brien P, Boisvert JL, Price S, Hur W, Yang W, Deng X, Butler A, Choi HG, Chang JW, **Baselga J**, Stamenkovic I, Engelman JA, Sharma SV, Delattre O, Saez-Rodriguez J, Gray NS, Settleman J, Futreal PA, Haber DA, Stratton MR, Ramaswamy S, McDermott U, Benes CH. "Systematic identification of genomic markers of drug sensitivity in cancer cells." *Nature*. 2012 Mar 28;483(7391):570-5. doi: 10.1038/nature11005. PubMed PMID: 22460902; PubMed Central PMCID: PMC3349233.
285. Serrano C, Cortés J, De Mattos-Arruda L, Bellet M, Gómez P, Saura C, Pérez J, Vidal M, Muñoz-Couselo E, Carreras MJ, Sánchez-Ollé G, Tabernero J, **Baselga J**, Di Cosimo S. "Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors." *Ann Oncol*. 2012 Apr;23(4):897-902. doi: 10.1093/annonc/mdr348. PubMed PMID: 21828361.
286. **Baselga J**, Segalla JG, Roché H, Del Giglio A, Pinczowski H, Ciruelos EM, Filho SC, Gómez P, Van Eyll B, Bermejo B, Llombart A, Garicochea B, Durán MÁ, Hoff PM, Espié M, de Moraes AA, Ribeiro RA, Mathias C, Gil Gil M, Ojeda B, Morales J, Kwon Ro S, Li S, Costa F. "Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer." *J Clin Oncol*. 2012 May 1;30(13):1484-91. doi: 10.1200/JCO.2011.36.7771. PubMed PMID: 22412143.
287. García-García C, Ibrahim YH, Serra V, Calvo MT, Guzmán M, Grueso J, Aura C, Pérez J, Jessen K, Liu Y, Rommel C, Tabernero J, **Baselga J**, Scaltriti M. "Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy." *Clin Cancer Res*. 2012 May 1;18(9):2603-12. doi: 10.1158/1078-0432.CCR-11-2750. PubMed PMID: 22407832.
288. Cortés J, Fumoleau P, Bianchi GV, Petrella TM, Gelmon K, Pivot X, Verma S, Albanell J, Conte P, Lluch A, Salvagni S, Servent V, Gianni L, Scaltriti M, Ross GA, Dixon J, Szado T, **Baselga J**. "Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer." *J Clin Oncol*. 2012 May 10;30(14):1594-600. doi: 10.1200/JCO.2011.37.4207. PubMed PMID: 22393084.
289. Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA Jr, Ellis P, Di Leo A, **Baselga J**, Sotiriou C, Piccart-Gebhart M. "Dissecting the heterogeneity of triple-negative breast cancer." *J Clin Oncol*. 2012 May 20;30(15):1879-87. doi: 10.1200/JCO.2011.38.2010. Review. PubMed PMID: 22454417.
290. **Baselga J**, Smith BL, Rafferty EA, Bombonati A. "Case records of the Massachusetts General Hospital. Case 16-2012. A 32-year-old woman with HER2-positive breast cancer." *N Engl J Med*. 2012 May 24;366(21):2018-26. doi: 10.1056/NEJMcpc1111576. PubMed PMID: 22621630.

291. Morancho B, Parra-Palau JL, Ibrahim YH, Bernadó Morales C, Peg V, Bech-Serra JJ, Pandiella A, Canals F, **Baselga J**, Rubio I, Arribas J. "A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers." *Oncogene*. 2013 Mar 14;32(11):1452-9. doi: 10.1038/onc.2012.152. PubMed PMID: 22641219.
292. Rodón J, Saura C, Dienstmann R, Vivancos A, Ramón y Cajal S, **Baselga J**, Tabernero J. "Molecular prescreening to select patient population in early clinical trials." *Nat Rev Clin Oncol*. 2012 Apr 3;9(6):359-66. doi: 10.1038/nrclinonc.2012.48. PubMed PMID: 22473105.
293. Tenbaum SP, Ordóñez-Morán P, Puig I, Chicote I, Arqués O, Landolfi S, Fernández Y, Herance JR, Gispert JD, Mendizabal L, Aguilar S, Ramón y Cajal S, Schwartz S Jr, Vivancos A, Espín E, Rojas S, **Baselga J**, Tabernero J, Muñoz A, Palmer HG. "β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer." *Nat Med*. 2012 Jun;18(6):892-901. doi: 10.1038/nm.2772. PubMed PMID: 22610277.
294. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY, Sougnez C, Zou L, Cortes ML, Fernandez-Lopez JC, Peng S, Ardlie KG, Auclair D, Bautista-Piña V, Duke F, Francis J, Jung J, Maffuz-Aziz A, Onofrio RC, Parkin M, Pho NH, Quintanar-Jurado V, Ramos AH, Rebollar-Vega R, Rodriguez-Cuevas S, Romero-Cordoba SL, Schumacher SE, Stransky N, Thompson KM, Uribe-Figueroa L, **Baselga J**, Beroukhir R, Polyak K, Sgroi DC, Richardson AL, Jimenez-Sanchez G, Lander ES, Gabriel SB, Garraway LA, Golub TR, Melendez-Zajgla J, Toker A, Getz G, Hidalgo-Miranda A, Meyerson M. "Sequence analysis of mutations and translocations across breast cancer subtypes." *Nature*. 2012 Jun 20;486(7403):405-9. doi: 10.1038/nature11154. PubMed PMID: 22722202; PubMed Central PMCID: PMC4148686.
295. Gregori J, Villarreal L, Méndez O, Sánchez A, **Baselga J**, Villanueva J. "Batch effects correction improves the sensitivity of significance tests in spectral counting-based comparative discovery proteomics." *J Proteomics*. 2012 Jul 16;75(13):3938-51. doi: 10.1016/j.jprot.2012.05.005. PubMed PMID: 22588121.
296. Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, **Baselga J**, O'Shaughnessy J. "Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study." *J Clin Oncol*. 2012 Jul 20;30(21):2585-92. doi: 10.1200/JCO.2011.35.6725. PubMed PMID: 22689807.
297. Garraway LA, **Baselga J**. "Whole-genome sequencing and cancer therapy: is too much ever enough?" *Cancer Discov*. 2012 Sep;2(9):766-8. doi: 10.1158/2159-8290.CD-12-0359. PubMed PMID: 22969114.
298. Cervantes A, Elez E, Roda D, Ecsedy J, Macarulla T, Venkatakrishnan K, Roselló S, Andreu J, Jung J, Sanchis-Garcia JM, Piera A, Blasco I, Maños L, Pérez-Fidalgo JA, Fingert H, **Baselga J**, Tabernero J. "Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors." *Clin Cancer Res*. 2012 Sep 1;18(17):4764-74. doi: 10.1158/1078-0432.CCR-12-0571. PubMed PMID: 22753585.
299. Dulak AM, Schumacher SE, van Lieshout J, Imamura Y, Fox C, Shim B, Ramos AH, Saksena G, Baca SC, **Baselga J**, Tabernero J, Barretina J, Enzinger PC, Corso G, Roviello F, Lin L, Bandla S, Luketich JD, Pennathur A, Meyerson M, Ogino S, Shivdasani RA, Beer DG, Godfrey TE, Beroukhir R, Bass AJ. "Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon

exhibit distinct patterns of genome instability and oncogenesis.” *Cancer Res.* 2012 Sep 1;72(17):4383-93. PubMed PMID: 22751462; PubMed Central PMCID: PMC3432726.

300. Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J, Rodríguez O, Calvo MT, Aura C, Díez O, Rubio IT, Pérez J, Rodón J, Cortés J, Ellisen LW, Scaltriti M, **Baselga J**. “PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.” *Cancer Discov.* 2012 Nov;2(11):1036-47. doi: 10.1158/2159-8290.CD-11-0348. PubMed PMID: 22915752; PubMed Central PMCID: PMC5125254.
301. Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmana J, Rajendran A, Papa A, Spencer K, Lyssiotis CA, Nardella C, Pandolfi PP, **Baselga J**, Scully R, Asara JM, Cantley LC, Wulf GM. “Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer.” *Cancer Discov.* 2012 Nov; 2(11):1048-63. PMID: 22915751
302. Verma S, Miles D, Gianni L, Krop IE, Welslau M, **Baselga J**, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K; EMILIA Study Group. “Trastuzumab emtansine for HER2-positive advanced breast cancer.” *N Engl J Med.* 2012 Nov 8;367(19):1783-91. doi: 10.1056/NEJMoa1209124. Epub 2012 Oct 1. Erratum in: *N Engl J Med.* 2013 Jun 20;368(25):2442. PubMed PMID: 23020162.
303. Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J, Rodríguez O, Calvo MT, Aura C, Díez O, Rubio IT, Pérez J, Rodón J, Cortés J, Ellisen LW, Scaltriti M, **Baselga J**. “PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.” *Cancer Discov.* 2012 Nov;2(11):1036-47. doi: 10.1158/2159-8290.CD-11-0348. Epub 2012 Aug 22. PubMed PMID: 22915752.
304. **Baselga J**, Mita AC, Schöffski P, Dumez H, Rojo F, Tabernero J, DiLea C, Mietlowski W, Low C, Huang J, Dugan M, Parker K, Walk E, van Oosterom A, Martinelli E, Takimoto CH. “Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788.” *Clin Cancer Res.* 2012 Nov 15;18(22):6364-72. doi: 10.1158/1078-0432.CCR-12-1499. PubMed PMID: 23014528.
305. Villarreal L, Méndez O, Salvans C, Gregori J, **Baselga J**, Villanueva J. “Unconventional secretion is a major contributor of cancer cell line secretomes.” *Mol Cell Proteomics.* 2013 May;12(5):1046-60. doi: 10.1074/mcp.M112.021618. PubMed PMID: 23268930; PubMed Central PMCID: PMC3650320.
306. Loi S, Michiels S, **Baselga J**, Bartlett JM, Singhal SK, Sabine VS, Sims AH, Sahmoud T, Dixon JM, Piccart MJ, Sotiriou C. “PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer.” *PLoS One.* 2013;8(1):e53292. doi: 10.1371/journal.pone.0053292. PubMed PMID: 23301057; PubMed Central PMCID: PMC3534682.
307. Angelini PD, Zacarias Fluck MF, Pedersen K, Parra-Palau JL, Guiu M, Bernadó Morales C, Vicario R, Luque-García A, Navalpotro NP, Giralt J, Canals F, Gomis RR, Tabernero J, **Baselga J**, Villanueva J, Arribas J. “Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence.” *Cancer Res.* 2013 Jan 1;73(1):450-8. doi: 10.1158/0008-5472.CAN-12-2301. Erratum in: *Cancer Res.* 2013 Oct 1;73(19):6095. PubMed PMID: 23288917.

308. Metzger-Filho O, de Azambuja E, Bradbury I, Saini KS, Bines J, Simon SD, Dooren VV, Aktan G, Pritchard KI, Wolff AC, Smith I, Jackisch C, Lang I, Untch M, Boyle F, Xu B, **Baselga J**, Perez EA, Piccart-Gebhart M. "Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience." *Oncologist*. 2013;18(2):134-40. doi: 10.1634/theoncologist.2012-0342. PubMed PMID: 23359433; PubMed Central PMCID: PMC3579596.
309. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel E, Sgroi D, **Baselga J**, Ramaswamy S, Toner M, Haber DA, Maheswaran S. "Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition." *Science*. 2013; 339(6119):580-4. Epub 2013/02/02. PMID: 23372014.
310. Gnant M, **Baselga J**, Rugo HS, Noguchi S, Burris HA, Piccart M, Hortobagyi GN, Eakle J, Mukai H, Iwata H, Geberth M, Hart LL, Hadji P, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwahl D, Campone M, Pritchard KI. "Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2." *J Natl Cancer Inst*. 2013 May 1;105(9):654-63. doi: 10.1093/jnci/djt026. PubMed PMID: 23425564.
311. Zardavas D, **Baselga J**, Piccart M. "Emerging targeted agents in metastatic breast cancer." *Nat Rev Clin Oncol*. 2013 Apr;10(4):191-210. doi: 10.1038/nrclinonc.2013.29. Review. PubMed PMID: 23459626.
312. Swain SM, Ewer MS, Cortés J, Amadori D, Miles D, Knott A, Clark E, Benyunes MC, Ross G, **Baselga J**. "Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study." *Oncologist*. 2013;18(3):257-64. doi: 10.1634/theoncologist.2012-0448. PubMed PMID: 23475636; PubMed Central PMCID: PMC3607520.
313. Soria JC, **Baselga J**, Hanna N, Laurie SA, Bahleda R, Felip E, Calvo E, Armand JP, Shepherd FA, Harbison CT, Berman D, Park JS, Zhang S, Vakkalagadda B, Kurland JF, Pathak AK, Herbst RS. "Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours." *Eur J Cancer*. 2013 May;49(8):1815-24. doi: 10.1016/j.ejca.2013.02.012. PubMed PMID: 23490650.
314. Burris HA 3rd, Lebrun F, Rugo HS, Beck JT, Piccart M, Neven P, **Baselga J**, Petrakova K, Hortobagyi GN, Komorowski A, Chouinard E, Young R, Gnant M, Pritchard KI, Bennett L, Ricci JF, Baully H, Taran T, Sahmoud T, Noguchi S. "Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial." *Cancer*. 2013 May 15;119(10):1908-15. doi: 10.1002/cncr.28010. PubMed PMID: 23504821.
315. Criscitiello C, Azim HA Jr, Agbor-tarh D, de Azambuja E, Piccart M, **Baselga J**, Eidtmann H, Di Cosimo S, Bradbury I, Rubio IT. "Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial." *Ann Oncol*. 2013 Aug;24(8):1980-5. doi: 10.1093/annonc/mdt129. PubMed PMID: 23567146.
316. Prat A, **Baselga J**. "Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: one more step toward

chemotherapy-free therapy.” *J Clin Oncol*. 2013 May 10;31(14):1703-6. doi: 10.1200/JCO.2012.48.4998. PubMed PMID: 23569319.

317. Modi S, Saura C, Henderson C, Lin NU, Mahtani R, Goddard J, Rodenas E, Hudis C, O’Shaughnessy J, **Baselga J**. “A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer.” *Breast Cancer Res Treat*. 2013 May;139(1):107-13. doi: 10.1007/s10549-013-2510-5. PubMed PMID: 23580070; PubMed Central PMCID: PMC3646160.
318. Metzger-Filho O, Procter M, de Azambuja E, Leyland-Jones B, Gelber RD, Dowsett M, Loi S, Saini KS, Cameron D, Untch M, Smith I, Gianni L, **Baselga J**, Jackisch C, Bell R, Sotiriou C, Viale G, Piccart-Gebhart M. “Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial.” *J Clin Oncol*. 2013 Jun 1;31(16):1954-60. doi: 10.1200/JCO.2012.46.2440. PubMed PMID: 23589556.
319. Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, **Baselga J**. “Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.” *Lancet Oncol*. 2013 May;14(6):461-71. doi: 10.1016/S1470-2045(13)70130-X. PubMed PMID: 23602601; PubMed Central PMCID: PMC4076842.
320. Serra V, Eichhorn PJ, García-García C, Ibrahim YH, Prudkin L, Sánchez G, Rodríguez O, Antón P, Parra JL, Marlow S, Scaltriti M, Pérez-García J, Prat A, Arribas J, Hahn WC, Kim SY, **Baselga J**. “RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer.” *J Clin Invest*. 2013 Jun;123(6):2551-63. doi: 10.1172/JCI66343. Erratum in: *J Clin Invest*. 2014 Mar 3;124(3):1418. PubMed PMID: 23635776; PubMed Central PMCID: PMC3668839.
321. André F, Bachelot T, Campone M, Dalenc F, Perez-Garcia JM, Hurvitz SA, Turner N, Rugo H, Smith JW, Deudon S, Shi M, Zhang Y, Kay A, Porta DG, Yovine A, **Baselga J**. “Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.” *Clin Cancer Res*. 2013 Jul 1;19(13):3693-702. doi: 10.1158/1078-0432.CCR-13-0190. PubMed PMID: 23658459.
322. **Baselga J**, Gómez P, Greil R, Braga S, Climent MA, Wardley AM, Kaufman B, Stemmer SM, Pêgo A, Chan A, Goeminne JC, Graas MP, Kennedy MJ, Ciruelos Gil EM, Schneeweiss A, Zubel A, Groos J, Melezínková H, Awada A. “Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.” *J Clin Oncol*. 2013 Jul 10;31(20):2586-92. doi: 10.1200/JCO.2012.46.2408. PubMed PMID: 23733761.
323. Campone M, Bachelot T, Gnant M, Deleu I, Rugo HS, Pistilli B, Noguchi S, Shtivelband M, Pritchard KI, Provencher L, Burris HA 3rd, Hart L, Melichar B, Hortobagyi GN, Arena F, **Baselga J**, Panneerselvam A, Héniquez A, El-Hashimyt M, Taran T, Sahnoud T, Piccart M. “Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.” *Eur J Cancer*. 2013 Aug;49(12):2621-32. doi: 10.1016/j.ejca.2013.04.011. PubMed PMID: 23735704.
324. Elkabets M, Vora S, Juric D, Morse N, Mino-Kenudson M, Muranen T, Tao J, Campos AB, Rodon J, Ibrahim YH, Serra V, Rodrik-Outmezguine V, Hazra S, Singh S, Kim P, Quadt C, Liu M, Huang A, Rosen N, Engelman JA, Scaltriti M, **Baselga J**. “mTORC1 inhibition is required for sensitivity to PI3K p110 $\alpha$  inhibitors in PIK3CA-mutant breast cancer.” *Sci Transl Med*. 2013 Jul



31;5(196):196ra99. doi: 10.1126/scitranslmed.3005747. PubMed PMID: 23903756; PubMed Central PMCID: PMC3935768.

325. Raina D, Uchida Y, Kharbanda A, Rajabi H, Panchamoorthy G, Jin C, Kharbanda S, Scaltriti M, **Baselga J**, Kufe D. "Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells." *Oncogene*. 2014 Jun 26;33(26):3422-31. doi: 10.1038/onc.2013.308. PubMed PMID: 23912457; PubMed Central PMCID: PMC3916940.
326. Serra V, Vivancos A, Puente XS, Felip E, Silberschmidt D, Caratù G, Parra JL, De Mattos-Arruda L, Grueso J, Hernández-Losa J, Arribas J, Prudkin L, Nuciforo P, Scaltriti M, Seoane J, **Baselga J**. "Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation." *Cancer Discov*. 2013 Nov;3(11):1238-44. doi: 10.1158/2159-8290.CD-13-0132. PubMed PMID: 23950206.
327. Cortés J, Swain SM, Kudaba I, Hauschild M, Patel T, Grincuka E, Masuda N, McNally V, Ross G, Brewster M, Marier JF, Trinh MM, Garg A, Nijem I, Visich J, Lum BL, **Baselga J**. "Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel." *Anticancer Drugs*. 2013 Nov;24(10):1084-92. doi: 10.1097/CAD.000000000000016. PubMed PMID: 23969513.
328. Eskens FA, Ramos FJ, Burger H, O'Brien JP, Piera A, de Jonge MJ, Mizui Y, Wiemer EA, Carreras MJ, **Baselga J**, Tabernero J. "Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors." *Clin Cancer Res*. 2013 Nov 15;19(22):6296-304. doi: 10.1158/1078-0432.CCR-13-0485. PubMed PMID: 23983259.
329. Campone M, Beck JT, Gnant M, Neven P, Pritchard KI, Bachelot T, Provencher L, Rugo HS, Piccart M, Hortobagyi GN, Nunzi M, Heng DY, **Baselga J**, Komorowski A, Noguchi S, Horiguchi J, Bennett L, Ziemiecki R, Zhang J, Cahana A, Taran T, Sahmoud T, Burris HA 3rd. "Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy." *Curr Med Res Opin*. 2013 Nov;29(11):1463-73. doi: 10.1185/03007995.2013.836078. PubMed PMID: 23962028.
330. Montemurro F, Prat A, Rossi V, Valabrega G, Sperinde J, Peraldo-Neia C, Donadio M, Galván P, Sapino A, Aglietta M, **Baselga J**, Scaltriti M. "Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer." *Mol Oncol*. 2014 Feb;8(1):20-6. doi: 10.1016/j.molonc.2013.08.013. PubMed PMID: 24075779.
331. Azim HA Jr, Rothé F, Aura CM, Bavington M, Maetens M, Rouas G, Gebhart G, Gamez C, Eidtmann H, **Baselga J**, Piccart-Gebhart M, Ellis C, Vuylsteke P, Cure H, Domont J, Ferro A, Toral-Peña JC, de Azambuja E, Sotiriou C, Di Cosimo S, Ignatiadis M. "Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO phase III trial." *Breast*. 2013 Dec;22(6):1060-5. doi: 10.1016/j.breast.2013.08.014. PubMed PMID: 24060577.
332. Gebhart G, Gámez C, Holmes E, Robles J, Garcia C, Cortés M, de Azambuja E, Fauria K, Van Dooren V, Aktan G, Coccia-Portugal MA, Kim SB, Vuylsteke P, Cure H, Eidtmann H, **Baselga J**, Piccart M, Flamen P, Di Cosimo S. "18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results

from Neo-ALTTO.” *J Nucl Med*. 2013 Nov;54(11):1862-8. doi: 10.2967/jnumed.112.119271. PubMed PMID: 24092940.

333. Miles D, **Baselga J**, Amadori D, Sunpaweravong P, Semiglazov V, Knott A, Clark E, Ross G, Swain SM. “Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA).” *Breast Cancer Res Treat*. 2013 Nov;142(1):89-99. doi: 10.1007/s10549-013-2710-z. PubMed PMID: 24129974; PubMed Central PMCID: PMC3825296.
334. Yan Y, Serra V, Prudkin L, Scaltriti M, Murli S, Rodríguez O, Guzman M, Sampath D, Nannini M, Xiao Y, Wagle MC, Wu JQ, Wongchenko M, Hampton G, Ramakrishnan V, Lackner MR, Saura C, Roda D, Cervantes A, Tabernero J, Patel P, **Baselga J**. “Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068.” *Clin Cancer Res*. 2013 Dec 15;19(24):6976-86. doi: 10.1158/1078-0432.CCR-13-0978. PubMed PMID: 24141624.
335. Yardley DA, Noguchi S, Pritchard KI, Burris HA 3rd, **Baselga J**, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS. “Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis.” *Adv Ther*. 2013 Oct;30(10):870-84. doi: 10.1007/s12325-013-0060-1. Erratum in: *Adv Ther*. 2014 Sep;31(9):1008-9. PubMed PMID: 24158787; PubMed Central PMCID: PMC3898123.
336. Shapiro GI, Rodon J, Bedell C, Kwak EL, **Baselga J**, Braña I, Pandya SS, Scheffold C, Laird AD, Nguyen LT, Xu Y, Egile C, Edelman G. “Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors.” *Clin Cancer Res*. 2014 Jan 1;20(1):233-45. doi: 10.1158/1078-0432.CCR-13-1777. Erratum in: *Clin Cancer Res*. 2015 May 1;21(9):2192. PubMed PMID: 24166903.
337. Vahdat LT, Vrdoljak E, Gómez H, Li RK, Bosserman L, Sparano JA, **Baselga J**, Mukhopadhyay P, Valero V. “Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer.” *J Geriatr Oncol*. 2013 Oct;4(4):346-52. doi: 10.1016/j.jgo.2013.07.006. PubMed PMID: 24472478.
338. Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, Hudis C, Chen D, Taran T, Hortobagyi G, Greene G, Berger M, **Baselga J**, Chandarlapaty S. “ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.” *Nat Genet*. 2013. PMID: 24185512.
339. Pritchard KI, Burris HA, 3rd, Ito Y, Rugo HS, Dakhil S, Hortobagyi GN, Campone M, Csozi T, **Baselga J**, Puttawibul P, Piccart M, Heng D, Noguchi S, Srimuninnimit V, Bourgeois H, Gonzalez Martin A, Osborne K, Panneerselvam A, Taran T, Sahmoud T, Gnant M. “Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor-Positive Breast Cancer in BOLERO-2.” *Clin Breast Cancer*. 2013; 13(6):421-32.e8. Epub 2013/11/26. PMID: 24267730.
340. Azim HA Jr, Agbor-Tarh D, Bradbury I, Dinh P, **Baselga J**, Di Cosimo S, Greger JG Jr, Smith I, Jackisch C, Kim SB, Aktas B, Huang CS, Vuylsteke P, Hsieh RK, Dreosti L, Eidtmann H, Piccart M, de Azambuja E. “Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial.” *J Clin Oncol*. 2013 Dec 20;31(36):4504-11. doi: 10.1200/JCO.2013.50.9448. Erratum in: *J Clin Oncol*. 2014 Feb 1;32(4):365. PubMed PMID: 24248687.

341. Bardia A, **Baselga J**. "Neoadjuvant therapy as a platform for drug development and approval in breast cancer." *Clin Cancer Res*. 2013 Dec 1;19(23):6360-70. doi: 10.1158/1078-0432.CCR-13-0916. Review. PubMed PMID: 24298066.
342. **Baselga J**, Manikhas A, Cortes J, Llombart A, Roman L, Semiglazov VF, Byakhov M, Lokanatha D, Forenza S, Goldfarb RH, Matera J, Azarnia N, Hudis CA, Rozenzweig M. "Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer." *Ann Oncol*. 2014. Epub 2014/01/10. PMID: 24401928.
343. Prat A, Bianchini G, Thomas M, Belousov A, Cheang MC, Koehler A, Gomez P, Semiglazov V, Eiermann W, Tjulandin S, Byakhov M, Bermejo B, Zambetti M, Vazquez F, Gianni L, **Baselga J**. "Research-Based PAM50 Subtype Predictor Identifies Higher Responses and Improved Survival Outcomes in HER2-Positive Breast Cancer in the NOAH Study." *Clin Cancer Res*. 2014; 20(2):511-21. Epub 2014/01/21. PMID: 24443618.
344. Will M, Qin AC, Toy W, Yao Z, Rodrik-Outmezguine V, Schneider C, Huang X, Monian P, Jiang X, De Stanchina E, **Baselga J**, Liu N, Chandarlapaty S, Rosen N. "Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling." *Cancer Discov*. 2014. Epub 2014/01/18. PMID: 24436048
345. Saura C, Bendell JC, Jerusalem G, Su S, Ru Q, De Buck S, Mills D, Ruquet S, Bosch A, Urruticoechea A, Beck JT, Ditomaso E, Sternberg DW, Massacesi C, Hirawat S, Dirix L, **Baselga J**. "Phase Ib study of buparlisib plus trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on trastuzumab-based therapy." *Clin Cancer Res*. 2014. Epub 2014/01/29. PMID: 24470511.
346. Rodon J, Tawbi HA, Thomas AL, Stoller R, Turtschi CP, **Baselga J**, Sarantopoulos J, Mahalingam D, Shou Y, Moles MA, Yang L, Granvil C, Hurh E, Rose KL, Amakye DD, Dummer R, Mita AC. "A Phase 1, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Hedgehog Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors." *Clin Cancer Res*. 2014. Epub 2014/02/14. PMID: 24523439.
347. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, **Baselga J**, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE, Jr., Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G. "Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis." *Lancet*. 2014. Epub 2014/02/18. PMID: 24529560.
348. Papadopoulos K, Tabernero J, Markman B, Patnaik A, Tolcher A, **Baselga J**, Shi W, Egile C, Ruiz-Soto R, Laird AD, Miles D, Lorusso PM. "Phase I safety, pharmacokinetic and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors." *Clin Cancer Res*. 2014. Epub 2014/03/04. PMID: 24583798.
349. Serra V, Eichhorn PJ, Garcia-Garcia C, Ibrahim YH, Prudkin L, Sanchez G, Rodriguez O, Anton P, Parra JL, Marlow S, Scaltriti M, Perez-Garcia J, Prat A, Arribas J, Hahn WC, Kim SY, **Baselga J**. "RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer." *J Clin Invest*. 2014; 124(3):1418. Epub 2014/03/05. PMID: 24590298; PMCID: PMC3934174.
350. Tao JJ, Castel P, Radosevic-Robin N, Elkabets M, Auricchio N, Aceto N, Weitsman G, Barber P, Vojnovic B, Ellis H, Morse N, Viola-Villegas NT, Bosch A, Juric D, Hazra S, Singh S, Kim P,

- Bergamaschi A, Maheswaran S, Ng T, Penault-Llorca F, Lewis JS, Carey LA, Perou CM, **Baselga J**, Scaltriti M. "Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer." *Sci Signal*. 2014; 7(318):ra29. Epub 2014/03/29. PMID: 24667376.
351. Rugo HS, Pritchard KI, Gnant M, Noguchi S, Piccart M, Hortobagyi G, **Baselga J**, Perez A, Geberth M, Csozsi T, Chouinard E, Srimuninnimit V, Puttawibul P, Eakle J, Feng W, Baully H, El-Hashimy M, Taran T, Burris HA, 3rd. "Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2." *Ann Oncol*. 2014; 25(4):808-15. Epub 2014/03/13. PMID: 24615500; PMCID: PMC3969554.
352. Taberero J, Elez ME, Herranz M, Rico I, Prudkin L, Andreu J, Mateos J, Carreras MJ, Han M, Gifford J, Credi M, Yin W, Agarwal S, Komarnitsky P, **Baselga J**. "A Pharmacodynamic/Pharmacokinetic Study of Ficlatusumab in Patients with Advanced Solid Tumors and Liver Metastases." *Clin Cancer Res*. 2014. Epub 2014/03/19. PMID: 24634378.
353. Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, Moliterni A, Vazquez F, Byakhov MJ, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Magazzu D, Heinzmann D, Steinseifer J, Valagussa P, **Baselga J**. "Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort." *Lancet Oncol*. 2014. Epub 2014/03/25. PMID: 24657003.
354. Swain SM, **Baselga J**, Miles D, Im YH, Quah C, Lee LF, Cortes J. "Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA." *Ann Oncol*. 2014. Epub 2014/04/02. PMID: 24685829.
355. Taberero J, Chawla SP, Kindler H, Reckamp K, Chiorean EG, Azad NS, Lockhart AC, Hsu CP, Baker NF, Galimi F, Beltran P, **Baselga J**. "Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab." *Target Oncol*. 2014. Epub 2014/05/13. PMID: 24816908.
356. Balmana J, Tung NM, Isakoff SJ, Grana B, Ryan PD, Saura C, Lowe ES, Frewer P, Winer E, **Baselga J**, Garber JE. "Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors." *Ann Oncol*. 2014. Epub 2014/05/16. PMID: 24827126.
357. Cho J, Bass AJ, Lawrence MS, Cibulskis K, Cho A, Lee SN, Yamauchi M, Wagle N, Pochanard P, Kim N, Park AK, Won J, Hur HS, Greulich H, Ogino S, Sougnez C, Voet D, Taberero J, Jimenez J, **Baselga J**, Gabriel SB, Lander ES, Getz G, Eck MJ, Park WY, Meyerson M. "Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab." *Mol Cancer*. 2014; 13:141. Epub 2014/06/05. PMID: 24894453; PMCID: PMC3969554.
358. Swain SM, Im YH, Im SA, Chan V, Miles D, Knott A, Clark E, Ross G, **Baselga J**. "Safety Profile of Pertuzumab With Trastuzumab and Docetaxel in Patients From Asia With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Results From the Phase III Trial CLEOPATRA." *Oncologist*. 2014; 19(7):693-701. Epub 2014/05/30. PMID: 24869931; PMCID: PMC3969554.

359. de Azambuja E, Procter MJ, van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O, Steinseifer J, Untch M, Smith IE, Gianni L, **Baselga J**, Jackisch C, Cameron DA, Bell R, Leyland-Jones B, Dowsett M, Gelber RD, Piccart-Gebhart MJ, Suter TM. "Trastuzumab-Associated Cardiac Events at 8 Years of Median Follow-Up in the Herceptin Adjuvant Trial (BIG 1-01)." *J Clin Oncol*. 2014; 32(20):2159-65. Epub 2014/06/11. PMID: 24912899.
360. Prat A, Carey LA, Adamo B, Vidal M, Taberero J, Cortes J, Parker JS, Perou CM, **Baselga J**. "Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer." *J Natl Cancer Inst*. 2014; 106(8). Epub 2014/08/21. PMID: 25139534.
361. De Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I, Smith I, Boyle F, Xu B, Barrios CH, Perez EA, Azim HA, Jr., Kim SB, Kuemmel S, Huang CS, Vuylsteke P, Hsieh RK, Gorbunova V, Eniu A, Dreosti L, Tavartkiladze N, Gelber RD, Eidtmann H, **Baselga J**. "Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response." *Lancet Oncol*. 2014; 15(10):1137-46. Epub 2014/08/19. PMID: 25130998.
362. Yardley DA, Noguchi S, Pritchard KI, Burris HA, 3rd, **Baselga J**, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwahl D, Rugo HS. "Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis." *Adv Ther*. 2014. Epub 2014/09/12. PMID: 25209875.
363. Zardavas D, Maetens M, Irrthum A, Goulioti T, Engelen K, Fumagalli D, Salgado R, Aftimos P, Saini KS, Sotiriou C, Campbell P, Dinh P, von Minckwitz G, Gelber RD, Dowsett M, Di Leo A, Cameron D, **Baselga J**, Gnant M, Goldhirsch A, Norton L, Piccart M. "The AURORA initiative for metastatic breast cancer." *Br J Cancer*. 2014. Epub 2014/09/17. PMID: 25225904.
364. Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, Noguchi S, Perez A, Rugo HS, Deleu I, Burris HA, 3rd, Provencher L, Neven P, Gnant M, Shtivelband M, Wu C, Fan J, Feng W, Taran T, **Baselga J**. "Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2." *Ann Oncol*. 2014. Epub 2014/09/19. PMID: 25231953.
365. Parra-Palau JL, Morancho B, Peg V, Escorihuela M, Scaltriti M, Vicario R, Zacarias-Fluck M, Pedersen K, Pandiella A, Nuciforo P, Serra V, Cortes J, **Baselga J**, Perou CM, Prat A, Rubio IT, Arribas J. "Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy." *J Natl Cancer Inst*. 2014; 106(11). Epub 2014/09/26. PMID: 25253614.
366. Saura C, Garcia-Saenz JA, Xu B, Harb W, Moroosse R, Pluard T, Cortes J, Kiger C, Germa C, Wang K, Martin M, **Baselga J**, Kim SB. "Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer." *J Clin Oncol*. 2014; 32(32):3626-33. Epub 2014/10/08. PMID: 25287822.
367. DiCosimo S, Sathyanarayanan S, Bendell JC, Cervantes A, Stein MN, Brana I, Roda Perez D, Haines BB, Zhang T, Winter C, Jha S, Xu Y, Frazier J, Klinghofer R, Leighton-Swayze A, Song Y, Ebbinghaus S, **Baselga J**. "Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial." *Clin Cancer Res*. 2014. Epub 2014/10/17. PMID: 25320355.

368. Hyman D, Diamond EL, Vibat CR, Hassaine L, Poole JC, Patel M, Holley VR, Cabrilo G, Lu TT, Arcila ME, Chung YR, Rampal R, Lacouture ME, Rosen N, Meric-Bernstam F, **Baselga J**, Kurzrock R, Erlander MG, Janku F, Abdel-Wahab O. "Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders." *Cancer Discov.* 2014. Epub 2014/10/18. PMID: 25324352.
369. Choy E, Butrynski JE, Harmon DC, Morgan JA, George S, Wagner AJ, D'Adamo D, Cote GM, Flamand Y, Benes CH, Haber DA, **Baselga J**, Demetri GD. "Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy." *BMC Cancer.* 2014; 14:813. Epub 2014/11/07. PMID: 25374341; PMCID: PMC4230717.
370. **Baselga J**, Cortes J, Im SA, Clark E, Ross G, Kiermaier A, Swain SM. "Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive, First-Line Metastatic Breast Cancer." *J Clin Oncol.* 2014; 32(33):3753-61. Epub 2014/10/22. PMID: 25332247.
371. Rodon J, Carducci MA, Sepulveda-Sanchez JM, Azaro A, Calvo E, Seoane J, Brana I, Sicart E, Gueorguieva I, Cleverly AL, Sokalingum Pillay N, Desai D, Estrem ST, Paz-Ares L, Holdoff M, Blakeley J, Lahn MM, **Baselga J**. "First-in-Human Dose Study of the Novel Transforming Growth Factor-beta Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma." *Clin Cancer Res.* 2014. Epub 2014/11/27. PMID: 25424852.
372. Scaltriti M, Nuciforo P, Bradbury I, Sperinde J, Agbor-Tarh D, Campbell C, Chenna A, Winslow J, Serra V, Parra JL, Prudkin L, Jimenez J, Aura C, Harbeck N, Puztai L, Ellis CE, Eidtmann H, Arribas J, Cortes J, De Azambuja E, Piccart M, **Baselga J**. "High HER2 expression correlates with response to the combination of lapatinib and trastuzumab." *Clin Cancer Res.* 2014. Epub 2014/12/04. PMID: 25467182.
373. Agzenai Y, Pozuelo J, Sanz J, Perez I, **Baselga J**. "Advanced Self-Healing Asphalt Composites in the Pavement Performance Field: Mechanisms at the Nano Level and New Repairing Methodologies." *Recent Pat Biotechnol.* 2014. Epub 2014/12/06. PMID: 25479339.
374. Kovacs RJ, Maldonado G, Azaro A, Fernandez MS, Romero FL, Sepulveda-Sanchez JM, Corretti M, Carducci M, Dolan M, Gueorguieva I, Cleverly AL, Pillay NS, **Baselga J**, Lahn MM. "Cardiac Safety of TGF-beta Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study." *Cardiovasc Toxicol.* 2014. Epub 2014/12/10. PubMed PMID: 25488804.
375. Rodon J, Carducci M, Sepulveda-Sanchez JM, Azaro A, Calvo E, Seoane J, Brana I, Sicart E, Gueorguieva I, Cleverly A, Pillay NS, Desai D, Estrem ST, Paz-Ares L, Holdhoff M, Blakeley J, Lahn MM, **Baselga J**. "Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-beta receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer." *Invest New Drugs.* 2014. Epub 2014/12/23. PMID: 25529192.
376. Schwartz S, Wongvipat J, Trigwell CB, Hancox U, Carver BS, Rodrik-Outmezguine V, Will M, Yellen P, de Stanchina E, **Baselga J**, Scher HI, Barry ST, Sawyers CL, Chandarlapaty S, Rosen N. "Feedback Suppression of PI3Kalpha Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kbeta." *Cancer Cell.* 2014. Epub 2014/12/30. PMID: 25544636.
377. Dang C, Iyengar N, Datko F, D'Andrea G, Theodoulou M, Dickler M, Goldfarb S, Lake D, Fasano J, Fournier M, Gilewski T, Modi S, Gajria D, Moynahan ME, Hamilton N, Patil S, Jochelson M, Norton L, **Baselga J**, Hudis C. "Phase II Study of Paclitaxel Given Once per Week Along With

- Trastuzumab and Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer." *J Clin Oncol*. 2014. Epub 2014/12/31. PMID: 25547504.
378. Majewski IJ, Nuciforo P, Mittempergher L, Bosma AJ, Eidtmann H, Holmes E, Sotiriou C, Fumagalli D, Jimenez J, Aura C, Prudkin L, Diaz-Delgado MC, de la Pena L, Loi S, Ellis C, Schultz N, de Azambuja E, Harbeck N, Piccart-Gebhart M, Bernardis R, **Baselga J**. "PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer." *J Clin Oncol*. 2015. Epub 2015/01/07. PMID: 25559818.
379. Juric D, Castel P, Griffith M, Griffith OL, Won HH, Ellis H, Ebbesen SH, Ainscough BJ, Ramu A, Iyer G, Shah RH, Huynh T, Mino-Kenudson M, Sgroi D, Isakoff S, Thabet A, Elamine L, Solit DB, Lowe SW, Quadt C, Peters M, Derti A, Schegel R, Huang A, Mardis ER, Berger MF, **Baselga J\***, Scaltriti M. "Convergent loss of PTEN leads to clinical resistance to a PI(3)K $\alpha$  inhibitor." *Nature*. 2015 Feb 12;518(7538):240-4. doi: 10.1038/nature13948. Epub 2014 Nov 17. PubMed PMID: 25409150; PubMed Central PMCID: PMC4326538. \*Corresponding author.
380. Swain SM, **Baselga J**, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J; CLEOPATRA Study Group.. "Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer." *N Engl J Med*. 2015 Feb 19;372(8):724-34. doi: 10.1056/NEJMoa1413513. PubMed PMID: 25693012.
381. Jonas O, Landry HM, Fuller JE, Santini JT Jr, **Baselga J**, Tepper RI, Cima MJ, Langer R. "An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors." *Sci Transl Med*. 2015 Apr 22;7(284):284ra57. doi: 10.1126/scitranslmed.3010564. PubMed PMID: 25904741; PubMed Central PMCID: PMC4825177.
382. Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, Van Allen EM, Lawrence MS, Horowitz PM, Cibulskis K, Ligon KL, Taberero J, Seoane J, Martinez-Saez E, Curry WT, Dunn IF, Paek SH, Park SH, McKenna A, Chevalier A, Rosenberg M, Barker FG 2nd, Gill CM, Van Hummelen P, Thorner AR, Johnson BE, Hoang MP, Choueiri TK, Signoretti S, Sougnez C, Rabin MS, Lin NU, Winer EP, Stemmer-Rachamimov A, Meyerson M, Garraway L, Gabriel S, Lander ES, Beroukhi R, Batchelor TT, **Baselga J**, Louis DN, Getz G, Hahn WC. "Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets." *Cancer Discov*. 2015 Nov;5(11):1164-77. doi: 10.1158/2159-8290.CD-15-0369. PubMed PMID: 26410082; PubMed Central PMCID: PMC4916970.
383. Muellner MK, Mair B, Ibrahim Y, Kerzendorfer C, Lechtermann H, Trefzer C, Klepsch F, Müller AC, Leitner E, Macho-Maschler S, Superti-Furga G, Bennett KL, **Baselga J**, Rix U, Kubicek S, Colinge J, Serra V, Nijman SM. "Targeting a cell state common to triple-negative breast cancers." *Mol Syst Biol*. 2015 Feb 19;11(1):789. doi: 10.15252/msb.20145664. PubMed PMID: 25699542; PubMed Central PMCID: PMC4358660.
384. Bennett KL, Baselga J, Rix U, Kubicek S, Colinge J, Serra V, Nijman SM, Ugalde-Olano A, Egia A, Fernandez-Ruiz S, Loizaga-Iriarte A, Zuniga-Garcia P, Garcia S, Royo F, Lacasa-Viscasillas I, Castro E, Cortazar AR, Zabala-Letona A, Martin-Martin N, Arruabarrena-Aristorena A, Torrano-Moya V, Valcarcel-Jimenez L, Sanchez-Mosquera P, Caro-Maldonado A, Gonzalez-Tampan J, Cachi-Fuentes G, Bilbao E, Montero R, Fernandez S, Arrieta E, Zorroza K, Castillo-Martin M, Serra V, Salazar E, Macias-Camara N, Taberero J, **Baselga J**, Cordon-Cardo C, Aransay AM, Villar AD, Iovanna JL, Falcon-Perez JM, Unda M, Bilbao R, Carracedo A. "Methodological

aspects of the molecular and histological study of prostate cancer: Focus on PTEN.” *Mol Syst Biol.* 2015. Epub 2015/02/24. doi: 10.1016/j.ymeth.2015.02.005. PMID: 25697760. Epub 2015/02/19. doi: 10.1056/NEJMoa1413513.

385. Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, Tao JJ, Spratt DE, Viola-Villegas NT, Castel P, Minuesa G, Morse N, Rodón J, Ibrahim Y, Cortes J, Perez-Garcia J, Galvan P, Grueso J, Guzman M, Katzenellenbogen JA, Kharas M, Lewis JS, Dickler M, Serra V, Rosen N, Chandarlapaty S\*, Scaltriti M\*, **Baselga J\***. “PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.” *Sci Transl Med.* 2015 Apr 15;7(283):283ra51. doi: 10.1126/scitranslmed.aaa4442. PubMed PMID: 25877889; PubMed Central PMCID: PMC4433148. \*Corresponding Authors.
386. Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelosof RA, Brook S, Benzaken AO, Rodon J, Morse N, Yan JJ, Liu M, Das R, Chen Y, Tam A, Wang H, Liang J, Gurski JM, Kerr DA, Rosell R, Teixidó C, Huang A, Ghossein RA, Rosen N, Bivona TG, Scaltriti M\*, **Baselga J\***. “AXL mediates resistance to PI3K $\alpha$  inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.” *Cancer Cell.* 2015 Apr 13;27(4):533-46. doi: 10.1016/j.ccell.2015.03.010. PubMed PMID: 25873175; PubMed Central PMCID: PMC4398915. \*Corresponding Authors.
387. Nuciforo PG, Aura C, Holmes E, Prudkin L, Jimenez J, Martinez P, Ameels H, de la Pena L, Ellis C, Eidtmann H, Piccart-Gebhart MJ, Scaltriti M, **Baselga J**. “Benefit to neoadjuvant anti-Human Epidermal Growth Factor Receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of Phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status.” *Ann Oncol.* 2015. Epub 2015/04/09. PMID: 25851628.
388. Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelosof RA, Brook S, Benzaken AO, Rodon J, Morse N, Yan JJ, Liu M, Das R, Chen Y, Tam A, Wang H, Liang J, Gurski JM, Kerr DA, Rosell R, Teixido C, Huang A, Ghossein RA, Rosen N, Bivona TG, Scaltriti M, **Baselga J**. “AXL Mediates Resistance to PI3K $\alpha$  Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas.” *Cancer Cell.* 2015; 27(4):533-46. Epub 2015/04/16. PMID: 25873175; PMCID: PMCPmc4398915.
389. **Baselga J**, Clark E, Kiermaier A, Swain SM. “Reply to A. Avan et al.” *J Clin Oncol.* 2015. Epub 2015/04/15. PMID: 25870094
390. Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, Tao JJ, Spratt DE, Viola-Villegas NT, Castel P, Minuesa G, Morse N, Rodon J, Ibrahim Y, Cortes J, Perez-Garcia J, Galvan P, Grueso J, Guzman M, Katzenellenbogen JA, Kharas M, Lewis JS, Dickler M, Serra V, Rosen N, Chandarlapaty S, Scaltriti M, **Baselga J**. “PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.” *Sci Transl Med.* 2015;7(283):283ra51. Epub 2015/04/17. PMID: 25877889. PMCID: PMC4433148.
391. Majewski IJ, Nuciforo P, Mittempergher L, Bosma AJ, Eidtmann H, Holmes E, Sotiriou C, Fumagalli D, Jimenez J, Aura C, Prudkin L, Díaz-Delgado MC, de la Peña L, Loi S, Ellis C, Schultz N, de Azambuja E, Harbeck N, Piccart-Gebhart M, Bernardis R, **Baselga J**. “PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.” *J Clin Oncol.* 2015 Apr 20;33(12):1334-9. doi: 10.1200/JCO.2014.55.2158. PubMed PMID: 25559818. PMCID: PMC5087318.



392. Swain SM, Clark E, **Baselga J**. "Treatment of HER2-positive metastatic breast cancer." *N Engl J Med*. 2015 May 14;372(20):1964-5. doi: 10.1056/NEJMc1503446. PubMed PMID: 25970056; PubMed Central PMCID: PMC4980989.
393. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, Chan E, Schuler M, Lasserre SF, Makrutzki M, Sirzen F, Veronese ML, Taberero J, **Baselga J**. "Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations." *N Engl J Med*. 2015 Aug 20;373(8):726-36. doi: 10.1056/NEJMoa1502309. PubMed PMID: 26287849; PubMed Central PMCID: PMC4971773.
394. **Baselga J**, Bhardwaj N, Cantley LC, DeMatteo R, DuBois RN, Foti M, Gapstur SM, Hahn WC, Helman LJ, Jensen RA, Paskett ED, Lawrence TS, Lutzker SG, Szabo E. "AACR Cancer Progress Report 2015." *Clin Cancer Res*. 2015 Oct 1;21(19 Suppl):S1-128. doi: 10.1158/1078-0432.CCR-15-1846. PubMed PMID: 26429991; PubMed Central PMCID: PMC5001568.
395. Hortobagyi GN, Chen D, Piccart M, Rugo HS, Burris HA, 3rd, Pritchard KI, Campone M, Noguchi S, Perez AT, Deleu I, Shtivelband M, Masuda N, Dakhil S, Anderson I, Robinson DM, He W, Garg A, McDonald ER, 3rd, Bitter H, Huang A, Taran T, Bachelot T, Lebrun F, Lebwohl D, **Baselga J**. "Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2." *J Clin Oncol*. 2015. Epub 2015/10/28. doi: 10.1200/jco.2014.60.1971. PMID: 26503204. PubMed Central PMCID: PMC5070556.
396. Llombart-Cussac A, Bermejo B, Villanueva C, Delalogue S, Morales S, Balmaña J, Amillano K, Bonnefoi H, Casas A, Manso L, Roché H, Gonzalez-Santiago S, Gavilá J, Sánchez-Rovira P, Di Cosimo S, Harbeck N, Charpentier E, Garcia-Ribas I, Radosevic-Robin N, Aura C, **Baselga J**. "SOLTI NeopARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer." *Breast Cancer Res Treat*. 2015 Nov;154(2):351-7. doi: 10.1007/s10549-015-3616-8. PubMed PMID: 26536871; PubMed Central PMCID: PMC4971774.
397. Piccart-Gebhart M, Holmes E, **Baselga J**, de Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, McFadden E, Holmes AP, Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck N, Tjulandin S, Im YH, Huang CS, Dieras V, Hillman DW, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Suter T, Gelber RD, Perez EA. "Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial." *J Clin Oncol*. 2015. Epub 2015/11/26. doi: 10.1200/jco.2015.62.1797. PMID: 26598744. PMCID: PMC4872016.
398. Hyman DM, Solit DB, Arcila ME, Cheng DT, Sabbatini P, **Baselga J**, Berger MF, Ladanyi M. "Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials." *Drug Discov Today*. 2015 Dec;20(12):1422-8. doi: 10.1016/j.drudis.2015.08.005. PubMed PMID: 26320725; PubMed Central PMCID: PMC4940024.
399. Limaye N, Kangas J, Mendola A, Godfraind C, Schlogel MJ, Helaers R, Eklund L, Boon LM, Vikkula M, **Baselga J**. "Somatic Activating PIK3CA Mutations Cause Venous Malformation."

*Am J Hum Genet.* 2015; 97(6):914-21. Epub 2015/12/08. doi: 10.1016/j.ajhg.2015.11.011. PMID: 26637981; PMCID: PMC4678782.

400. García-García C, Rivas MA, Ibrahim YH, Calvo MT, Gris-Oliver A, Rodríguez O, Grueso J, Antón P, Guzmán M, Aura C, Nuciforo P, Jessen K, Argilés G, Dienstmann R, Bertotti A, Trusolino L, Matito J, Vivancos A, Chicote I, Palmer HG, Taberero J, Scaltriti M, **Baselga J**, Serra V. “MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.” *Clin Cancer Res.* 2015 Dec 15;21(24):5499-510. doi: 10.1158/1078-0432.CCR-14-3091. PubMed PMID: 26272063; PubMed Central PMCID: PMC5087596.
401. Metzger-Filho O, de Azambuja E, Procter M, Krieguer M, Smith I, **Baselga J**, Cameron D, Untch M, Jackisch C, Bell R, Gianni L, Goldhirsch A, Piccart M, Gelber RD; HREA Study Team.. “Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience.” *Breast Cancer Res Treat.* 2016 Jan;155(1):127-32. doi: 10.1007/s10549-015-3656-0. PubMed PMID: 26708471; PubMed Central PMCID: PMC4947530.
402. Grego-Bessa J, Bloomekatz J, Castel P, Omelchenko T, **Baselga J**, Anderson KV. “The tumor suppressor PTEN and the PDK1 kinase regulate formation of the columnar neural epithelium.” *Elife.* 2016 Jan 26;5:e12034. doi: 10.7554/eLife.12034. PubMed PMID: 26809587; PubMed Central PMCID: PMC4739759.
403. Diamond EL, Durham BH, Haroche J, Yao Z, Ma J, Parikh SA, Wang Z, Choi J, Kim E, Cohen-Aubart F, Lee SC, Gao Y, Micol JB, Campbell P, Walsh MP, Sylvester B, Dolgalev I, Aminova O, Heguy A, Zappile P, Nakitandwe J, Ganzel C, Dalton JD, Ellison DW, Estrada-Veras J, Lacouture M, Gahl WA, Stephens PJ, Miller VA, Ross JS, Ali SM, Briggs SR, Fasan O, Block J, Héritier S, Donadieu J, Solit DB, Hyman DM, **Baselga J**, Janku F, Taylor BS, Park CY, Amoura Z, Dogan A, Emile JF, Rosen N, Gruber TA, Abdel-Wahab O. “Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.” *Cancer Discov.* 2016 Feb;6(2):154-65. doi: 10.1158/2159-8290.CD-15-0913. PubMed PMID: 26566875; PubMed Central PMCID: PMC4744547.
404. Hortobagyi GN, Chen D, Piccart M, Rugo HS, Burris HA 3rd, Pritchard KI, Campone M, Noguchi S, Perez AT, Deleu I, Shtivelband M, Masuda N, Dakhil S, Anderson I, Robinson DM, He W, Garg A, McDonald ER 3rd, Bitter H, Huang A, Taran T, Bachelot T, Lebrun F, Lebwohl D, **Baselga J**. “Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.” *J Clin Oncol.* 2016 Feb 10;34(5):419-26. doi: 10.1200/JCO.2014.60.1971. PubMed PMID: 26503204; PubMed Central PMCID: PMC5070556.
405. Scaltriti M, Elkabets M, **Baselga J**. “Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy.” *Clin Cancer Res.* 2016 Mar 15;22(6):1313-7. doi: 10.1158/1078-0432.CCR-15-1458. Epub 2016 Jan 13. Review. PubMed PMID: 26763248; PubMed Central PMCID: PMC4957976.
406. Iyengar NM, Fournier MN, Sugarman SM, Theodoulou M, Troso-Sandoval TA, D'Andrea GM, Drullinsky PR, Gajria D, Goldfarb SB, Comen EA, Lake DE, Modi S, Traina TA, Lacouture ME, Chen MF, Patil S, **Baselga J**, Norton L, Hudis CA, Dang CT. “A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer.” *Clinical breast cancer.* 2016 Apr;16(2):87-94. Epub 2015/10/12. doi: 10.1016/j.clbc.2015.09.009. PubMed PMID: 26454612; PubMed Central PMCID: PMC4968930.

407. **Baselga J\***, Lewis Phillips GD, Verma S, Ro J, Huober J, Guardino E, Samant M, Olsen S, de Haas S, Pegram MD. "Relationship Between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer." *Clin Cancer Res*. 2016 Aug. Epub 2016/02/28. doi: 10.1158/1078-0432.ccr-15-2499. PMID: 26920887. PMCID: PMC5485412. \*Corresponding Author.
408. Piscuoglio S, Ng CK, Murray M, Burke KA, Edelweiss M, Geyer FC, Macedo GS, Inagaki A, Papanastasiou AD, Martelotto LG, Marchio C, Lim RS, Ioris RA, Nahar PK, Bruijn ID, Smyth L, Akram M, Ross D, Petrini JH, Norton L, Solit DB, **Baselga J**, Brogi E, Ladanyi M, Weigelt B, Reis-Filho JS. "Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression." *J Pathol*. 2016 Mar;238(4):508-18. doi: 10.1002/path.4672. PubMed PMID: 26832993; PubMed Central PMCID: PMC4962788.
409. Carmona FJ, Montemurro F, Kannan S, Rossi V, Verma C, **Baselga J**, Scaltriti M. "AKT signaling in ERBB2-amplified breast cancer." *Pharmacol Ther*. 2016 Feb;158:63-70. doi: 10.1016/j.pharmthera.2015.11.013. Review. PubMed PMID: 26645663; PubMed Central PMCID: PMC4747800.
410. Ebbesen SH, Scaltriti M, Bialucha CU, Morse N, Kastenhuber ER, Wen HY, Dow LE, **Baselga J**, Lowe SW. "Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas." *Proc Natl Acad Sci U S A*. 2016 Mar 15;113(11):3030-5. doi: 10.1073/pnas.1523693113. Epub 2016 Feb 29. PubMed PMID: 26929372; PubMed Central PMCID: PMC4801318.
411. Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, Pearson A, Guzman M, Rodriguez O, Grueso J, Bellet M, Cortés J, Elliott R, Pancholi S, **Baselga J**, Dowsett M, Martin LA, Turner NC, Serra V. "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer." *Cancer Res*. 2016 Apr 15;76(8):2301-13. doi: 10.1158/0008-5472.CAN-15-0728. Epub 2016 Mar 28. Erratum in: *Cancer Res*. 2016 Oct 1;76(19):5907. PubMed PMID: 27020857; PubMed Central PMCID: PMC5426059.
412. Toska E, **Baselga J**. "Pharmacology in the Era of Targeted Therapies: The Case of PI3K Inhibitors." *Clin Cancer Res*. 2016 May 1;22(9):2099-101. doi: 10.1158/1078-0432.CCR-16-0038. PubMed PMID: 26957555; PubMed Central PMCID: PMC4946572.
413. Zumsteg ZS, Morse N, Krigsfeld G, Gupta G, Higginson DS, Lee NY, Morris L, Ganly I, Shiao SL, Powell SN, Chung CH, Scaltriti M, **Baselga J**. "Taselisib (GDC-0032), a Potent  $\beta$ -Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations." *Clin Cancer Res*. 2016 Apr 15;22(8):2009-19. doi: 10.1158/1078-0432.CCR-15-2245. PubMed PMID: 26589432; PubMed Central PMCID: PMC4870591.
414. Fumagalli D, Venet D, Ignatiadis M, Azim HA Jr, Maetens M, Rothé F, Salgado R, Bradbury I, Pusztai L, Harbeck N, Gomez H, Chang TW, Coccia-Portugal MA, Di Cosimo S, de Azambuja E, de la Peña L, Nuciforo P, Brase JC, Huober J, **Baselga J**, Piccart M, Loi S, Sotiriou C. "RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTO Randomized Clinical Trial." *JAMA Oncol*. 2016 Sep 29. doi: 10.1001/jamaoncol.2016.3824. [Epub ahead of print] PubMed PMID: 27684533; PubMed Central PMCID: PMC5374044.

415. Chandarlapaty S, Chen D, He W, Sung P, Samoila A, You D, Bhatt T, Patel P, Voi M, Gnant M, Hortobagyi G, **Baselga J**, Moynahan ME. "Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial." *JAMA Oncol*. 2016 Oct 1;2(10):1310-1315. doi: 10.1001/jamaoncol.2016.1279. PubMed PMID: 27532364; PubMed Central PMCID: PMC5063698.
416. Castel P, Carmona FJ, Grego-Bessa J, Berger MF, Viale A, Anderson KV, Bague S, Scaltriti M, Antonescu CR, Baselga E, **Baselga J**. "Somatic PIK3CA mutations as a driver of sporadic venous malformations." *Sci Transl Med*. 2016 Mar 30;8(332):332ra42. doi: 10.1126/scitranslmed.aaf1164. PubMed PMID: 27030594; PubMed Central PMCID: PMC4962922.
417. Wehrenberg-Klee E, Turker NS, Heidari P, Larimer B, Juric D, **Baselga J**, Scaltriti M, Mahmood U. "Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance." *J Nucl Med*. 2016 Sep;57(9):1413-9. doi: 10.2967/jnumed.115.169417. Epub 2016 Apr 14. PubMed PMID: 27081168; PubMed Central PMCID: PMC5093919.
418. Gonzalez M, Crespo M, **Baselga J**, Pozuelo J. "Carbon nanotube scaffolds with controlled porosity as electromagnetic absorbing materials in the gigahertz range." *Nanoscale*. 2016;8(20):10724-30. Epub 2016/05/07. doi: 10.1039/c6nr02133f. PubMed PMID: 27152472. PMCID: PMC5477658.
419. Shamay Y, Elkabets M, Li H, Shah J, Brook S, Wang F, Adler K, Baut E, Scaltriti M, Jena PV, Gardner EE, Poirier JT, Rudin CM, **Baselga J**, Haimovitz-Friedman A, Heller DA. "P-selectin is a nanotherapeutic delivery target in the tumor microenvironment." *Sci Transl Med*. 2016 Jun 29;8(345):345ra87. doi: 10.1126/scitranslmed.aaf7374. PubMed PMID: 27358497; PubMed Central PMCID: PMC5064151.
420. Smyth LM, Iyengar NM, Chen MF, Popper SM, Patil S, Wasserheit-Lieblich C, Argolo DF, Singh JC, Chandarlapaty S, Sugarman SM, Comen EA, Drullinsky PR, Traina TA, Troso-Sandoval T, **Baselga J**, Norton L, Hudis CA, Dang CT. "Weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer: overall survival and updated progression-free survival results from a phase II study." *Breast Cancer Res Treat*. 2016 Jul;158(1):91-7. doi: 10.1007/s10549-016-3851-7. Epub 2016 Jun 15. PubMed PMID: 27306421; PubMed Central PMCID: PMC5017157.
421. Castel P, Ellis H, Bago R, Toska E, Razavi P, Carmona FJ, Kannan S, Verma CS, Dickler M, Chandarlapaty S, Brogi E, Alessi DR, **Baselga J\***, Scaltriti M.\* "PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3K $\alpha$  Inhibition." *Cancer Cell*. 2016 Aug 8;30(2):229-42. doi: 10.1016/j.ccell.2016.06.004. Epub 2016 Jul 21. PubMed PMID: 27451907; PubMed Central PMCID: PMC4982440. \*Corresponding authors.
422. Bago R, Sommer E, Castel P, Crafter C, Bailey FP, Shpiro N, **Baselga J**, Cross D, Eyers PA, Alessi DR. "The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth." *EMBO J*. 2016 Sep 1;35(17):1902-22. doi: 10.15252/embj.201693929. Epub 2016 Aug 1. PubMed PMID: 27481935; PubMed Central PMCID: PMC5007552.
423. Bonner JA, Giralt J, Harari PM, **Baselga J**, Spencer S, Bell D, Raben D, Liu J, Schulten J, Ang KK, Rosenthal DI. "Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial." *Eur J Cancer*. 2016 Sep;64:1-11. doi:

10.1016/j.ejca.2016.05.008. Epub 2016 Jun 17. PubMed PMID: 27323346; PubMed Central PMCID: PMC5027878.

424. Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart M, von Minckwitz G, **Baselga J**. “PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.” *Ann Oncol*. 2016 Aug;27(8):1519-25. doi: 10.1093/annonc/mdw197. PubMed PMID: 27177864.
425. Martín-Martín N, Piva M, Urosevic J, Aldaz P, Sutherland JD, Fernández-Ruiz S, Arreal L, Torrano V, Cortazar AR, Planet E, Guiu M, Radosevic-Robin N, Garcia S, Macías I, Salvador F, Domenici G, Rueda OM, Zabala-Letona A, Arruabarrena-Aristorena A, Zúñiga-García P, Caro-Maldonado A, Valcárcel-Jiménez L, Sánchez-Mosquera P, Varela-Rey M, Martínez-Chantar ML, Anguita J, Ibrahim YH, Scaltriti M, Lawrie CH, Aransay AM, Iovanna JL, **Baselga J**, Caldas C, Barrio R, Serra V, Vivanco Md, Matheu A, Gomis RR, Carracedo A. “Stratification and therapeutic potential of PML in metastatic breast cancer.” *Nat Commun*. 2016 Aug 24;7:12595. doi: 10.1038/ncomms12595. PubMed PMID: 27553708; PubMed Central PMCID: PMC4999521.
426. Bonner J, Giralt J, Harari P, Spencer S, Schulten J, Hossain A, Chang SC, Chin S, **Baselga J**. “Cetuximab and Radiotherapy in Laryngeal Preservation for Cancers of the Larynx and Hypopharynx: A Secondary Analysis of a Randomized Clinical Trial.” *JAMA Otolaryngol Head Neck Surg*. 2016 Sep 1;142(9):842-9. doi: 10.1001/jamaoto.2016.1228. PubMed PMID: 27389475; PubMed Central PMCID: PMC5025385.
427. Bruna A, Rueda OM, Greenwood W, Batra AS, Callari M, Batra RN, Pogrebniak K, Sandoval J, Cassidy JW, Tufegdizic-Vidakovic A, Sammut SJ, Jones L, Provenzano E, Baird R, Eirew P, Hadfield J, Eldridge M, McLaren-Douglas A, Barthorpe A, Lightfoot H, O'Connor MJ, Gray J, Cortes J, **Baselga J**, Marangoni E, Welm AL, Aparicio S, Serra V, Garnett MJ, Caldas C. “A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds.” *Cell*. 2016 Sep 22;167(1):260-274.e22. doi: 10.1016/j.cell.2016.08.041. PubMed PMID: 27641504; PubMed Central PMCID: PMC5037319
428. Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, **Baselga J**, Pusztai L. “Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.” *Ann Oncol*. 2016 Sep 29. pii: mdw434. PubMed PMID: 27687302.
429. Le X, Antony R, Razavi P, Treacy DJ, Luo F, Ghandi M, Castel P, Scaltriti M, **Baselga J**, Garraway LA. “Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer.” *Cancer Discov*. 2016 Oct;6(10):1134-1147. PubMed PMID: 27604488; PubMed Central PMCID: PMC5050154.
430. Yang C, Li Z, Bhatt T, Dickler M, Giri D, Scaltriti M, **Baselga J**, Rosen N, Chandarlapaty S. “Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence.” *Oncogene*. 2017 Apr 20;36(16):2255-2264. doi: 10.1038/onc.2016.379. Epub 2016 Oct 17. PubMed PMID: 27748766; PubMed Central PMCID: PMC5393973.

431. Bago R, Sommer E, Castel P, Crafter C, Bailey FP, Shpiro N, **Baselga J**, Cross D, Eyers PA, Alessi DR. Erratum to "The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth." *EMBO J*. 2016 Oct 17;35(20):2263. PubMed PMID: 27798145; PubMed Central PMCID: PMC5069549.
432. Johnson SF, Cruz C, Greifenberg AK, Dust S, Stover DG, Chi D, Primack B, Cao S, Bernhardt AJ, Coulson R, Lazaro JB, Kochupurakkal B, Sun H, Unitt C, Moreau LA, Sarosiek KA, Scaltriti M, Juric D, **Baselga J**, Richardson AL, Rodig SJ, D'Andrea AD, Balmaña J, Johnson N, Geyer M, Serra V, Lim E, Shapiro GI. "CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer." *Cell Rep*. 2016 Nov 22;17(9):2367-2381. doi: 10.1016/j.celrep.2016.10.077. PubMed PMID: 27880910; PubMed Central PMCID: PMC5176643.
433. Saura C, Roda D, Roselló S, Oliveira M, Macarulla T, Pérez-Fidalgo JA, Morales-Barrera R, Sanchis-García JM, Musib L, Budha N, Zhu J, Nannini M, Chan WY, Sanabria Bohórquez SM, Meng RD, Lin K, Yan Y, Patel P, **Baselga J**, Tabernero J, Cervantes A. "A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors." *Cancer Discov*. 2017 Jan;7(1):102-113. doi: 10.1158/2159-8290.CD-16-0512. Epub 2016 Nov 21. PubMed PMID: 27872130; PubMed Central PMCID: PMC5463454.
434. Soler A, Figueiredo AM, Castel P, Martin L, Monelli E, Angulo-Urarte A, Milà-Guasch M, Viñals F, **Baselga J**, Casanovas O, Graupera M. "Therapeutic Benefit of Selective Inhibition of p110 $\alpha$  PI3-Kinase in Pancreatic Neuroendocrine Tumors." *Clin Cancer Res*. 2016 Dec 1;22(23):5805-5817. Epub 2016 May 25. PubMed PMID: 27225693; PubMed Central PMCID: PMC5338478.
435. Luen SJ, Salgado R, Fox S, Savas P, Eng-Wong J, Clark E, Kiermaier A, Swain SM, **Baselga J**, Michiels S, Loi S. "Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study." *Lancet Oncol*. 2017 Jan;18(1):52-62. doi: 10.1016/S1470-2045(16)30631-3. Epub 2016 Dec 7. PubMed PMID: 27964843; PubMed Central PMCID: PMC5477653.
436. Toy W, Weir H, Razavi P, Lawson M, Goeppert AU, Mazzola AM, Smith A, Wilson J, Morrow C, Wong WL, De Stanchina E, Carlson KE, Martin TS, Uddin S, Li Z, Fanning S, Katzenellenbogen JA, Greene G, **Baselga J**, Chandarlapaty S. "Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists." *Cancer Discov*. 2017 Mar;7(3):277-287. doi: 10.1158/2159-8290.CD-15-1523. PubMed PMID: 27986707; PubMed Central PMCID: PMC5340622.
437. Wang Y, Ayres K, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer EP, Fredrickson J, Arteaga CL, **Baselga J**, Manning HC, Mahmood U, Ulaner GA. "18F-fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression During a Phase I Trial of the Novel Estrogen Receptor-targeted Therapeutic GDC-0810." *Clin Cancer Res*. 2016 Dec 23. pii: clincanres.2197.2016. doi: 10.1158/1078-0432.CCR-16-2197. [Epub ahead of print] PubMed PMID: 28011460. NIH Public Access Compliance: In process at NIHMS. [Edit Status] NIHMS ID: NIHMS839395
438. Ross DS, Zehir A, Cheng DT, Benayed R, Nafa K, Hechtman JF, Janjigian YY, Weigelt B, Razavi P, Hyman DM, **Baselga J**, Berger MF, Ladanyi M, Arcila ME. "Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status: Clinical Validation in

the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay.” *J Mol Diagn*. 2017 Mar;19(2):244-254. doi: 10.1016/j.jmoldx.2016.09.010. Epub 2016 Dec 25. PubMed PMID: 28027945; PubMed Central PMCID: PMC5397722.

439. Osmanbeyoglu HU, Toska E, Chan C, **Baselga J**, Leslie CS. “Pancancer modelling predicts the context-specific impact of somatic mutations on transcriptional programs.” *Nat Commun*. 2017 Jan 31;8:14249. doi: 10.1038/ncomms14249. PubMed PMID: 28139702; PubMed Central PMCID: PMC5290314.
440. Swain SM, Schneeweiss A, Gianni L, Gao JJ, Stein A, Waldron-Lynch M, Heeson S, Beattie MS, Yoo B, Cortes J, **Baselga J**. “Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.” *Ann Oncol*. 2017 Jan 5. pii: mdw695. doi: 10.1093/annonc/mdw695. [Epub ahead of print] PubMed PMID: 28057664. NIH Public Access Compliance: PMC Journal – In Process. NIHMS 881127.
441. Singh JC, Mamtani A, Barrio A, Morrow M, Sugarman S, Jones LW, Yu AF, Argolo D, Smyth LM, Modi S, Schweber S, Boafu C, Patil S, Norton L, **Baselga J**, Hudis CA, Dang C. “Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.” *Oncologist*. 2017 Feb;22(2):139-143. doi: 10.1634/theoncologist.2016-0268. Epub 2017 Feb 6. PubMed PMID: 28167568; PubMed Central PMCID: PMC5330708.
442. Moynahan ME, Chen D, He W, Sung P, Samoila A, You D, Bhatt T, Patel P, Ringeisen F, Hortobagyi GN, **Baselga J**, Chandarlapaty S. “Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2.” *Br J Cancer*. 2017 Mar 14;116(6):726-730. doi: 10.1038/bjc.2017.25. Epub 2017 Feb 9. PubMed PMID: 28183140; PubMed Central PMCID: PMC5355930.
443. Hyman DM, Taylor BS, **Baselga J**. “Implementing Genome-Driven Oncology.” *Cell*. 2017 Feb 9;168(4):584-599. doi: 10.1016/j.cell.2016.12.015. Review. PubMed PMID: 28187282; PubMed Central PMCID: PMC5463457.
444. Mizrachi A, Shamay Y, Shah J, Brook S, Soong J, Rajasekhar VK, Humm JL, Healey JH, Powell SN, **Baselga J**, Heller DA, Haimovitz-Friedman A, Scaltriti M. “Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma.” *Nat Commun*. 2017 Feb 13;8:14292. doi: 10.1038/ncomms14292. PubMed PMID: 28194032; PubMed Central PMCID: PMC5316830.
445. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G Jr, Untch M, Smith I, Gianni L, **Baselga J**, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C; Herceptin Adjuvant (HERA) Trial Study Team.. “11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.” *Lancet*. 2017 Mar 25;389(10075):1195-1205. doi: 10.1016/S0140-6736(16)32616-2. Epub 2017 Feb 17. PubMed PMID: 28215665; PubMed Central PMCID: PMC5465633.
446. Juric D, Krop I, Ramanathan RK, Wilson TR, Ware JA, Sanabria Bohorquez S, Savage H, Sampath D, Salphati L, Lin R, Jin H, Parmar H, Hsu JY, Von Hoff DD, **Baselga J**. “Phase I Dose Escalation Study of Taselisib (GDC-0032), an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors.” *Cancer Discov*. 2017 Mar 22. pii: CD-16-1080. doi: 10.1158/2159-8290.CD-16-1080. [Epub ahead of print] PubMed PMID: 28331003. PMCID: PMC5501742.

447. Toska E, Osmanbeyoglu HU, Castel P, Chan C, Hendrickson RC, Elkabets M, Dickler MN, Scaltriti M, Leslie CS, Armstrong SA\*, **Baselga J\***. "PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D." *Science*. 2017 Mar 24;355(6331):1324-1330. doi: 10.1126/science.aah6893. PubMed PMID: 28336670. PMCID: PMC5485411. \*Corresponding authors.
448. Jordan EJ, Kim HR, Arcila ME, Barron D, Chakravarty D, Gao J, Chang MT, Ni A, Kundra R, Jonsson P, Jayakumaran G, Gao SP, Johnsen HC, Hanrahan AJ, Zehir A, Rekhtman N, Ginsberg MS, Li BT, Yu HA, Paik PK, Drilon A, Hellmann MD, Reales DN, Benayed R, Rusch VW, Kris MG, Chaft JE, **Baselga J**, Taylor BS, Schultz N, Rudin CM, Hyman DM, Berger MF, Solit DB, Ladanyi M, Riely GJ. "Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies." *Cancer Discov*. 2017 Jun;7(6):596-609. doi: 10.1158/2159-8290.CD-16-1337. Epub 2017 Mar 23. PubMed PMID: 28336552. PubMed Central PMCID: PMC5482929.
449. Mondello P, Brea EJ, De Stanchina E, Toska E, Chang AY, Fennell M, Seshan V, Garippa R, Scheinberg DA, **Baselga J**, Wendel HG, Younes A. "Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations." *JCI Insight*. 2017 Mar 23;2(6):e90196. doi: 10.1172/jci.insight.90196. PubMed PMID: 28352655; PubMed Central PMCID: PMC5358483.
450. Hanker AB, Garrett JG, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford EM, Owns P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Samira M, Brohée S, Venet D, Brown D, **Baselga J**, Piccart M, Sotiriou C, Arteaga CL. "HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2." *Clin Cancer Res*. 2017 Apr 5. pii: clincanres.2287.2016. doi: 10.1158/1078-0432.CCR-16-2287. [Epub ahead of print] PubMed PMID: 28381415. NIHMS 866494.
451. Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, **Baselga J**, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF. "Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients." *Nat Med*. 2017 Jun;23(6):703-713. doi: 10.1038/nm.4333. Epub 2017 May 8. PubMed PMID: 28481359; PubMed Central PMCID: PMC5461196.
452. Hyman DM, Smyth LM, Donoghue MTA, Westin SN, Bedard PL, Dean EJ, Bando H, El-Khoueiry AB, Pérez-Fidalgo JA, Mita A, Schellens JHM, Chang MT, Reichel JB, Bouvier N, Selcuklu SD, Soumerai TE, Torrisi J, Erinjeri JP, Ambrose H, Barrett JC, Dougherty B, Foxley A, Lindemann JPO, McEwen R, Pass M, Schiavon G, Berger MF, Chandarlapaty S, Solit DB, Banerji U, **Baselga**



- J**, Taylor BS. “AKT Inhibition in Solid Tumors With AKT1 Mutations.” *J Clin Oncol*. 2017 May 10;JCO2017730143. doi: 10.1200/JCO.2017.73.0143. [Epub ahead of print] PubMed PMID: 28489509. NIHMS 878066.
453. Diéras V, Miles D, Verma S, Pegram M, Welslau M, **Baselga J**, Krop IE, Blackwell K, Hoersch S, Xu J, Green M, Gianni L. “Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.” *Lancet Oncol*. 2017 May 16. pii: S1470-2045(17)30312-1. doi: 10.1016/S1470-2045(17)30312-1. [Epub ahead of print] PubMed PMID: 28526536. NIHMS 882684.
454. Dickler MN, Tolaney S, Rugo HS, Cortés J, Dieras V, Patt DA, Wildiers H, Hudis CA, O’Shaughnessy JA, Zamora E, Yardley D, Frenzel M, Koustenis AG, **Baselga J**. “MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer.” *Clin Cancer Res*. 2017 May 22. pii: clincanres.0754.2017. doi: 10.1158/1078-0432.CCR-17-0754. [Epub ahead of print] PubMed PMID: 28533223. NIHMS 881827.
455. **Baselga J\***, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone M. “Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.” *Lancet Oncol*. 2017 May 30. pii: S1470-2045(17)30376-5. doi: 10.1016/S1470-2045(17)30376-5. [Epub ahead of print] PubMed PMID: 28576675.  
\*Corresponding Author. NIHMS 883300.
456. **Baselga J**, Morales SM, Awada A, Blum JL, Tan AR, Ewertz M, Cortes J, Moy B, Ruddy KJ, Haddad T, Ciruelos EM, Vuylsteke P, Ebbinghaus S, Im E, Eaton L, Pathiraja K, Gause C, Mauro D, Jones MB, Rugo HS. “A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.” *Breast Cancer Res Treat*. 2017 Jun;163(3):535-544. doi: 10.1007/s10549-017-4199-3. Epub 2017 Mar 21. PubMed PMID: 28324268; PubMed Central PMCID: PMC5448790.
457. von Minckwitz G\*, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, **Baselga J\***; APHINITY Steering Committee and Investigators.. “Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.” *N Engl J Med*. 2017 Jun 5. doi: 10.1056/NEJMoa1703643. [Epub ahead of print] PubMed PMID: 28581356. \*Co-corresponding authors. NIHMS 883304.
458. Rheinbay E, Parasuraman P, Grimsby J, Tiao G, Engreitz JM, Kim J, Lawrence MS, Taylor-Weiner A, Rodriguez-Cuevas S, Rosenberg M, Hess J, Stewart C, Maruvka YE, Stojanov P, Cortes ML, Seepo S, Cibulskis C, Tracy A, Pugh TJ, Lee J, Zheng Z, Ellisen LW, Iafrate AJ, Boehm JS, Gabriel SB, Meyerson M, Golub TR, **Baselga J**, Hidalgo-Miranda A, Shioda T, Bernards A, Lander ES, Getz G. “Recurrent and functional regulatory mutations in breast cancer.” *Nature*. 2017 Jun 28. doi: 10.1038/nature22992. [Epub ahead of print] PubMed PMID: 28658208. NIHMS 890993.

459. Zabala-Letona A, Arruabarrena-Aristorena A, Martín-Martín N, Fernandez-Ruiz S, Sutherland JD, Clasquin M, Tomas-Cortazar J, Jimenez J, Torres I, Quang P, Ximenez-Embun P, Bago R, Ugalde-Olano A, Loizaga-Iriarte A, Lacasa-Viscasillas I, Unda M, Torrano V, Cabrera D, van Liempd SM, Cendon Y, Castro E, Murray S, Revandkar A, Alimonti A, Zhang Y, Barnett A, Lein G, Pirman D, Cortazar AR, Arreal L, Prudkin L, Astobiza I, Valcarcel-Jimenez L, Zuñiga-García P, Fernandez-Dominguez I, Piva M, Caro-Maldonado A, Sánchez-Mosquera P, Castillo-Martín M, Serra V, Beraza N, Gentilella A, Thomas G, Azkargorta M, Elortza F, Farràs R, Olmos D, Efeyan A, Anguita J, Muñoz J, Falcón-Pérez JM, Barrio R, Macarulla T, Mato JM, Martinez-Chantar ML, Cordon-Cardo C, Aransay AM, Marks K, **Baselga J**, Tabernero J, Nuciforo P, Manning BD, Marjon K, Carracedo A. "mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer." *Nature*. 2017 Jun 28. doi: 10.1038/nature22964. [Epub ahead of print] PubMed PMID: 28658205. NIHMS 874017.
460. Rugo HS, Trédan O, Ro J, Morales SM, Campone M, Musolino A, Afonso N, Ferreira M, Park KH, Cortes J, Tan AR, Blum JL, Eaton L, Gause CK, Wang Z, Im E, Mauro DJ, Jones MB, Denker A, **Baselga J**. "A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer." *Breast Cancer Res Treat*. 2017 Jul 5. doi: 10.1007/s10549-017-4375-5. [Epub ahead of print] PubMed PMID: 28681171. NIHMS 891751.

Non-peer reviewed scientific/medical publications (print or other media)

1. Seidman AD, Hudis CA, Fennelly D, Raptis G, **Baselga J**, Norton L. "Memorial Sloan Kettering Cancer Center experience with paclitaxel in the treatment of breast cancer". *Semin Oncol*. 1995 Oct; 22(5 Supplement 12):108-16.
2. Hudis CA, Seidman AD, **Baselga J**, Raptis G, Lebwohl D, Gilewski T, Currie V, Moynahan ME, Sklarin N, Fennelly D, et al. "Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes". *Semin Oncol*. 1995 Dec; 22(6 Supplement 15):18-23.
3. Seidman AD, Hudis CA, Raptis G, **Baselga J**, Fennelly D, Norton L. "Paclitaxel for breast cancer: The Memorial Sloan Kettering Cancer Center experience". *Oncology (Williston Park)*. 1997 Mar; 11(3 Supplement 2):20-8.
4. **Baselga J**, Seidman AD, Rosen PP, Norton L. "HER2 overexpression and paclitaxel sensitivity in breast cancer: Therapeutic implications". *Oncology (Williston Park)*. 1997 Mar; 11(3 Supplement 2):43-8.
5. **Baselga J**, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. "Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer". *Semin Oncol*. 1999 Aug; 26(4 Supplement 12):78-83.
6. **Baselga J**. "New horizons: Gene therapy for cancer". *Anticancer Drugs*. 1999 Nov; 10 Supplement 1:S39-42.
7. Albanell J, **Baselga J**. "Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer". *Drugs Today (Barc)*. 1999 Dec; 35(12):931-46.
8. Albanell J, **Baselga J**. "Systemic therapy emergencies". *Semin Oncol*. 2000 Jun; 27(3):347-61.

9. Bellmunt J, Guillem V, Paz-Ares L, Gonzalez-Larriba JL, Carles J, Albanell J, Tabernero JM, Cortes-Funes H, **Baselga J**. "Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer". *Eur J Cancer*. 2000 Jul; 36 Supplement 2:17-25.
10. **Baselga J**. "Clinical trials of single-agent trastuzumab (Herceptin)". *Semin Oncol*. 2000 Oct; 27(5 Supplement 9):20-6.
11. **Baselga J**. "Current and planned clinical trials with trastuzumab (Herceptin)". *Semin Oncol*. 2000 Oct; 27(5 Supplement 9):27-32.
12. **Baselga J**. "New therapeutic agents targeting the epidermal growth factor receptor". *J Clin Oncol*. 2000 Nov 1; 18(21 Supplement):54S-9S.
13. **Baselga J**. "Monoclonal antibodies directed at growth factor receptors". *Ann Oncol*. 2000; 11 Supplement 3:187-90.
14. **Baselga J**, Averbuch SD. "ZD1839 ('Iressa') as an anticancer agent". *Drugs*. 2000; 60 Supplement 1:33-40; discussion 41-2.
15. **Baselga J**. "Clinical trials of single-agent trastuzumab (Herceptin)". *Eur J Cancer*. 2001 Jan; 37 Supplement 1:S18-24.
16. **Baselga J**, Tabernero JM. "Weekly docetaxel in breast cancer: applying clinical data to patient therapy". *Oncologist*. 2001; 6 Supplement 3:26-9.
17. **Baselga J**, Albanell J. "Mechanism of action of anti-HER2 monoclonal antibodies". *Ann Oncol*. 2001; 12 Supplement 1:S35-41.
18. **Baselga J**. "Phase I and II clinical trials of trastuzumab". *Ann Oncol*. 2001; 12 Supplement 1:S49-55
19. **Baselga J**. "The EGFR as a target for anticancer therapy--focus on cetuximab". *Eur J Cancer*. 2001 Sep; 37 Supplement 4:S16-22.
20. **Baselga J**, Albanell J, Molina MA, Arribas J. "Mechanism of action of trastuzumab and scientific update". *Semin Oncol*. 2001 Oct; 28(5 Supplement 16):4-11.
21. Albanell J, Rojo F, **Baselga J**. "Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839". *Semin Oncol*. 2001 Oct; 28(5 Supplement 16):56-66.
22. **Baselga J**. "Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials". *Oncology*. 2001; 61 Supplement 2:14-21.
23. **Baselga J**. "Why the epidermal growth factor receptor? The rationale for cancer therapy". *Oncologist*. 2002; 7 Supplement 4:2-8.
24. **Baselga J**, Hammond LA. "HER-targeted tyrosine-kinase inhibitors". *Oncology*. 2002; 63 Supplement 1:6-16.
25. Yarden Y, **Baselga J**, Miles D. "Molecular approach to breast cancer treatment". *Semin Oncol*. 2004 Oct; 31(5 Supplement 10):6-13.
26. Spano JP, Milano G, **Baselga J**. "EGFR/VEGF signaling pathway in colorectal cancer: the way we are!" *Bull Cancer*. 2005 Aug; 92(Spec no):S3-4.
27. Mendelsohn J, **Baselga J**. "Epidermal growth factor receptor targeting in cancer". *Semin Oncol*. 2006 Aug; 33(4):369-85.

28. **Baselga J**, Perez EA, Pienkowski T, Bell R. "Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer". *Oncologist*. 2006; 11 Suppl 1:4-12.
29. Cortes J, **Baselga J**. "Targeting the microtubules in breast cancer beyond taxanes: "The epothilones". *Oncologist*. 2007 Mar; 12(3):271-80.
30. Prat A, **Baselga J**. Biologic therapy: "Current and future applications in oncology" *Med Clin (Barc)*. 2007 Jun 30; 129(5):184-93.
31. **Baselga J**, Senn HJ. European Society for Medical Oncology. "The perspective and role of the medical oncologist in cancer prevention: a position paper by the European Society for Medical Oncology." *Ann Oncol*. 2008 Jun; 19(6):1033-5.
32. ESMO, **Baselga J**. "Creating a stronger front against cancer: ESMO and ECCO join forces". *Ann Oncol*. 2008 Aug; 19(8):1367-8.
33. **Baselga J**. "Novel agents in the era of targeted therapy: What have we learned and how has our practice changed?" *Ann Oncol*. 2008 Sep; 19 Suppl 7:vii281-8.
34. Higgins MJ, Baselga J. "Breast cancer in 2010: Novel targets and therapies for a personalized approach." *Nat Rev Clin Oncol*. 2011 Feb; 8(2):65-6.
35. Arribas J, **Baselga J**, Pedersen K, Parra-Palau JL. "p95HER2 and breast cancer." *Cancer Res*. 2011 Mar 1; 71(5):1515-9.
36. Reck M, Hermes A, Tan EH, Felip E, Klughammer B, **Baselga J**. "Tissue sampling in lung cancer: A review in light of the MERIT experience. *Lung Cancer*." 2011, Jun 7.

Date: 7/10/2017

Signature: \_\_\_\_\_

A handwritten signature in blue ink, appearing to read 'J. Baselga', is written over a horizontal line. The signature is stylized and cursive.